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Abstract.  
Clinically used RAF inhibitors are ineffective in RAS-mutant tumors, enhancing homo- and 
heterodimerization of RAF kinases, and leading to paradoxical activation of ERK signaling. 
Numerous mechanisms of RAF inhibitor resistance result in enhanced RAF dimerization and cannot 
be overcome by existing RAF inhibitors. A way to overcome resistance is the use of inhibitor 
combinations, but it is unclear how the best combinations can be chosen. Using a combined 
experimental and computational approach, we built a mechanistic dynamic model to analyze 
combinations of structurally different RAF inhibitors, which can efficiently suppress MEK/ERK 
signaling. This next-generation model of the RAS/ERK pathway integrates thermodynamics and 
kinetics of drug-protein interactions, structural elements, post-translational modifications and cell 
mutational status, predicting best RAF inhibitor combinations for cancer cells harboring oncogenic 
RAS and/or BRAFV600E. Synergistic inhibition of ERK signaling in mutant NRAS, HRAS and 
BRAFV600E cells was corroborated by experiments, demonstrating the power of structure-based 
dynamic modeling.   
 
Bullet points   
Next-generation model integrates kinetic, thermodynamic and cellular data 
RAF dimers are effectively targeted by two structurally different RAF inhibitors 
Best RAF inhibitor combinations are selected for diverse genetic backgrounds 
Predicted RAF inhibitor combinations overcome oncogenic RAS signaling to ERK 
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Introduction 
The RAS/RAF/MEK/ERK pathway is pivotal for cell proliferation and survival and is frequently 
hyperactivated in tumors. Oncogenic mutations in the RAS genes (H-RAS, K-RAS, and N-RAS) 
occur in about 30% of cancers (Prior et al., 2012; Stephen et al.). Despite a three-decade long effort 
at developing RAS inhibitors, there is still no clinically available drug.  As a result, the development 
of inhibitors of the kinases downstream of RAS has become a hot topic in drug development (Caunt 
et al., 2015; Rahman et al., 2014). Considerable efforts have focused on RAF kinases, owing to 
frequent BRAF mutations that drive cancer and developmental disorders (Rauch et al., 2016). The 
most common oncogenic BRAF mutation, BRAFV600E is found in ca 8% of human tumors and 
60% of melanomas (Weinstein et al., 2013; Holderfield et al., 2014)). The ATP-competitive RAF 
inhibitors in clinical use, vemurafenib and dabrafenib, show high initial response rates in patients 
with mutant BRAFV600E malignant melanomas, but the effects are short-lived (Holderfield et al., 
2014). Moreover, about 30% of patients develop secondary skin hypertrophy or malignances because 
of paradoxical ERK activation in wild-type (WT) BRAF cells (Yaktapour et al., 2014). Paradoxical 
ERK activation is particularly pronounced in mutant RAS tumors conveying intrinsic resistance to 
RAF inhibitors (Zhang et al., 2015), which can even accelerate tumor growth and invasion (Sanchez-
Laorden et al., 2014). 
Homo- and hetero-dimerization of the RAF kinases BRAF and CRAF (gene name RAF1) 
significantly increases their catalytic activities and represents a key event in the activation of normal 
and oncogenic RAF pathways (Freeman et al., 2013; Garnett et al., 2005; Rushworth et al., 2006). 
The binding of RAF molecules to active RAS drives RAF dimerization by inducing conformational 
changes, dephosphorylation of inhibitory residues and bringing RAF molecules into proximity of 
each other (Dhillon et al., 2002; Kholodenko et al., 2000; Weber et al., 2001). Enhanced RAF kinase 
dimerization driven by oncogenic RAS mutations or upregulation of upstream receptors leads to 
intrinsic or acquired resistance to RAF inhibitors (Lito et al., 2013; Nazarian et al., 2010). Other 
resistance mechanisms connected with increased RAF dimerization include CRAF overexpression 
(Holderfield et al., 2014; Lito et al., 2013), BRAF amplification (Shi et al., 2012), and BRAFV600E 
splice variants exhibiting enhanced dimerization potential (Poulikakos et al., 2011). All clinically 
used RAF inhibitors are ineffective against RAS mutant tumors (Hatzivassiliou et al., 2010; 
Poulikakos et al., 2010) and show poor performance in BRAF mutant colorectal cancers (Holderfield 
et al., 2014). Thus, more effective therapeutic strategies are currently needed to target mutant BRAF 
driven cancers.  
4 
 
Protein kinases toggle between inactive and active conformations that differ by the positions of the 
highly conserved DFG motif and αC-helix. ATP-competitive RAF inhibitors can be classified based 
on their preferential binding to different (IN or OUT) conformations of the DFG motif and αC-helix 
(IN and OUT positions correspond to active and inactive kinase conformations, respectively) 
(Fabbro, 2015; Karoulia et al., 2016; Roskoski, 2016). A broad classification includes three inhibitor 
types: αC-IN/DFG-IN (denoted CI/DI, Type I), αC-OUT/DFG-IN (CO/DI, Type I ½), and αC-
IN/DFG-OUT (CI/DO, Type II), see table S1. The observation that ATP-competitive inhibitors bind 
with different affinities to active and inactive kinase conformations received much attention in the 
drug discovery effort, but mostly in terms of inhibitor structures. We have recently reported that 
fundamental thermodynamic principles governing allosteric inhibitor effects can explain both 
paradoxical RAF kinase activation and common resistance mechanisms to RAF inhibitors 
(Kholodenko, 2015). Our work suggested that a combination of two structurally different RAF 
inhibitors may offer a path to abolish resistance (Kholodenko, 2015). However, to understand which 
inhibitor types to combine and in which cellular contexts, we need to connect thermodynamic and 
structural analyses of inhibitor-RAF interactions with biochemical, mutational and pathway 
regulation data, including dynamics of posttranslational modifications (PTMs) and feedback loops. 
Here, we present a mechanistic ERK pathway model that integrates the structural, thermodynamic 
and kinetic analyses of RAF kinases, inhibitors and their interactions with pathway biochemical data 
and cellular genetic profiles to faithfully predict RAF inhibitor responses at the network level. This 
comprehensive model is based on extended studies of RAF kinase regulation by multiple 
phosphosites and dimerization, and intensive RAF inhibitor research. Our model predicts a number 
of surprising, hidden properties of network responses to different types of RAF inhibitors and makes 
new strides in understanding resistance to these drugs. The model suggests that synergy can emerge 
between Type I and Type II, as well as between Type I ½ and Type II inhibitors and predicts new 
ways of overcoming RAF inhibitor resistance in RAS mutant cells. Our experimental results on 
responses of MEK/ERK signaling to different RAF inhibitor types and their combinations in 
melanoma cells bearing oncogenic RAS, BRAFV600E mutations, or both BRAFV600E and NRAS 
mutations support model predictions. Inhibition of oncogenic RAS signaling in MEL-JUSO cells 
(NRASQ61L/WT, HRASG13D/G13D) is associated with reduced cell proliferation and colony formation. 
The results suggest a new principle of targeting the same kinase with two structurally different 
inhibitors that bind to different kinase conformations.  
 
5 
 
Results 
Exploiting RAF dimer asymmetry as drug target  
Structural studies of the BRAF and CRAF kinase domains show that dimers are asymmetric, and that 
RAF inhibitors often only bind one protomer. This asymmetry allows allosteric activation of a RAF 
protomer by a drug-bound protomer and is a critical feature of the paradoxical ERK pathway 
activation induced by many RAF inhibitors (Hu et al., 2013; Jambrina et al., 2014; Jambrina et al., 
2016; Kholodenko, 2015; Yao et al., 2015). This asymmetry is hallmarked by different (IN-OUT) 
orientations of the αC-helix together with distinct IN and OUT conformations of the DFG motif 
(Figs. 1 and S1). These conformations occur naturally (Fig. 1B), but can be stabilized by RAF 
inhibitors, as suggested by crystallographic structures of BRAF with different inhibitors (Figs. 1C, 
1D and S1). These structural changes combined with the evidence from thermodynamic studies that 
dimerization can substantially change the affinity of protomers for a drug (Kholodenko, 2015), 
prompted us to hypothesize that combining RAF inhibitors that preferentially bind to alternative αC-
helix and DFG motif conformations should be able to block RAF dimer activity. As RAF 
dimerization involves not only conformational changes but also is governed by dynamic PTMs, 
which are difficult to track by structural and biochemical studies, we developed an integrated 
computational model that allowed us to analyze both the phosphorylation and conformational 
dynamics in mechanistic detail.  
Structural, thermodynamic and kinetic mechanisms integrated in a model 
Protein functions are regulated by (de)phosphorylation of specific residues on multiple interacting, 
regulatory and catalytic domains (Pawson and Nash, 2003; Romano et al., 2014; Rubinstein et al., 
2016). The ensuing protein states determine the affinities and rates of numerous interactions, 
including homo- and hetero dimerization, other protein associations, binding of inhibitors, and 
catalysis. To precisely account for the complexity of these interactions that occur sequentially or in 
parallel, we implement a rule-based, domain-oriented approach, which explicitly monitors the 
conformational and phosphorylation states of pathway kinases, including inhibiting and activating 
phosphosites (Borisov et al., 2008; Chylek et al., 2014; Varga et al., 2017). Our model describes 
conformational states of RAF monomers and dimers in terms of IN and OUT positions of the DFG 
motif and the αC-helix. These positions depend on RAF binding to RAS-GTP, the phosphorylation 
states of key residues (see below), the dimerization status (e.g., allosteric transactivation of a free 
RAF protomer by inhibitor-bound protomer (Hu et al., 2013)), and binding of RAF inhibitors that 
can stabilize the αC-helix and the DFG motif in the IN or OUT position, depending on the inhibitor 
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structure. Each rule in our RAS/ERK pathway model determines a set of chemical reactions, whose 
rates depend on the conformational, phosphorylation and spatial localization states of RAS, BRAF, 
CRAF, MEK and ERK (see Methods and Supplemental Experimental Procedures, SI). Below we 
briefly outline the main features of the complex RAF regulation, conformational transitions and 
allosteric interactions with RAF inhibitors that are integrated in the model. A detailed list of 
assumptions, a description of processes and parameters, and a program file that can be processed by 
the open source software package BioNetGen (Chylek et al., 2014) are given in SI.  
RAF activation cycle. Our model recapitulates how the activities of WT RAF kinases are controlled 
by (i) inhibitory phosphorylation on S259 for CRAF and S365 for BRAF, (ii) activating 
phosphorylation on S338 for CRAF, (iii) homo- and heterodimerization, and (iv) inhibitory feedback 
phosphorylation by ERK on several sites (including S642 on CRAF and T753 on BRAF), as 
illustrated in Figs. S2 and 2 (Baljuls et al., 2013; Dhillon et al., 2002; Ritt et al., 2010). RAS-GTP is 
considered an input to the ERK cascade. In the absence of RAS-GTP, both CRAF and BRAF reside 
in the cytoplasm in inactive states characterized by pS259 (p denotes phosphorylation) and S338 for 
CRAF and pS365 for BRAF. Active RAS recruits CRAF and BRAF to the plasma membrane. This 
is followed by RAF conformational changes, the dissociation of 14-3-3 proteins, dephosphorylation 
of inhibitory pS259 or pS365, and phosphorylation of S338, resulting in catalytic activity of RAF 
monomers (Chiloeches et al., 2001; Dhillon et al., 2002), Fig. S2. Strikingly, catalytic activities 
increase more than 10-fold following RAF heterodimerization (Freeman et al., 2013; Rushworth et 
al., 2006).  
Influence of ERK feedback on RAF activity. In the model, ERK phosphorylation affects RAF 
activities through three different mechanisms (see SI, section 1.6 for details). First, it lowers the 
binding affinities of both CRAF and BRAF for RAS-GTP (Dougherty et al., 2005; Ritt et al., 2010). 
Second, it dramatically decreases the activity of CRAF monomers (Dougherty et al., 2005). Third, 
ERK phosphorylation lowers the affinities of monomers to dimerize.  This leads to dissociation of 
RAF dimers, resulting in a precipitous drop in the total kinase activity (Ritt et al., 2010; Rushworth 
et al., 2006). Owing to these mechanisms, the activity of RAF kinases is tightly controlled by ERK-
mediated feedback in the absence of oncogenic RAS and BRAF mutations (Kholodenko and 
Birtwistle, 2009; Sturm et al., 2010). 
Oncogenic BRAF mutant. We model both WT RAF and mutant BRAFV600E heterozygous and 
homozygous cells (see SI, section 2). In the model BRAFV600E monomers are constitutively active, 
irrespective of the phosphorylation state of inhibitory S365, as suggested by structural and 
biochemical studies (Hu et al., 2013). Similar to wild-type, BRAFV600E is recruited to the plasma 
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membrane by active RAS. The dimerization potential of mutant BRAF is higher than that of wild-
type protein, and the stability of BRAFV600E dimers is less affected by ERK feedback 
phosphorylation than in the case of WT BRAF (Lavoie and Therrien, 2015). A complete list of the 
relative kinase activities of CRAF, WT BRAF and BRAFV600E monomers and homo- and hetero-
dimers is given in SI, section 4, List S4.1.  
Allosteric interactions of RAF monomers and dimers with inhibitors.  Structurally diverse RAF 
inhibitors preferentially bind to different specific conformations of RAF molecules. Owing to 
thermal motions, these conformations can spontaneously transition between IN and OUT positions of 
the DFG motif and αC-helix (Lavoie and Therrien, 2015; Shao et al., 2017). Therefore, the apparent 
dissociation constants (Kd) of inhibitor binding to RAF monomers and dimers will depend on the 
equilibrium constants of these transitions, which in turn critically depend on the RAF binding, 
phosphorylation and dimerization states captured in the model. Distinct inhibitor types differentially 
stabilize IN or OUT positions of the αC-helix and the DFG motif and allosterically change these 
equilibrium constants and Kd’s (Kholodenko, 2015), see SI, section 3 and Lists S3.2 – S3.4. Thus, a 
unique feature of our model is its inclusion of conformational transitions of the αC-helix and the 
DFG motif in kinase monomers and dimers, which are driven by the kinetics of RAF activation 
cycles, interactions with inhibitors and thermal intramolecular motions (illustrated in Fig. 2, see SI, 
section 3 for details). 
Summarizing, the model describes how the dynamic assortment of different RAF states determines 
the Kd of inhibitor binding within a cell. These Kd values critically depend on BRAF and RAS 
oncogenic mutations, thermal RAF motions, and the rate constants of inhibitor binding to different 
RAF conformations (see SI, section 3). Importantly, structurally diverse RAF inhibitors will have 
different Kd’s for different RAF molecular states, which is a prerequisite for inhibitor synergy or 
antagonism in cellular dose-responses. Next, using our comprehensive, structure-based model, we 
will assess which combinations of structurally different RAF inhibitors can effectively suppress ERK 
signaling in cancer cells with distinct genetic and protein expression background and then test the 
model predictions in experiments. 
BRAFV600E mutant-driven cells with WT RAS: what combinations of RAF inhibitors 
are more effective than individual inhibitors?  
Signaling by BRAFV600E monomers is successfully blocked by RAF inhibitors that are used in the 
clinic, such as vemurafenib and dabrafenib. However, these drugs cannot effectively suppress 
signaling by RAF dimers, leading to paradoxical ERK activation and the emergence of resistance, 
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when RAF dimerization is increased through different adaptive mechanisms. Importantly, model 
simulations suggest that in both homo- and heterozygous cells harboring mutant BRAF and WT 
RAS, BRAFV600E homo- and heterodimers considerably contribute to the total RAF activity (Figs. 
S3A-S3F). Therefore, synergy between RAF inhibitors will occur if they cooperate to efficiently 
inhibit RAF dimers (Kholodenko, 2015). Our hypothesis is that two RAF inhibitors binding to 
alternative conformations of the αC-helix and/or DFG motif could block RAF dimer activity. 
Binding of a CO/DI inhibitor to an inhibitor-free RAF dimer stabilizes the dimer and the αC-helix of 
the respective protomer in an OUT position, whereas the αC-helix of the other protomer shifts to an 
IN position (because two αC-OUT protomer positions are generally incompatible with the dimer 
structure (Karoulia et al., 2016)). As drugs preferentially binding to an IN position of the αC-helix 
will select this protomer, a CO/DI and CI/DO inhibitor pair and a CI/DI and CO/DI pair may 
potentially synergize in the ERK pathway inhibition.  
Using the model, we simulated the stationary dependencies of active MEK and ERK on the doses of 
RAF inhibitors, applied separately or in combination (these dependences are referred to as dose-
responses). The levels of active MEK (ppMEK, Figs. 3A-3B) and ERK (ppERK, Fig. S3G) were 
normalized by their basal levels in growing cells, and drug exposure was simulated for several hours 
to reach the system steady state. To compare dose-response curves for different inhibitors, doses are 
commonly normalized by the IC50 values for each drug, which are the doses that inhibit the basal 
MEK or ERK activity by 50% (or by other ICZ values where 0 ≤ Z < 100%) (Chou, 2006; Greco et 
al., 1995; Yeh et al., 2009). Accordingly, normalized dose-response curves for two different 
inhibitors always cross at the point where the normalized dose of each drug equals one (see blue and 
green dose-response curves in Fig. 3). Several quantitative metrics exist to estimate if two different 
inhibitors synergize, antagonize or act independently in suppressing pathway signaling, which are 
discussed in detail in SI, section 6. The Talalay-Chou combination index (CI) identifies drug 
synergy, additivity or antagonism, if the CI is smaller than 1, equal 1 or greater than 1, respectively 
(Chou, 2006). An advantage of using CI is the smaller amount of required data points, as compared 
with other, more comprehensive drug interaction metrics (see below and also SI, section 6 for more 
details).  
Our simulations suggest that in BRAFV600E/WT RAS cells, two structurally distinct RAF inhibitors 
can synergize, if they preferably bind to protomers with different orientations of the αC-helix in a 
dimer (see the inserts in Fig. 3 panels showing that the CI is smaller than 1 over a range of doses). A 
combination of CO/DI and CI/DO inhibitors is most effective, suppressing ppERK with almost no 
paradoxical activation, whereas a combination of CO/DI and CI/DI inhibitors that can also be 
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synergistic shows substantial paradoxical activation mainly induced by a CI/DI inhibitor (Fig. 3C 
and S3H). Also, in BRAFV600E/WT RAS cells, CI/DI and CI/DO inhibitors will not be synergistic 
(Fig S3J where the CI is greater than 1 over a range of doses), because BRAFV600E homodimers 
and BRAFV600E-BRAF dimers will be ineffectively inhibited by this drug pair. A comparison of 
the calculated dose-responses (Fig. 3A) with experimentally measured response curves in A375 
(BRAFV600E/V600E, WT RAS) cells (Fig. 3B) demonstrates that the model accurately predicts 
synergistic inhibition of the ERK pathway by B0R (CO/DI) and sorafenib (CI/DO).   
The synergy between CI/DO and CO/DI inhibitors increases, if a CO/DI inhibitor has a low 
dissociation rate constant (koff ), as, e.g., LGX818  with 1/koff  ≥ 2hrs (Yao et al., 2015). Strikingly, 
this low koff does not change the efficiency of this inhibitor applied separately, but it markedly 
enhances the synergistic effect of the drug combination (Fig. 3D, cf. the CI values in Fig. 3C and 
3D). Intriguingly, if a CI/DO drug has a low koff, this almost does not affect the efficacy of this drug 
applied separately or in combination with a CO/DI drug (Fig. S3I).   
Inhibition of mutant RAS-driven cells with WT BRAF by combinations of RAF 
inhibitors: systematic search for synergy.  
Specific RAF inhibitors used in the clinic are ineffective against tumors harboring oncogenic RAS 
mutations (Heidorn et al., 2010; Zhang et al., 2015). A combination of a RAF inhibitor (dabrafenib 
or vemurafenib) and a MEK inhibitor (trametinib) is standard of care for BRAFV600E-driven 
metastatic melanoma (Grob et al., 2015; Larkin et al., 2014). However, our model simulations 
suggest that this drug combination does not synergize to inhibit ERK signaling in oncogenic mutant 
RAS and WT BRAF cells (Figs. 4A and S4A). In fact, the model predicts that this combination 
increases the ppERK signal compared to MEK inhibitor alone (Fig. 4A). We tested this prediction 
using the oncogenic RAS mutant-driven melanoma cell line MEL-JUSO (NRASQ61L/WT and 
HRASG13D/G13D (Forbes et al., 2015)). The experimental results corroborate model predictions, 
demonstrating that in MEL-JUSO cells the addition of dabrafenib to trametinib (at the doses that do 
not fully inhibit ERK activation) increases rather than decreases ERK signaling (Fig. 4B). Therefore 
next, we explore whether RAF inhibitor combinations can effectively suppress ERK signaling in 
RAS mutant-driven cells.  
Combination of CI/DI and CI/DO RAF inhibitors: model predictions. Oncogenic RAS increases 
the abundance of BRAF-CRAF dimers. Because in a dimer, the BRAF protomer is dephosphorylated 
on S365, the equilibrium position of its DFG motif is shifted to the DFG-IN conformation. 
Consequently, CI/DI inhibitors preferentially bind to this BRAF protomer, stabilizing the DFG-IN 
10 
 
conformation. Experimental data suggest that in growing cells the CRAF protomer is not 
phosphorylated on S338 in a considerable fraction of BRAF-CRAF dimers (Dhillon et al., 2002; 
Diaz et al., 1997), which is recapitulated in our simulations (Fig. S5A). Consequently, the DFG-
motif of this CRAF protomer has a higher probability to be in an OUT position than in an IN 
position. As a result, this protomer will preferentially bind a CI/DO inhibitor, underpinning a 
potential synergy between CI/DI and CI/DO inhibitors. Importantly, this mechanism of synergy does 
not depend on which type of inhibitor binds first to a heterodimer; a CI/DI inhibitor would 
predominantly bind to a BRAF S365 protomer, whereas a CI/DO inhibitor would predominantly 
bind to a CRAF S259, S338 protomer. The model suggests that a substantial fraction of fully 
inhibited CRAF-BRAF heterodimers will contain a pair of CI/DO and CI/DI inhibitor molecules 
instead of two copies of either inhibitor (see Fig. S5B). The simulated dose-responses show that 
either inhibitor induces a strong paradoxical ERK activation, Fig. 5A (data for ppMEK are shown in 
Fig. S5C). In agreement with experimental studies (Karoulia et al., 2016), CI/DI inhibitors are 
predicted to show a higher paradoxical ERK activation than CI/DO inhibitors. Notably, the 
concentration ranges in which inhibitors lead to paradoxical activation become wider with increasing 
RAS-GTP levels (Fig. S5D). 
The inhibitory effect of a two drug combination can be comprehensively assessed by calculating or 
measuring the ppERK response across a two-dimensional plane of drug doses, Fig. 5B (Keith et al., 
2005; Yeh et al., 2009). Lines of constant ppERK inhibition are termed Loewe isoboles (Greco et al., 
1995) (IC20, IC50 and IC80 isoboles are shown in Fig. 5B). For non-interacting drugs, these 
isoboles are straight lines. If two inhibitors synergize, Loewe isoboles are concave, since lesser doses 
result in the same inhibitory effect. Convex isoboles indicate antagonism between inhibitors, because 
their combinations require increased doses to achieve the same inhibition. Importantly, these 
distinctive features of Loewe isoboles do not depend on the normalization method (any ICZ value 
can be used), or even absolute, non-normalized inhibitor doses can be plotted (see SI, section 6). The 
blue and green dose-response curves for separate inhibitors in Fig. 5A correspond to directions along 
the axes of the response plane in Fig. 5B, whereas different directions inside the plane correspond to 
different ratios of inhibitor doses in a combination, Fig. S5E. Different ratios result in different total 
doses for achieving the same ppERK inhibition. For each desired inhibition level (Z) there is a 
minimal total dose determined by an optimal ratio of drug doses, which together achieve the Z level 
of inhibition (a method for deriving optimal inhibitor ratios is given in SI, section 6.3). Therefore, the 
commonly used 1:1 ratio of normalized inhibitor doses can be suboptimal for desired inhibition 
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levels, which suggests that in preclinical studies, a two-dimensional plane of inhibitor doses might 
need to be analyzed. 
Whereas in BRAFV600E/WT RAS cells, a combination of CI/DI and CI/DO inhibitors does not 
show synergy (Fig S3J), this combination synergistically suppresses ERK activity in oncogenic RAS 
mutant, WT BRAF cells, Figs. 5A and Fig. S5C. The combined response shown in Fig. 5A 
corresponds to the 2.2:1 ratio of normalized doses of CI/DI and CI/DO inhibitors. The response 
plane in Fig. 5B shows that this ratio is optimal for achieving 80% inhibition of ppERK at the 
minimal total dose of both inhibitors (see SI, section 6 and Scheme S6.2). Following paradoxical 
ERK activity increase, the inhibitor combination becomes more effective than either inhibitor, 
starting at the doses around 1/2 of the IC50. For instance, when the sum of two inhibitor doses equals 
1 (i.e., when each inhibitor is added at 0.5 of its IC50), the ppERK level drops more than 2-fold, 
compared to the level when each inhibitor is applied separately at the IC50 dose. At the same time, 
this inhibitor combination failed to considerably reduce paradoxical activation, suggesting that other 
inhibitor type combinations need to be also analyzed.  
Synergy between CI/DI and CI/DO inhibitors strengthens when a CI/DO inhibitor has a low 
dissociation rate constant, koff, such as TAK-632 and AZ-628 with 1/koff ≥ 2 hrs (Hatzivassiliou et al., 
2010; Okaniwa et al., 2013). After this CI/DO inhibitor binds to inactive RAF monomers, it 
facilitates RAF dimerization and remains bound, because of its low koff. This leads to the 
accumulation of heterodimers where one RAF protomer is bound to a CI/DO inhibitor, whereas the 
other protomer is inhibitor-free (Kholodenko, 2015). An inhibitor-bound and kinase-inactive RAF 
protomer in a dimer allosterically transactivates the free RAF protomer, which then assumes an 
active DFG-IN conformation and has higher affinity for a CI/DI inhibitor than for the second CI/DO 
inhibitor molecule. Our modeling results demonstrate that lowering koff of a CI/DO inhibitor (while 
keeping the Kd value the same) markedly enhances synergy between CI/DI and CI/DO inhibitors 
(Fig. 5C) but does not considerably change the efficiency of this inhibitor as a single agent.  
Testing modeling predictions for oncogenic RAS mutant cells. To test model predictions, we 
conducted experiments in the MEL-JUSO (NRASQ61L/WT and HRASG13D/G13D) melanoma cell line 
(Figs. 5D-E and S5F-H). In these cells, we measured the dose-responses of active MEK and ERK to 
increasing doses of SB-590885 (CI/DI RAF inhibitor (Heidorn et al., 2010)) and sorafenib (CI/DO 
RAF inhibitor (Heidorn et al., 2010; Holderfield et al., 2014)) added separately or in combination. 
Experimental data allowed reconstruction of a substantial part of the dose-response plane across 
multiple inhibitor combinations (Figs. 5D and S5G). The data along the axes correspond to ppERK 
12 
 
responses to each inhibitor applied separately, also shown by blue and green dose-response curves in 
Figs. 5E and S5G. Responses to each inhibitor show marked paradoxical ERK activation, extending 
into the micromolar range for either inhibitor, while in in vitro kinase assays both inhibitors inhibit 
all RAF isoforms in the low nM range (King et al., 2006; Wan et al., 2004; Wilhelm et al., 2004). 
Because in mutant NRAS and HRAS MEL-JUSO cells, SB-590885 did not suppress ERK activity 
(in the dose range we used), we could not normalize inhibitor doses by commonly used IC50 levels, 
and plot responses versus absolute inhibitor doses. Therefore, for each ppERK response to a 
combination of SB-590885 and sorafenib shown on the dose-response plane in Fig. 5D, the total 
inhibitor dose is the sum of the absolute SB-590885 and sorafenib concentrations (that can be found 
by projections of the corresponding ERK response point onto axes). The concave shapes of the 
Loewe isoboles (lines of constant ppERK inhibition) in Figs. 5D confirm our model predictions, 
demonstrating marked synergy for the combination of SB-590885 with sorafenib. The optimal ratio 
of sorafenib to SB-590885 doses to achieve 75% ppERK inhibition was about 1.5:1. The section of 
the dose-response plane corresponding to this ratio is shown in Fig. 5E demonstrating that a 
combination of SB-590885 and sorafenib substantially inhibits ERK signaling in MEL-JUSO cells at 
the same total doses, for which either inhibitor on its own is unable to suppress ERK activity 
efficiently.  
When the number of data points across the two-dimensional plane of inhibitor doses is insufficient to 
reconstruct the Loewe isoboles, the combination index CI is commonly used to identify synergy or 
antagonism (Chou, 2006). For any particular drug combination ratio, the CI detects if at this ratio the 
Loewe isoboles will be concave (under a straight line of non-interacting drugs), in which case CI < 1, 
or convex (above this line), in which case CI > 1, see SI, section 6. Importantly, the classic metrics 
for assessing drug interactions, such as the Chou combination index or Loewe isoboles cannot apply 
to the range of doses, at which individual inhibitors and their combinations paradoxically activate a 
pathway. An objective measure of suppressing pathway signaling is the area under the dose response 
curves for each inhibitor taken separately and in combination (Kholodenko, 2015), see SI, section 6. 
Inserts to Fig. 5A, 5C and 5E demonstrate that this area and therefore, resistance to inhibition, 
substantially diminishes for a combination of CI/DI and CI/DO inhibitors.  
Combination of CI/DO and CO/DI RAF inhibitors. Next, in oncogenic RAS mutant cells we 
analyzed combinations of RAF inhibitors that preferably bind distinct orientations of both DFG 
motif and αC-helix. These drugs, and also inhibitors that preferentially bind only distinct αC-helix 
orientations, can potentially synergize in both BRAFV600E/WT RAS cells (Fig. 3 and S3) and in 
RAS mutant cells. Yet, model simulations show that the best combination for RAS mutant cells is a 
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pair of CI/DO and CO/DI inhibitors (Fig. 6A,B), whereas a pair of CI/DI and CO/DI inhibitors 
induces marked MEK/ERK paradoxical activation (Fig. S6A,B). Experiments in MEL-JUSO 
(NRASQ61L/WT, HRASG13D/G13D) and SKMEL2 (NRASQ61R/WT) cells, bearing an activating RAS 
mutations and WT BRAF, have collaborated modeling predictions that combinations of CO/DI and 
CI/DO inhibitors are more efficient than either of inhibitors alone (see Fig. 6C for ppERK dose-
responses in SKMEL2 cells treated with B0R (CO/DI), sorafenib (CI/DO) and their combination, 
and Fig. 6D for ppERK dose-responses in MEL-JUSO cells treated with vemurafenib (CO/DI), 
sorafenib (CI/DO) and their combination).  
In SKMEL2 cells, following marked paradoxical activation of ERK by B0R or sorafenib (a peak 
value of 8 to 10 times of the basal level), none of these drugs on their own could decrease the ppERK 
signal back to the basal level. The best inhibition was 250% of the basal level. Therefore, the drug 
doses were normalized by the doses corresponding to 250% activation (also referred to as IC-250). 
Fig. 6C shows that the dose-response curve for the combination of inhibitors is lower than the dose-
response curves of these inhibitors on their own. For example, although the maximal concentration 
of sorafenib and B0R each resulted in 2.5-fold higher activation of ERK than the basal level, when 
these drugs were combined, the same total dose reduced the ppERK signal more than 2.5-fold 
compared to each drug alone. Although this drug combination dramatically decreases paradoxical 
ERK activation, it fails to significantly decrease the basal ERK activity in SKMEL2 cells. Our 
simulations suggest that if a CO/DI inhibitor has a low koff  (e.g. LGX818 (Yao et al., 2015)), it will 
increase the residence time of this inhibitor binding to a RAF dimer, promoting binding of a CI/DO 
or a CI/DI inhibitor (Fig. 6C). This will increase synergy between inhibitors (Figs. 6A and 6B). 
Remarkably, decreasing koff for CI/DO and CI/DI inhibitors does not facilitate their potential synergy 
with a CO/DI inhibitor (Fig. S6G).  
Interestingly, vemurafenib applied in doses up to 50 μM could only activate ppERK in MEL-JUSO 
cells (Fig. 6C), as reported for other RAS-mutant cancer cells (Adelmann et al., 2016; Karoulia et al., 
2016). Sorafenib applied separately could only slightly inhibit ppERK at high doses (12 μM), 
following paradoxical activation. Remarkably, a combination of vemurafenib and sorafenib could 
effectively inhibit the ERK pathway (following paradoxical ERK activation) at the total doses over 8 
μM (5 μM vemurafenib and 3 μM sorafenib). In line with our model predictions, even RAF 
inhibitors, which on their own only activated ERK signaling, could inhibit the pathway when given 
in a proper combination.  
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Inhibition of oncogenic RAS signaling correlates with reduced cell proliferation and colony 
formation.   
A combination of CI/DO and CO/DI RAF inhibitors blocked oncogenic RAS signaling in MEL-
JUSO cells. Therefore, next we explored how these combinations affect cell proliferation and colony 
formation potential, which tests for the ability of a single cell to survive and grow into a colony. Both 
vemurafenib and sorafenib applied individually inhibited MEL-JUSO cell proliferation with the 
GI50 (a dose inhibiting cell proliferation by 50%) of 32 μM and 8 μM, respectively (Fig. 6E). At 1:1 
ratio, a combination of these drugs synergistically inhibited proliferation. When both drugs were 
combined at 50% of the corresponding GI50 dose, the combination inhibited the cell growth 2-fold 
more efficiently than each drug at its GI50 dose. Moreover, both drug synergy metrics, the CI and 
AUC, demonstrated a pronounced synergy between vemurafenib and sorafenib in inhibiting MEL-
JUSO cell proliferation (insert to Fig. 6E demonstrates that the CI for inhibition of proliferation was 
smaller than 0.6 over a range of doses). Likewise, a combination of vemurafenib and sorafenib 
synergistically inhibited colony formation in MEL-JUSO cells (Fig. 6F). Our data demonstrate that 
oncogenic RAS signaling, proliferation and the ability to form colonies were synergistically inhibited 
by a combination of CI/DO and CO/DI RAF inhibitors in MEL-JUSO cells (NRASQ61L/WT, 
HRASG13D/G13D).  
 
Combinations of RAF inhibitors suppress ERK signaling in cells bearing both 
oncogenic RAS and BRAFV600E mutations 
One of the common mechanisms of resistance to RAF inhibitors in BRAFV600E melanomas is the 
appearance of a secondary NRAS mutation in the ERK pathway (Johnson et al., 2015; Lito et al., 
2013; Nazarian et al., 2010). Some melanoma patients develop secondary malignancies from cells 
harboring pre-existing RAS mutations, whereas for others, RAS mutations frequently occur during 
treatments with BRAF inhibitors (Nazarian et al., 2010). Instructively, the model predicts that 
inhibitor combinations that synergistically suppress ERK signaling in RAS mutant cells also 
synergistically inhibit ppERK in co-mutated RAS and BRAF600E cells (Fig. 7A-D). This model 
prediction is explained by the enhanced RAF dimerization and the fact that emerging dimers can be 
effectively inhibited only by a combination of RAF inhibitors. A combination of a CI/DO inhibitor 
with a low koff CO/DI inhibitor is predicted to be particularly effective in suppressing ERK activity in 
these cells (Fig. 7C).  
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To test these predictions, we treated parental (BRAFV600E/WT/WT RAS) and vemurafenib resistant 
M249 (BRAFV600E/WT/NRASQ61K/WT) cells (Nazarian et al., 2010) with vemurafenib alone, sorafenib 
alone and the combination of these drugs. The data confirm that a combination of CI/DO and CO/DI 
inhibitors effectively suppresses ERK signaling in cells bearing both RAS and RAF oncogenic 
mutations (Fig. 7E). NRAS mutation results in about 3.5-fold increase in the basal ppERK level 
compared to parental cells (Fig. 7E). After treatment with 3 μM vemurafenib, the ppERK level in 
resistant M249 cells reaches the value equal to the basal level in the parental cells. Increasing the 
doses of vemurafenib from 3 to 10 μM does not substantially decrease the ppERK level in M249 
cells. Although resistant to vemurafenib, ERK signaling is effectively inhibited in these cells by a 1:1 
molar combination of vemurafenib and sorafenib starting from a total drug concentration of 3 μM. 
These results support model predictions. 
How robust are model predictions? The predictive power of our structure-based, dynamic model of 
ERK signaling and inhibitor – kinase interactions was tested against experiments and corroborated 
by the resulting data. Yet, a question arises of how robust these model predictions are, when we go 
beyond the possibilities of direct experimental testing. To answer this question, we carried out the 
sensitivity analysis of model-predicted drug interaction metrics to the changes in model parameters. 
We explored how the area under dose-response curves (AUC, an objective measure of pathway 
inhibition for a range of drug doses), and the Talalay-Chou combination index (CI) are sensitive to 
parameter changes, by calculating the response coefficients, 𝑅𝑝
𝐴𝑈𝐶 and 𝑅𝑝
𝐶𝐼. These response 
coefficients (also known as the control or sensitivity coefficients, see, e.g., (Kholodenko et al., 1987; 
Kholodenko et al., 1997; Kholodenko and Westerhoff, 1995)) determine the fractional change in the 
AUC and CI brought about by a small fractional change in a model parameter p, which in the limit of 
infinitesimal changes reads, 𝑅𝑝
𝑋 = lim((Δ𝑋/𝑋)/(Δ𝑝/𝑝)) = 𝑑 ln 𝑋 /𝑑 ln 𝑝 , 𝑋 = {𝐴𝑈𝐶, 𝐶𝐼}. Thus, 
𝑅𝑝
𝐴𝑈𝐶 and 𝑅𝑝
𝐶𝐼 are essentially equal the % changes in the AUC and CI caused by a 1% change in a 
parameter. If 𝑅𝑝
𝐴𝑈𝐶 and 𝑅𝑝
𝐶𝐼 are substantially smaller than 1, the model predictions are robust to the 
changes in the corresponding parameter.  
We explored robustness of model predictions for two types of drug resistant melanoma cells, 
harboring either oncogenic RAS mutations and WT BRAF (MEL-JUSO, SKMEL2) or bearing both 
oncogenic RAS and heterozygous BRAFV600E mutations (vemurafenib resistant M249 cells). Figs. 
7F-G and S7I-J illustrate the distribution of the response coefficients 𝑅𝑝
𝐶𝐼 and 𝑅𝑝
𝐴𝑈𝐶 to the parameter 
changes. Strong responses were induced by the changes in the parameters describing the kinase 
activity of RAF isoforms and formation of RAF dimers. These results are not surprising, because our 
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model suggests that the prerequisite to pronounced synergy between different types of RAF 
inhibitors is their cooperation to efficiently inhibit RAF homo- and heterodimers. For cells bearing 
both mutant oncogenic RAS and heterozygous BRAFV600E, the largest responses were induced by 
changing the kinase activity of semi-inhibited (harboring only one RAF inhibitor molecule) 
BRAFV600E homo-dimers. The AUC and CI decreased by about 0.6% (corresponding to a 0.6% 
increase in drug synergy) with the increase in this kinase activity by 1%. Likewise, synergy between 
CO/DI and CI/DO RAF inhibitors was also controlled by (i) the thermodynamic factors that quantify 
the facilitation of RAF dimerization by inhibitors, (ii) the parameter describing a decrease in the 
apparent Kd’s of RAF homo-/heterodimerization due to the spatial co-localization of both RAF 
molecules bound to RAS-GTP, and (iii) the affinities of BRAFV600E binding to RAS-GTP and 
BRAFV600E dimerization  and the parameters describing decreases in these affinities following 
RAF feedback phosphorylation by active ERK (Fig. 7 and S7). The most sensitive responses to the 
protein abundance changes were found for the abundances of mutant BRAFV600E, ERK, and 
oncogenic RAS.  
Cells bearing oncogenic RAS mutations and WT BRAF exhibited a similar distribution of CI and 
AUC responses to parameter changes (excluding those related to BRAFV600E). In the absence of 
BRAFV600E, the CI and AUC were sensitive to the parameters describing (i) the spatial co-
localization effects on the affinities of BRAF and CRAF dimerization and binding to RAS-GTP, (ii) 
decreases in these affinities following RAF feedback phosphorylation by active ERK, and (iii) BRAF 
abundance and its (de)phosphorylation on S365. Similar as above, synergy between CO/DI and 
CI/DO RAF inhibitors was also strongly controlled by the thermodynamic factors that quantify the 
facilitation of RAF dimerization by inhibitors and, additionally, by potential cooperativity between 
IN/OUT transitions of the DFG-motif and the αC-helix (see Section 3, SI). Also, in the absence of 
strong signaling by mutant BRAFV600E monomers, the parameters that affect the signal transfer 
between MEK and ERK (such as the abundances of MEK and ERK phosphatases) more substantially 
influence drug synergy for oncogenic RAS and WT BRAF cells than for double RAS and 
BRAFV600E mutant cells.  The absolute sensitivity values of the AUC and CI to the remaining 
parameters were smaller than 0.2, Fig. 7 and S7. We, therefore, conclude that our model predictions 
are robust and the highest sensitivities to parameter changes can be predicted by their influence on 
the RAF dimer formation.   
 
DISCUSSION 
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Intrinsic or acquired resistance to kinase inhibitors, including RAF inhibitors in melanoma and other 
cancers remains a pressing clinical problem. While different combinations of kinase inhibitors are 
routinely tested in clinical trials, it is unclear how the best combinations can be chosen. A plethora of 
confounding factors, including allosteric drug–kinase interactions, phosphorylation-induced 
conformational changes and kinase dimerization, multiple feedback loops and diverse cell mutational 
and expression profiles hamper intuitive reasoning about optimal drug combinations. Understanding 
each drug’s mode of action and the mode of their combined actions at the network level would 
enable a systematic and robust design of the best combinations. Different dynamics of 
phosphorylation responses to inhibitors that preferentially bind to active or inactive conformations 
were previously reported (Kleiman et al., 2011). To describe the experimental data the authors 
designed a simplified kinetic model that correlates changes in phosphorylation of the EGFR with 
drug binding without elaborating the underlying molecular mechanisms. Here we present a next-
generation pathway model that allows mechanistic and predictive analysis by dynamically 
integrating thermodynamics and kinetics of drug interactions, structural elements, PTMs, mutational 
status and pathway regulation. This model unravels salient features of the systems-level dose-
responses to different types of RAF inhibitors that show similar inhibition of isolated RAF kinases, 
but preferentially bind to alternative conformations of the DFG motif and αC-helix adopted by RAF 
kinases as a result of different oncogenic activation mechanisms. Previous attempts of predicting 
dose-responses failed (Costello et al., 2014; de Gramont et al., 2015; Prasad, 2016; Saez-Rodriguez 
et al., 2015), because both the employed network models and machine learning methods could not 
embrace highly dynamic nature of allosteric interactions of structurally different drugs with multiple 
kinase conformations governed by thermal motions and posttranslational modifications (Nussinov et 
al., 2013). The type of next-generation models presented here can be instrumental in the future 
analysis of mechanisms of drug actions and the design of efficacious combinations. For instance, this 
approach could be extended to optimize combinations of RAF and MEK inhibitors. 
Although our model explores RAF inhibitor combinations, it is based on general principles 
applicable to any kinases that undergo dimerization during activation (Bessman et al.). The model 
makes a surprising prediction that two drugs targeting the same protein pocket can synergize, while 
normally they would compete, as known from enzyme kinetics. However, a reason for potential 
synergy is asymmetry of protomer conformations that is induced by PTMs and/or binding of the first 
inhibitor molecule to a dimer (Jambrina et al., 2016; Kholodenko, 2015). These unexpected results 
would not have been discovered without mathematical and structural modeling, accounting for the 
asymmetry of protomer conformations in a kinase dimer. The model precisely predicts for which 
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mutational profiles and which drugs will preferentially bind different protomers in a kinase dimer 
and together completely inhibit these dimers. This suggests an alternative principle that two 
structurally different inhibitors, which target the same kinase, but in different conformations, can be 
synergistic.   
Different mechanisms of intrinsic or acquired resistance in melanoma have a common feature of the 
increased abundance of RAF dimers. Moreover, recent clinical sequencing of 10,000 metastatic 
cancers (Zehir et al., 2017) not only revealed the relatively common co-occurrence of NRAS and 
BRAF mutations that increase RAF dimerization, but also BRAF in-frame deletions, which produce 
isoforms predicted to enable RAS-independent BRAF dimerization similar to the BRAF splice 
variants previously associated with acquired resistance to vemurafenib (Poulikakos et al., 2011). 
Whereas pharmacological research concentrated on creating RAF inhibitors that do not induce RAF 
dimers and thereby avoid paradoxical ERK activation (Zhang et al., 2015), our model suggested 
exploiting structural and thermodynamic features of dimer-drug interactions to completely inhibit 
RAF dimers. Based on model predictions, we showed that both BRAFV600E monomers and RAF 
dimers are best inhibited together by specific combinations of RAF inhibitors, even when each 
inhibitor is ineffective on its own. Importantly, the total dose of two combined drugs is considerably 
smaller than the dose of each inhibitor, which could substantially reduce toxicity resulting from off-
target effects.   
Experiments corroborate model predictions. In cancer cells bearing BRAFV600E mutation and WT 
RAS (A375 cell line, Fig. 3), BRAFV600E and NRAS Q61K co-mutations (resistant M249 cell line, 
Fig. 7) or oncogenic RAS and WT BRAF (MEL-JUSO cells, Fig. 6), a combination of CI/DO and 
CO/DI inhibitors showed pronounced synergy, effectively inhibiting ERK activation. The results 
suggest that for mutant BRAFV600E-driven cells, adding a CI/DO inhibitor (e.g., sorafenib, AZ-628, 
TAK-632, LY3009120) to a standardly used CO/DI inhibitor (vemurafenib, dabrafenib or 
encorafenib) can be beneficial not only because of more effective inhibition of ERK signaling in WT 
RAS cancer cells, but also because of synergistic inhibition of signaling in pre-existing or emerging 
resistant cancer cell clones with both BRAFV600E and RAS mutations. For these mutational 
profiles, especially for cells with mutant BRAF600E and WT RAS, a combination of CI/DI and 
CI/DO inhibitors is predicted to show additive rather than synergistic effects (Figs. S3J and S7). 
Almost counterintuitively, the model predicts, and experiments confirm that the same combination of 
CI/DI and CI/DO inhibitors is markedly synergistic in oncogenic RAS mutant cells with WT BRAF 
(MEL-JUSO cells, NRASQ61L/WT and HRASG13D/G13D), Figs. 5 and Fig. S5. The combinations of 
RAF inhibitors described above can also be effective in suppressing RAF/ERK signaling in cells 
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with other mechanisms of resistance, such as CRAF/BRAF overexpression and BRAF splicing 
variants that enable RAS-independent BRAF dimerization (see SI, section 8 and Figs. 7F-7H). 
Summarizing, although in cells bearing oncogenic RAS mutations, individual RAF inhibitors are 
commonly ineffective, proper combinations of RAF inhibitors with particular modes of action 
efficiently inhibit ERK signaling. Biologically, this effective ERK inhibition is accompanied by a 
synergistic suppression of proliferation and colony formation in MEL-JUSO cells (Fig. 6).  
Similarly, modeling can also address the open question whether RAF inhibitors increase the affinity 
of RAF kinases for RAS. RAF inhibitors increase the amount of RAS-RAF complexes 
(Hatzivassiliou et al., 2010; Karoulia et al., 2016), which was interpreted as the facilitation of RAF 
binding to RAS-GTP by these drugs. Although this explanation is plausible, structural evidence is 
lacking. Moreover, the model demonstrates that allosteric inhibitor effects resulting in enhancement 
of RAF dimerization can fully explain the increase in RAS-RAF complexes without an assumption 
that RAF inhibitors increase RAF affinities for RAS-GTP (Fig. S7E). Because each of the RAF 
protomers in a RAF dimer is bound to RAS in the narrow layer near the membrane, the apparent 
affinity of RAF for RAS increases due to spatial localization effects. Also, recent data on RAS 
dimerization (Nan et al., 2015) suggest that the increase in the apparent affinity of RAF for RAS can 
be explained by spatial localization. To further illustrate the interconnection between RAF 
dimerization and RAF binding to RAS, we developed a toy model (see SI, section 7) that shows how 
spatial localization effects result in an inhibitor-induced increase in the RAS-RAF complexes.  If the 
structural mechanisms for the RAF dimerization-independent induction of RAS-RAF interactions are 
elucidated, these mechanisms can be readily incorporated into the model.  
In summary, the type of next generation dynamic model presented here can address salient issues in 
drug targeting as well as help discover new aspects of drugs mode of action. These insights can be 
exploited to rationally design drug combinations that would be difficult to find through trial-and-
error approach. 
 
Materials and Methods 
RAF inhibitors 
Vemurafenib (PLX4032) was obtained from Selleckchem (Cat No. S1267). Sorafenib tosylate and 
SB-590885 were purchased from Axon Medchem (Axon 1397) and R&D Systems (2650/10), 
respectively. B0R (2,6-difluoro-N-(3-methoxy-2H-pyrazolo[3,4-b]pyridin-5-yl)-3-[(propylsulfonyl) 
amino]benzamide) (Wenglowsky et al., 2011) was kindly provided by Genentech. All inhibitors 
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were dissolved in DMSO to yield 10 mM stocks and stored at -20oC. 
Cell culture 
Cell lines were either purchased from ATCC (SKMEL2, A375) or DSMZ (MEL-JSUO). M249 cells 
and the isogenic Vemurafenib-resistant cell line M249R were kindly provided by Antoni Ribas 
(Nazarian et al., 2010). All cells were grown in RPMI (Gibco) supplemented with 2 mM L-glutamine 
and 10% (v/v) fetal bovine serum in a humidified atmosphere of 5% CO2 at 37
oC. Cells were seeded 
in 12-well plates (Greiner CELLSTAR dishes) at the density of 105 cells per well. After reaching 
sufficient confluency, cells were treated with different concentrations of inhibitors and DMSO as 
control as indicated. To prepare the protein lysates, plates were transferred on ice, washed with ice-
cold PBS and harvested by scraping in specific ELISA buffers as indicated below.  
MSD Multi-Spot Assay ELISA System: 
ERK and MEK activation was assessed by ELISA using the MESOSCALE MSD Phospho/Total 
ERK1/2 assay whole cell lysate Kit [phospho(Thr202/Tyr204; Thr185/Tyr187)/Total ERK1/2 Assay 
Whole Cell Lysate Kit, K15107D] or MEK kit [Phospho(Ser217/221)/Total MEK1/2 Assay Whole 
Cell Lysate Kit, K15129D] according to the manufacturer’s instructions. Briefly, following the 
addition of complete MSD lysis buffer and scraping the cells from the surface of the dish, the cellular 
debris was removed from the lysate by centrifugation at 10000xg at 4oC for 10 min. Protein 
concentration was determined using the BCA test according to the manufacturer’s instructions 
(Pierce™ BCA Protein Assay Kit). Lysates were adjusted to 0.1g/L protein concentrations for 
ERK kit and 0.8 g/mL for MEK kit and relative MEK and ERK activation assessed according to the 
manufacturer’s instructions using the MSD Sector Imager 2400 (model 1250).  
xMAP assays: 
Following the addition of complete Luminex lysis buffer and scraping the cells from the surface of 
the dish, the cellular debris was removed from the lysate by centrifugation at 10000xg at 4oC for 
10 min. The pellet was discarded and the protein concentration of lysates was adjusted to 0.3 g/L 
using the BCA assay kit. xMAP assays were performed on a Luminex-3D platform (Luminex, 
Austin, TX) using commercially available phosphoprotein antibody-coupled beads (ProtATonce, 
Athens, Greece). A custom multiplex phosphoprotein assay was used to determine the levels of test 
phosphoproteins in cell lysates: dual specificity mitogen-activated protein kinase kinase-1 (MEK1) 
with phosphorylation site S217/S221, and extracellular signal-regulated kinase-1 (ERK1) with 
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phosphorylation site T202/Y204. Additionally, for loading control the levels of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) protein were analyzed in a separate setting. Custom antibody-
coupled beads were technically validated as described before (Poussin et al., 2014). 
Western blot: 
Cells were transferred on ice, scraped using lysis buffer (10mM Tris pH 7.5, 150mM NaCl, and 
0.5% (v/v) NP-40) complemented with protease and phosphatase inhibitors, and the cellular debris 
removed from the lysate by centrifugation at 10,000xg at 4oC for 10 min. Protein concentration was 
determined using the BCA test according to the manufacturer’s instructions (Pierce™ BCA Protein 
Assay Kit). Lysates were then resolved by SDS PAGE (12%) and transferred on a polyvinylidene 
difluoride membrane (Millipore). Protein visualization was performed in combination with 
horseradish peroxidase–conjugated secondary antibodies (Cell Signalling Technologies) and the 
enhanced chemiluminescence system (GE Healthcare) using the Advanced Molecular Vision Chemi 
Image Unit associated with ChemoStar Imager (INTAS Science Imaging Instruments GmbH) for the 
following antibodies: Polyclonal rabbit anti-human mitogen-activated protein (MAP) kinase [extra-
cellular signal-regulated kinase (ERK) 1 and ERK2] antibody (Sigma), monoclonal mouse anti-
human MAP kinase activated (diphosphorylated ERK1 and ERK2) antibody (Sigma).  
Cell proliferation assay 
Cell proliferation was analyzed by CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
(MTS; Promega) according to manufacturer’s instructions. For this, 5,000 cells were plated per well 
of 96-well tissue culture plates (in 200 μL of medium). Proliferation and viability of inhibitor- and 
control-treated cells was assayed after 96 hrs. The results represent the mean ±SD of triplicate 
samples, expressed as a percentage of control.  
Colony formation assay  
For colony formation assay, 1,000 cells per well were seeded into 6-well plates and on the next day 
drug treatments were performed. Two weeks after the treatment, cells were fixed and stained using 
the Fixing / Staining solution (Crystal Violet (0.05% w/v), Formaldehyde (1%), PBS (1X), Methanol 
(1%)). Washed and air dried dishes were scanned and analysed by eye and using Clono-Counter 
software package (Niyazi et al., 2007). 
Molecular Dynamics Simulations.  
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We previously modeled the ATP-pBRAF homodimer using atomistic molecular dynamics (MD) 
simulations (Jambrina et al., 2016). We run longer simulation and analyzed the dynamic adjustment 
of the αC-helix position by defining the  angle via the C and N terminal residues of the αC-helix 
(C atoms of Q493 and T508), the anchoring αF-helix (C atom of A641).  
Our initial conformation for the molecular dynamics (MD) simulation was based on the PDB 
structures 4E26 (Qin et al., 2012) corresponding to the active forms of the BRAF kinase domain. The 
ATP and the two Mg2+ ions were docked in the active site based on the 4DFX structure (Bastidas et 
al., 2012). The initial coordinates of the missing residues (439-447, and 604-609) were modeled 
using the M4T server (Fernandez-Fuentes et al., 2007a; Fernandez-Fuentes et al., 2007b; Rykunov et 
al., 2009). The homodimer system included a short, 20 amino acid-long substrate-like peptide (SP20 
(Bastidas et al., 2012)) bound in the active site of each monomer. The ATP-pBRAF homodimer has 
the following phosphorylated activating residues: S446 in the NtA motif, T599 and S602 in the 
activation loop, and S579 in the catalytic domain. The initial model was essentially symmetrical, the 
all-atom RMSD between the protomers was 0.07 Å and the dimer interactions are remarkably similar 
(all-atom RMSD = 0.7 Å obtained for the alignment of the dimer but with the positions of the 
protomers inter-switched). 
The simulation was performed using explicit water with the CHARMM-27 force field (MacKerell et 
al., 1998; Mackerell et al., 2004) at constant temperature (298 K) and pressure (1 bar). Langevin 
dynamics was used with a Langevin damping coefficient of 1 ps-1. For long range electrostatics 
treatment, the non-bonded switching distance was set to 10 Å and a cut off distance of 12 Å was 
used. The ShakeH algorithm (Ryckaert et al., 1977) was used with 2 fs time steps. The trajectory was 
saved every 0.2 ns. 
Mathematical model.  
The RAS/RAF/MEK/ERK pathway mathematical model was formulated using a rule-based 
approach (Chylek et al., 2014), in which protein-protein interactions are represented by rules. Each 
rule is associated with a rate law and defines a class of reactions related by a common 
transformation. The model was specified using BNGL, a formal language for writing rule-based 
models (Faeder et al., 2009). The model specification file, supplied in electronic format in the 
supplemental online material, was processed by the BioNetGen software package (Blinov et al., 
2004; Harris et al., 2016) to derive the reaction network and the corresponding system of coupled 
ordinary differential equations (ODEs) implied by the rules. The ODEs were numerically integrated 
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using BioNetGen’s default algorithmic parameter settings and interface to CVODE in the 
SUNDIALS software package (Hindmarsh et al., 2005). Sensitivity coefficients of the model-
predicted drug interaction metrics (CI and AUC) were calculated as the fractional change in the AUC 
or CI divided by the fractional parameter change (variation of the parameter change between 1 and 
5% practically did not affect the sensitivity values).  
Methods to assess additivity, synergy or antagonism between two drugs are presented in SI, 
section 6. Details of activating and inhibiting phosphorylation sites for each protein in the model, 
kinetic, thermodynamic and spatial localization parameters are provided in the SI.   
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Figure legends  
Fig. 1. Asymmetry of BRAF homodimers. (A) Definitions of the αC-helix angle (ω) IN (ω > 54o) 
or OUT (ω < 52o) positions (Jambrina et al., 2014) as well as the DFG-motif IN (d < 7 Å) or OUT (d 
> 9.5 Å) conformations via the L505-F595 distance (d). The structure is illustrated using the PDB 
structure 3TV4. (B) Molecular dynamics simulation showing that the αC-helix positions of two RAF 
protomers in a dimer dynamically adjust to asymmetric positions in BRAF homodimers (blue – αC-
IN, red – αC-OUT). (C) Distribution of the αC-helix conformations in 92 BRAF kinase domain 
protomers based on the analysis of 46 BRAF dimer structures deposited in PDB. (Insert) Distribution 
of the αC-helix positions in BRAF dimers with only one inhibitor molecule bound, based on 6 PDB 
structures: 3OG7, 3Q4C, 4FK3, 4H58, 4XV1, 4XV3. (D) Distribution of the αC-helix and DFG 
motif conformations in the 90 BRAF protomers analyzed. Among 45 analyzed RAF dimer PDB 
structures, 6 of the structures contain only 1 inhibitor molecule, and the rest have two inhibitors 
molecules bound to the dimer. See also Figure S1. 
Figure 2. Rule-based modeling of binding and phosphorylation reactions and concomitant 
conformational changes of RAF kinases. (A) Illustration of rules governing RAF binding to RAS 
and RAF activation and dimerization cycles. Protein domains and phosphosites that are 
phosphorylated (p) or dephosphorylated are shown by rectangles.  Switch is the RAS switch domain. 
RBD and DIM are the RAS-binding and dimerization domains; bI and cI are the inhibitor binding 
sites on BRAF and CRAF. The domains that are bound in a protein complex are colored. In the S338 
rectangle the asterisk (*) indicates that the S338 phosphorylation state does not influence the CRAF 
association/dissociation reactions with RAS-GTP, whereas the rates of those reactions are affected 
by the states of the RAF residues (pS642 and pT753) that are phosphorylated by ERK. 
(B) Simplified BRAF-CRAF (B-C) dimerization cycle and allosteric inhibitor (I) interactions with 
RAF monomers and dimers. (C) The reaction of inhibitor (I) binding to BRAF (reaction 2) is 
expanded into 12 reactions that take into account possible positions of the DFG-motif and αC-helix. 
See also Figure S2. 
Figure 3. Combination of CO/DI and CI/DO drugs synergistically inhibits the ERK pathway in 
cells bearing BRAFV600E mutation and WT RAS. (A) Model-predicted responses of MEK 
signaling to CO/DI and CI/DO inhibitors and their combinations in cells with homozygous 
BRAFV600E mutation. [RAS-GTP]=25 nM, [BRAFV600E]=50 nM, [BRAFWT]=0, basal ppMEK 
level is 609 nM. (B) MEK signaling responses of growing A375 (WT RAS, BRAFV600E/V600E) cells to 
B0R and sorafenib and their combination measured using MESOSCALE system, 1 hr, IC50 of B0R 
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is 0.075 μM, IC50 of sorafenib is 44 μM, in a combination the ratio of B0R and sorafenib is 1.2:1. 
(C-D) Simulated responses of ERK signaling to CO/DI and CI/DO inhibitors and their combination 
are presented for cells with heterozygous BRAFV600E mutation. The residence times 1/koff of 
CO/DI inhibitor are 1 s (C) and 104 s (D). [RAS-GTP]=25 nM, [BRAFV600E]=25 nM, [BRAFWT]=25 
nM, basal ppERK level is 1363 nM. (A, C-D) In each combination, the ratio of CO/DI and CI/DO 
inhibitor doses is 1.2:1. The remaining parameters are given in Lists S4.1 and S5.1 in SI. In each 
panel, the insert assesses drug synergy using the Talalay-Chou combination index (CI). See also 
Figure S3. 
Figure 4. A combination of dabrafenib and trametinib shows antagonism in cells harboring 
oncogenic RAS mutation and WT BRAF. (A) Simulated responses of ERK signaling to individual 
drugs and their combination. Inhibitor doses are normalized by IC50. [RAS-GTP]=250 nM, 
[BRAFWT]=50 nM, [BRAFV600E]=0, basal ppERK level is 480 nM. The ratio of CO/DI RAF 
(dabrafenib) and MEK inhibitor (trametinib) normalized doses applied in combination is 1:6.4. (B) 
ERK signaling responses of growing MEL-JUSO cells (NRASQ61L/WT, HRASG13D/G13D, BRAFWT/WT) 
to dabrafenib (CO/DI RAF inhibitor), trametinib (MEK inhibitor) and their combination measured 
using Western Blot, 1 hr. See also Figure S4. 
Figure 5. Combination of CI/DI and CI/DO inhibitors synergistically inhibits the ERK 
pathway in cells harboring oncogenic RAS mutations and WT BRAF. (A-C) Simulated 
stationary responses of ERK signaling to individual drugs and their combinations. The residence 
time toff ~1/koff of CI/DO inhibitor is 1 s (A-B) and 10
4 s (C). Inhibitor doses are normalized by IC50, 
the total doses shown for the combination correspond to the optimal ratios of CI/DI and CI/DO 
doses. [RAS-GTP]=250 nM, [BRAFV600E]=0, [BRAFWT]=50 nM, basal ppERK level is 480 nM, the 
ratios of CI/DI and CI/DO inhibitor doses applied in combination are 2.2:1 (A) and 2.6:1 (C). (D-E) 
ERK signaling responses of growing MEL-JUSO cells (NRASQ61L/WT, HRASG13D/G13D, BRAFWT/WT) 
to SB-590885 (CI/DI), sorafenib (CI/DO) and their combination measured using LUMINEX system, 
24 hr. In a combination, the ratio of SB590885 to sorafenib is 1:1.5. The ppERK responses are 
plotted vs the absolute concentrations of inhibitors applied separately and vs the sum of absolute 
concentrations for their combination. Areas under the dose-response curves that assess efficiency of 
inhibitor combination are presented as inserts (A, C, E). See also Figure S5.  
Figure 6. Combination of CI/DO and CO/DI inhibitors synergistically inhibits ERK signaling, 
proliferation, and colony formation in cells bearing oncogenic RAS mutations and WT BRAF. 
(A, B) Simulated responses of ERK signaling to CO/DI and CI/DO inhibitors and their combination. 
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The residence time toff ~1/koff of a CO/DI inhibitor is 1 s (A) and 10
4 s (B). Inhibitor doses are 
normalized by IC50, the total doses shown for the combination correspond to the optimal dose ratio 
that is nearly 1:1. [RAS-GTP]=250 nM, [BRAFV600E]=0, [BRAFWT]=50 nM, basal ppERK level is 
484 nM. (C) ERK signaling responses of growing SKMEL2 (NRASQ61R/WT, BRAFWT/WT) to B0R 
(CO/DI), sorafenib (CI/DO) and their combination measured using MESOSCALE system, 24 hr 
treatment. Doses are normalized by the doses that correspond to 250% of the basal ppERK level 
(20.7 μM for B0R and 5 μM for Sorafenib). This was the minimal ppERK level, reached by either 
inhibitor following paradoxical ERK activation. The ratio of B0R and sorafenib applied in 
combination is 1:1. (D, E) ERK signaling (D) and cell proliferation (E) responses of growing 
MEL-JUSO cells (NRASQ61L/WT, HRASG13D/G13D, BRAFWT/WT) to vemurafenib (CO/DI), sorafenib 
(CI/DO) and their combination measured using MESOSCALE system, 24 hr treatment. Doses are 
normalized by GI50 levels, i.e. by the levels of 50% inhibition of cellular growth. The ratio of 
vemurafenib and sorafenib applied in combination is 1:1. (E) Error bars are calculated using 4 
biological replicates. The Talalay-Chou combination index (CI) assessing drug synergy in inhibiting 
cell proliferation is shown as insert. Areas under the dose-response curves (AUC) that assess 
efficiency of inhibitor combinations are presented as inserts (A-E). (F) Colony formation of 
MEL-JUSO cells treated with vemurafenib (VEM) and sorafenib (SOR) applied separately and in 
combination, a representative of 3 biological replicates. See also Figure S6.  
Figure 7. Combinations of RAF inhibitors can synergistically inhibit ERK signaling in cells 
bearing both oncogenic RAS and BRAFV600E mutations. (A-D) Model-predicted stationary 
responses of ERK signaling to CI/DO and CO/DI inhibitors and their combinations. The residence 
time toff ~1/koff of a CO/DI inhibitor is 1 s (A) and 10
4 s (C), and the residence time of a CI/DO 
inhibitor is 1 s (B) and 104 s (D). Inhibitor doses are normalized by IC50. In combinations, the ratio 
of CO/DI and CI/DO inhibitor doses are 1:1 (A, C), the ratios of CI/DI and CI/CO inhibitor doses are 
6:1 (B) and 5:1 (D). [RAS-GTP]=250 nM, [BRAFV600E]=25 nM, [BRAFWT]=25 nM, basal ppERK 
level is 2151 nM. (E) ERK signaling responses to vemurafenib (CO/DI), sorafenib (CI/DO) and a 
combination measured using MESOSCALE system, 24 hr treatment for growing parental 
(BRAFV600E/WT/WT RAS) and resistant (BRAFV600E/WT/NRASQ61K/WT) M249 cells. The ppERK 
response is plotted vs the absolute concentrations of inhibitors applied separately and vs the sum of 
absolute concentrations for combinations, in which the ratio of vemurafenib and sorafenib doses is 
1:1. (A-E) Inserts assess drug synergy using the Talalay-Chou combination index (CI). 
(F-G) Sensitivity analysis of the Talalay-Chou combination index (CI). The response coefficients of 
the CI (calculated for 50% inhibition of ERK signaling) to a change in each model parameter are 
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determined for a combination of CO/DI (inhibitor a) and CI/DO (inhibitor b) RAF inhibitors for cells 
bearing both oncogenic RAS and BRAFV600E mutations (F) or only oncogenic RAS and WT 
BRAF (G). The CI is most sensitive to the changes in: (F) BRAFV600, ERK, and oncogenic RAS 
abundances (cyan ); Spatial co-localization of RAF and RAS-GTP (yellow ); BRAFV600E 
affinities for dimerization and RAS-GTP and the decrease in these affinities after ERK feedback 
phosphorylation of RAF (magenta ); Facilitation of RAF dimerization by inhibitors (green ); 
Kinase activity of semi-inhibited BRAFV600E homo-dimers (red ); (G) BRAF abundance and 
kinetic parameters of BRAF (de)phosphorylation on S365 (cyan  ); Parameters of signal transfer 
between MEK and ERK (dark-purple ); Decrease in RAF affinity for RAS-GTP after RAF is 
phosphorylated by ERK (magenta ); Spatial co-localization of RAF and RAS-GTP (yellow ); 
Thermodynamic factors describing (i) facilitation of RAF dimerization by inhibitors and (ii) 
cooperativity between IN/OUT transitions of DFG-motif and αC-helix in BRAF (green ); Kinase 
activity of RAF dimers (red ). 
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Table S1 related to Figures 1 and 2. Summary of the structural properties of RAF inhibitors 
Type of 
inhibitor 
Orientation 
of αC-helix 
Orientation 
of DFG-motif 
Abbreviation Examples of inhibitors 
I IN IN CI/DI SB590885, GDC-0879 
I½ OUT IN CO/DI 
vemurafenib, B0R, dabrafenib, 
LGX818 
II IN OUT CI/DO 
sorafenib, AZ-628, TAK-632, 
LY3009120 
  
5 
 
Supplemental Figures 
Figure S1 related to Figure 1. (A) Overlay of two structures, one of which is αC-helix-IN (4YHT, blue 
color), and the other is αC-helix-OUT (3TV4, red color). The αC-helix angle ω, which defines IN (ω > 
54o) or OUT (ω < 52o) positions is highlighted in blue and red. (B) Overlay of the 46 BRAF dimer 
structures analysed showing the αC-helix IN and OUT in blue and red respectively.  (C) Overlay of two 
structures one of which is DFG-IN (4YHT, blue color) and the other is DFG-OUT (4DBN, red color). 
The L505-F595 distance, which defines IN (d < 7 Å) and OUT (d > 9.5 Å) conformations, is depicted in 
blue and red lines, respectively. (D) Overlay of the 45 BRAF dimer structures analysed showing the DFG 
IN (blue) and OUT (red) (3C4C was not included because it has a different DFG conformation). (E) 
Distribution of the DFG conformations in 90 BRAF kinase domain protomers based on the analysis of 45 
BRAF dimer structures deposited in PDB.  
Figure S2 related to Figure 2. Kinetic schemes of the rules governing: (A) CRAF binding to RAS and 
CRAF activation cycle; (B) BRAF binding to RAS and BRAF activation cycle; (C) Influence of ERK 
feedback phosphorylation on binding of RAF kinases to RAS; (D) RAF hetero-dimerization cycle; (E) 
Influence of ERK feedback phosphorylation on CRAF-BRAF hetero-dimerization. Protein domain 
designations are the same as in Fig. 2. Parameter notations on the arrows are explained in the SI, sections 
1 and 2, see also List S5.1.  
Figure S3 related to Figure 3. (A-F) Model-predicted relative contribution of kinase activity of RAF 
monomers and dimers into the total RAF kinase activity during treatment with CO/DI (A, D), CI/DO (B, 
E) and CI/DI (C, F) inhibitors and in the absence of inhibitors (inserts) for cells with heterozygous (A-C) 
and homozygous (D-F) BRAFV600E mutation and WT RAS. (G-J) Model-predicted response of MEK 
and ERK signaling to: CO/DI and CI/DO inhibitors and their combination (G, I), CI/DI and CO/DI 
inhibitors and their combination (H), and CI/DI and CI/DO inhibitors and their combination (J) in cells 
with homozygous (G) and heterozygous (H-J) BRAFV600E mutation. Inhibitor doses are normalized by 
IC50. The residence time 1/koff of CO/DI and CI/DI inhibitors is 1 s. The residence times 1/koff of CI/DO 
inhibitor are 1 s (B, E, G, J) and 104 s (I). In each combination, the ratio of CO/DI and CI/DO inhibitor 
doses is 1.2:1, the ratio of CI/DI and CO/DI inhibitor doses is 1.2:1, and the ratio of CI/DI and CI/DO 
inhibitor doses is 1.2:1. Parameters for (A-C) and (H-J) are: [RAS-GTP]=25 nM, [BRAFV600E]=25 nM, 
[BRAFWT]=25 nM. Parameters for (D-F) and (G) are: [RAS-GTP]=25 nM, [BRAFV600E]=50 nM, 
[BRAFWT]=0 nM.  The remaining parameters are given in Lists S4.1 and S5.1 in SI. In panels (G-J), the 
inserts assess synergy, additivity or antagonism, using the Talalay-Chou combination index (CI). 
Figure S4 related to Figure 4. Predictive simulations of Loewe isoboles demonstrate antagonism rather 
than synergy of inhibiting ERK signaling by combinations of CO/DI RAF inhibitor and MEK inhibitor in 
cells bearing oncogenic RAS and WT BRAF (cf. Figs. S5 and 5). [RAS-GTP]=250 nM, [BRAFV600E]=0, 
[BRAFWT]=50 nM, basal ppERK level is 480 nM.  
Figure S5 related to Figure 5. (A-E) Model predicted stationary responses to CI/DI and CI/DO 
inhibitors and their combination of: (A) CRAF phosphorylation on S259 and S338; (B) RAF 
heterodimers bound with two molecules of RAF inhibitor; (C) MEK signaling; (D-E) ERK signaling. (C) 
Talalay-Chou index for MEK and ERK inhibition is presented on the insert. [RAS-GTP]=250 nM (A-E), 
[RAS-GTP]=100 nM (D), [BRAFV600E]=0, [BRAFWT]=50 nM, basal ppERK levels are 480 nM (A-E) and 
279 nM (D), the ratio of CI/DI and CI/DO inhibitor doses applied in combination is 2.2:1 (A-E). (F-I). 
ERK (F-G, I) and MEK (H) signaling responses in growing MEL-JUSO (NRASQ61L/WT, HRASG13D/G13D, 
BRAFWT/WT) cells to SB-590885 (CI/DI), sorafenib (CI/DO) and their combination, which are measured 
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using MESOSCALE (F) and LUMINEX (G-H) systems, and Western Blot (I), 24 hr. The Western Blots 
(I) are taken from a single membrane which was obtained using multistrip western blotting (Aksamitiene 
et al., 2007). For inhibitor combinations, the ratio of SB590885 to sorafenib is 1:1.5. The ppERK 
responses are plotted vs the absolute concentrations of inhibitors applied separately and vs the sum of the 
absolute concentrations for their combination. 
Figure S6 related to Figure 6. Model-predicted responses of MEK (B-C, E-F) and ERK (A, D, G) 
signaling to CI/DI, CO/DI inhibitors and their combination (A-B, D-E) and to CO/DI, CI/DO inhibitors 
and their combination (C, F, G). The residence times toff ~1/koff of CO/DI inhibitor are 1 s (A-C, G) and 
104 s (D-F). Inserts assess synergy, additivity or antagonism, using the AUC (A, D, G) and CI (B, C, E-
G).The residence times of CI/DO inhibitor are 1 s (C, F) and 104 s (G). Inhibitor doses are normalized by 
IC50, the total doses shown for the combination correspond to the optimal ratios of inhibitor doses. 
[RAS-GTP]=250 nM, [BRAFV600E]=0, [BRAFWT]=50 nM, basal ppERK level is 484 nM. The ratios of 
CI/DI and CO/DI inhibitor doses applied in combination are 3:5 (A-B) and 1:1 (D-E). The ratios of 
CO/DI and CI/DO inhibitor doses applied in combination are 1:1 (C, F, G).  
Figure S7 related to Figure 7. (A-D) Model-predicted stationary responses of ERK (A-B) and MEK (C-
D) signaling in cells with oncogenic RAS mutation and heterozygous BRAFV600E mutation to: CI/DI 
and CO/DI inhibitors and their combination (A-B), CO/DI and CI/DO inhibitors and their combination 
(C), and CI/DI and CI/DO inhibitors and their combination (D). The residence time toff ~1/koff of all 
inhibitors is 1 s. Inhibitor doses are normalized by IC50. In combinations, the ratio of CI/DI and CO/DI 
inhibitor doses are 1:1 (A) and 2.2:1 (B), the ratio of CO/DI and CI/DO inhibitor doses is 1:1 (C), and the 
ratio of CI/DI and CI/DO inhibitor doses is 6:1 (D). [RAS-GTP]=250 nM, [BRAFV600E]=25 nM, 
[BRAFWT]=25 nM, basal ppERK level is 2151 nM. (E) Model-predicted response of RAS-RAF 
complexes concentration to different RAF inhibitors in cells with WT BRAF and oncogenic RAS. [RAS-
GTP]=250 nM, [BRAFV600E]=0, [BRAFWT]=50 nM, basal ppERK level is 480 nM. (F) Model-predicted 
stationary response of ERK signaling to CO/DI, CI/DO inhibitors and their combination in cells with WT 
RAS and p61 splice variant of heterozygous BRAFV600E. [RAS-GTP]=25 nM, [BRAFV600E]=0, 
[p61BRAFV600E]=25 nM, [BRAFWT]=25 nM, basal ppERK level is 1627 nM. Inhibitor doses are 
normalized by IC50. In combination, the ratio of CO/DI and CI/DO inhibitor doses is 7:1. (A, B, F) 
Inserts assess drug synergy using the Talalay-Chou combination index (CI). G-H. Model-predicted 
stationary responses of ERK signaling in cells with WT RAS, heterozygous BRAFV600E mutation and 
CRAF overexpression to: CI/DI, CI/DO inhibitors and their combination, and to CO/DI, CI/DO inhibitors 
and their combination. Inhibitor doses are normalized by IC50 (G) and IC30 (H). [RAS-GTP]=25 nM, 
[BRAFV600E]=25 nM, [BRAFWT]=25 nM, [CRAF]=250 nM, basal ppERK level is 2603 nM. (I–J)  
Sensitivities of the areas under dose-response curves (AUC) to parameter changes for a combination of 
CO/DI (inhibitor a) and CI/DO (inhibitor b) RAF inhibitors in cells bearing both oncogenic RAS and 
BRAFV600E mutations (I) or only oncogenic RAS and WT BRAF (J). 
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Supplemental Experimental Procedures  
1. A model of the RAF kinase activation cycle.  
1.1. CRAF and BRAF phosphorylation sites and binding domains considered in the model 
The model monitors the states of the three phosphorylation sites on CRAF (S259, S338 and S642) and 
two phosphorylation sites on BRAF (S365 and T753). S259 on CRAF and S365 on BRAF are inhibitory 
sites (Roskoski, 2010). Phosphorylation of these sites (yielding pS259 and pS365) and binding of 14-3-3 
protein stabilize the inactive conformations of CRAF and BRAF (Dhillon and Kolch, 2002; Dhillon et al., 
2002; Leicht et al., 2007; Roskoski, 2010). S338 is an activating site on CRAF (Dhillon and Kolch, 2002; 
Leicht et al., 2007). Phosphorylation of inhibitory S259 and phosphorylation of activating S338 sites on 
CRAF are mutually exclusive (Chiloeches et al., 2001). Following S259 dephosphorylation, CRAF 
requires S338 phosphorylation for full activation in the model. Next, the model includes sites of feedback 
phosphorylation by ERK, S642 and T753, on CRAF and BRAF, respectively (Ritt et al., 2010).  
Binding and dimerization of RAF kinases is described in the model through the RAS Binding Domain 
(RBD), MEK-Binding domain (MEKB), dimerization domain (DIM) and Inhibitor-binding pocket (CI 
and BI on CRAF and BRAF). The rates of these reactions depend on the particular CRAF and BRAF 
phosphorylation states and the spatial localization of these molecules. Binding and dissociation reactions 
are described by mass-action rate laws in the model. When the available data suggest that 
(de)phosphorylation reactions are far from saturation, they are described by first order kinetics, otherwise 
(de)phosphorylation reactions are described by Michaelis – Menten kinetics (see below)    
1.2. Binding of CRAF monomers to RAS-GTP and (de)phosphorylation of S259 and S338 
In the absence of the RAS-GTP signal, CRAF mainly resides in the cytoplasm where it is phosphorylated 
on S259 (the inhibiting residue), and dephosphorylated on S338 (the residue has to be phosphorylated for 
full activation) and S642 (the site of feedback phosphorylation by ERK). The rate constant of 
phosphorylation of CRAF on S259 in the cytoplasm is kS259. The model assumes that there is a low 
basal rate of dephosphorylation of CRAF on S259 in the cytoplasm, described by the rate constant 
kS_259. The values of all parameters in the model are given in List S5.1.  
CRAF is activated by binding to RAS-GTP leading to the CRAF recruitment to plasma membrane. The 
data suggest that both CRAF phosphorylated on S259 and CRAF dephosphorylated on S259 can bind to 
RAS-GTP (Jaumot and Hancock, 2001). The rate constants for association of CRAF with RAS-GTP and 
dissociation are kC1 and kC_1, respectively. 
After binding of CRAF to RAS-GTP, the rate of dephosphorylation of CRAF on S259 is much faster, 
whereas the rate of its phosphorylation on S259 is much slower than the corresponding rates in the 
cytoplasm, due to that the dissociation of 14-3-3 proteins (Matallanas et al., 2011). In the model the 
corresponding rate constants are multiplied by parameters pMd259 and pM259 (List S5.1). Because 14-3-
3 proteins are highly abundant in the cell, and their abundance does not change under the conditions 
analyzed in the paper, the model does not explicitly consider these proteins. CRAF can be phosphorylated 
on S259 both in a monomeric form and as a protomer in a dimer. If CRAF is phosphorylated on S259 
when it is a protomer in a dimer with another RAF molecule, the dimer quickly dissociates. We assume 
that S338 phosphorylation on CRAF occurs only at the membrane when CRAF is bound to RAS-GTP 
(the rate constant kpS338), while S338 dephosphorylation occurs both at the membrane (i.e. when CRAF 
is bound to RAS-GTP) and in the cytoplasm (the rate constant kS338).   
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1.3. Binding of wild-type BRAF monomers and BRAF homodimers to RAS-GTP and 
(de)phosphorylation of S365 
In the absence of the RAF-GTP signal, BRAF mainly resides in the cytoplasm where it is phosphorylated 
on S365 (the inhibiting residue), and dephosphorylated on T753 (the site of feedback phosphorylation by 
ERK). We assume that both BRAF phosphorylated on S365 and BRAF dephosphorylated on S365 can 
bind to RAS-GTP. The rate constants for association of BRAF with RAS-GTP and dissociation are kB1 
and kB_1, respectively. Literature data suggest that the dissociation constant for BRAF binding to RAS-
GTP is less than this constant for CRAF binding to RAS-GTP (Fischer et al., 2007). 
The rate constants of phosphorylation and dephosphorylation of BRAF on S365 in the cytoplasm are 
kS365 and kS_365. On the plasma membrane (i.e., when BRAF is bound to RAS-GTP), the 
phosphorylation of BRAF on S365 is slower and its dephosphorylation is faster than in the cytoplasm, 
which is described by the parameters pM365 and pMd365 (List S5.1). We also assume that BRAF can be 
phosphorylated on S365 both in a monomeric form and as a protomer in a dimer. If BRAF is 
phosphorylated on S365 when it is a protomer in a dimer with another RAF molecule, the dimer quickly 
dissociates described in the model by a process coupled to the S365 phosphorylation on BRAF protomer.  
1.4. CRAF and BRAF dimerization. 
When RAF kinases are in active conformations, they form dimers (Lavoie and Therrien, 2015). 
Accordingly, in the model only CRAF dephosphorylated on S259 and BRAF dephosphorylated on S365 
can participate in dimerization reactions. As mentioned above, if CRAF gets phosphorylated on S259 in a 
homo/hetero dimer, or BRAF gets phosphorylated on S365 in a homo/hetero dimer, the dimer rapidly 
dissociates. Influence of feedback phosphorylation of CRAF and BRAF by ERK on dimerization 
reactions is explained in Section 1.6. The rate constants for association and dissociation of BRAF 
homodimers are kBBd1 and kBBd_1, respectively; the rate constants for CRAF homodimer association 
and dissociation are kCCd1 and kCCd_1, respectively (List S5.1). The rate constants of association and 
dissociation of BRAF-CRAF heterodimers in the model are kCBd1 and kCBd_1 respectively. The 
literature data suggest that the dissociation constants of WT BRAF homodimers and CRAF-BRAF 
heterodimers are slightly less (by a factor of 2) than the dissociation constant for CRAF homodimers 
(Rajakulendran et al., 2009). The data also suggest that the phosphorylation state of S338 does not 
influence the rates of CRAF dimerization but substantially affects the activity of the dimer (Garnett et al., 
2005). 
In our model all intracellular concentrations are based on to the cytoplasmic water volume. The values of 
dissociation constants for RAF dimers in the cytoplasm are high compared to the BRAF/CRAF 
abundances (Lavoie and Therrien, 2015; Rajakulendran et al., 2009). As a result, RAF dimers are nearly 
absent in the cytoplasm. However, if RAF molecules are bound to RAS-GTP, they are localized on the 
plasma membrane, and all interactions take place in a much smaller volume, localized near the 
membrane. Because the effective local concentrations of RAF molecules become much higher than in the 
cytoplasm (Kholodenko, 2006; Kholodenko et al., 2000; Lamson et al., 2006), the apparent Kd’s of RAF 
homo-/heterodimerization dramatically decrease of both RAF molecules are bound to RAS-
GTP(Kholodenko et al., 2000; Markevich et al., 2004). In the model, the association rate constants for 
RAF homo-/heterodimerization are increased by a factor of p2 if both RAF molecules are bound to RAS-
GTP and the corresponding dissociation constant is decreased by a factor of p2. Thus, p2
2 reflects a ratio 
of volumes (Kholodenko et al., 2000; Markevich et al., 2004). 
9 
 
1.5. Binding of CRAF and BRAF homo- and heterodimers to RAS-GTP 
The spatial co-localization effect also affects the binding of RAF to RAS-GTP. If at least one protomer in 
a RAF dimer is bound to RAS, the dimer is localized in the plasma membrane compartment, and 
therefore the other RAF protomer has a higher propensity to bind the second RAS-GTP (Kholodenko, 
2006; Kholodenko et al., 2000). To account for this effect, the corresponding kinetic constants describing 
binding of RAF to RAS-GTP were rescaled as follows (Kholodenko et al., 2000; Markevich et al., 2004). 
The association rate constants for RAF binding to RAS-GTP are increased by a factor of p2 if a RAF 
molecule is in a dimer that is bound to RAS-GTP via one of its protomers. The corresponding 
dissociation constants are decreased by a factor of p2. Thus, p2
2 reflects a ratio of volumes (Kholodenko et 
al., 2000; Markevich et al., 2004). 
1.6. Feedback phosphorylation of CRAF and BRAF monomers by active ERK and 
dephosphorylation by phosphatases.  
It is known that ERK-mediated feedback strongly affects RAF kinase activities by inhibiting RAS-GTP 
binding and RAF dimerization (Dougherty et al., 2005; Ritt et al., 2010). For the sake of simplicity, the 
inhibitory sites that are phosphorylated on RAFs by ERK are represented by just one site S642 on CRAF 
and T753 on BRAF. We assume that only active ERK (where Y and T sites on ERK are phosphorylated) 
can bind to RAF monomers and phosphorylate them. Computational analysis of ERK binding sites on 
RAF molecules performed using ScanSite (Ehrenberger et al., 2015; Obenauer et al., 2003) suggests that 
active ERK binds to RAFs via the domain that overlaps with the RAF dimerization interface (Dm); this 
rules out ERK feedback phosphorylation of RAF homo- and heterodimers. Thus, in the model, ERK can 
bind to and phosphorylate only RAF monomers.  
Based on experimental data (Dougherty et al., 2005; Ritt et al., 2010), our model considers that if CRAF 
is phosphorylated on S642, the rate constants for CRAF-RAS association become p1-fold lower, and the 
dissociation rate constants become p1-fold higher (see figure S1C) than the corresponding values before 
CRAF phosphorylation by ERK. As a result, the equilibrium dissociation constant increases by a factor 
𝑝1
2, List S5.1. Similarly, if BRAF is phosphorylated on T753 the rate constants for BRAF-RAS 
association are p1-fold lower, and the corresponding dissociation rate constants are p1-fold higher (see 
figure S1C). Likewise, when CRAF is phosphorylated on S642, the association rate constants for CRAF 
homo- and heterodimerization become p3-fold lower and the dissociation rate constants become p3-fold 
higher (Ritt et al., 2010). Similarly, if BRAF is phosphorylated on T753 the association rate constants for 
BRAF homo- and heterodimerization become p3-fold lower and the corresponding dissociation rate 
constants become p3-fold higher. The influence of the different modifiers (such as p1, p2, p3, etc.) can be 
multiplicative. For instance, when a CRAF monomer that is bound to RAS-GTP and phosphorylated on 
S642 dimerizes with a BRAF monomer that is bound to RAS-GTP and phosphorylated on T753, the 
association rate constant becomes kCBd1·p2/p3
2, and the corresponding dissociation rate constant 
becomes kCBd_1·p3
2/p2. 
1.7. Kinase activity of RAF monomers and dimers. 
A BRAF monomer dephosphorylated on S365 is catalytically active, whereas the kinase activity of 
CRAF monomers that are dephosphorylated on S259 depends on additional S338 phosphorylation (see 
List S4.1). The kinase activity of active BRAF monomers is five times higher than the activity of active 
CRAF monomers phosphorylated on S338 (Rushworth et al., 2006). ERK feedback phosphorylation of 
CRAF on S642 dramatically suppresses CRAF activity (Dougherty et al., 2005; Ritt et al., 2010) (see 
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List S4.1). ERK feedback phosphorylation of BRAF on T753 does not directly affect BRAF kinase 
activity (Dougherty et al., 2005; Ritt et al., 2010). 
Kinase activity of RAF homodimers is the sum of activities of the corresponding RAF protomers. The 
literature data suggest that kinase activity of CRAF-BRAF heterodimers is 15-times higher than the 
activity of BRAF homodimers (Freeman et al., 2013; Rushworth et al., 2006). The data show that when in 
a dimer S338 on CRAF is not phosphorylated, the dimer activity is only about 40-50% of the full activity 
of the dimer with CRAF phosphorylated on S338 (Garnett et al., 2005). Kinase activities of all monomer 
and dimer forms are summarized in List S4.1. 
2. Oncogenic BRAFV600E mutant. 
We assume that the S365 state does not influence BRAFV600E, and thus the model does not track the 
S365 state on BRAFV600E. The model monitors only the state of the ERK feedback phosphorylation 
site, T753, on BRAFV600E. BRAFV600E monomers are assumed to have higher kinase activity than 
WT BRAF monomers, and dimers containing BRAFV600E have higher kinase activity than dimers with 
WT BRAF or CRAF (see List S4.1).  
Binding and dimerization of BRAFV600E kinase is described in the model in the same way as for CRAF 
and BRAF. The following binding sites are taken into account for BRAFV600E: RAS Binding Domain 
(RBD), MEK-Binding domain (MEKB), dimerization domain (DIM) and Inhibitor-binding pocket (EI).  
The rate constants for association and dissociation of BRAFV600E and RAS-GTP are assumed to be 
similar to the rate constants for WT BRAF. The dimerization rate constants for BRAFV600E are assumed 
to be the same as the dimerization rate constants for BRAF dephosphorylated on S365. We assume that 
the feedback phosphorylation by ERK less affects BRAFV600E than WT BRAF. Accordingly, the 
changes in the corresponding association/dissociation rate constants are described by the parameters 
pBE1 and pBE3, which are smaller than the parameters p1 and p3 for WT BRAF (see List S5.1).   
3. Core model for allosteric interactions of RAF monomers and dimers with inhibitors. 
Each state of a RAF molecule is characterized by the phosphorylation states of key amino acid residues, 
which control RAF conformational changes and activity, S259, S338 and S642 for CRAF and S365 and 
T753 for BRAF. Furthermore, the RAF conformational and activity state depends on binding to RAS-
GTP, another RAF molecule in a dimer or an inhibitor. For any particular phosphorylation state and set of 
binding partners there exists a thermodynamic equilibrium for the kinase in active and inactive 
conformations due to thermal motions of the molecule (Arora and Brooks, 2007; Daily et al., 2010; 
Hakulinen and Puranen, 2016; Lavoie and Therrien, 2015; Shao et al., 2017). Structurally, the state of a 
RAF molecule is described by the positions of the DFG motif and αC-helix, which in turn depend on 
phosphorylation and its binding partner. Because of thermal motions, in each phosphorylation and 
binding state, a RAF molecule can switch between DFG-IN and DFG-OUT positions of the DFG-motif, 
and between αC-IN and αC-OUT positions of αC-helix.  
A RAF inhibitor generally binds to different conformations of RAF molecule with different microscopic 
Kd‘s. The smallest Kd corresponds to the preferential RAF conformation for this inhibitor. Because of the 
thermal motions, a RAF molecule can spontaneously switch between different conformations. This 
dynamic equilibrium is described by the equilibrium constants of conformational transitions, which in 
turn depend on the phosphorylation and dimerization state of a molecule. As a result, inhibitor binding is 
determined by the apparent dissociation constant (𝐾𝑑
𝑎𝑝𝑝
) whose difference with the smallest microscopic 
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Kd depends on both thermal transition equilibrium constants and factors that describe the inhibitor 
preference for different RAF conformations. Here we set to derive the relationships that express the 
apparent 𝐾𝑑
𝑎𝑝𝑝
 in terms of the microscopic Kd’s, the equilibrium constants of DFG-IN/DFG-OUT 
transitions, αC-IN/αC-OUT transitions and factors that describe the inhibitor preference for different 
conformational states of RAF molecules. In each kinetic scheme below, it is assumed that the 
phosphorylation and dimerization states of a RAF molecule shown do not change during thermal 
movements of the DFG motif and αC-helix between their IN and OUT positions. For simplicity, we first 
consider only DFG-IN and DFG-OUT transitions (sections A1 and A2) and then analyze the general case 
of thermal motions of both the DFG motif and αC-helix (section B).  
3.1 Thermodynamics of binding of structurally diverse RAF inhibitors to DFG-IN/OUT RAF 
conformations. 
3.1.1. DFG-IN inhibitors.  
A kinetic scheme of a DFG-IN inhibitor binding to RAF and the thermal transitions between DFG-OUT 
and DFG-IN conformations of free and inhibitor-bound RAF molecules are shown in Scheme S3.1. For 
simplicity, Scheme S3.1 assumes that the illustrated RAF molecule states maintain the preferred αC-helix 
position for binding of this DFG-IN inhibitor.  
   Scheme S3.1. 
Here Kd is the smallest microscopic equilibrium dissociation constant for a DFG-IN inhibitor binding to a 
specific RAF form in a DFG-IN conformation, and b is the equilibrium constant for a transition of this 
RAF form (which is free of inhibitor) from a DFG-OUT conformation to a DFG-IN conformation. A 
DFG-IN inhibitor can also bind the same RAF form in a DFG-OUT conformation, but the corresponding 
dissociation constant is larger because of the assumed preference of the inhibitor for the DFG-IN 
conformation. This constant equals the smallest microscopic dissociation constant Kd multiplied by a 
preference factor a2 > 1, i.e., a2∙Kd. The equilibrium relationships between the concentrations of free and 
inhibitor-bound RAF molecules in each conformational state are given in Eq. S3.1,  
[𝐷𝐹𝐺 − 𝐼𝑁] = 𝑏 ⋅ [𝐷𝐹𝐺 − 𝑂𝑈𝑇] 
[(𝐷𝐹𝐺 − 𝐼𝑁) − 𝐼𝐷𝐹𝐺−𝐼𝑁] =
[𝐷𝐹𝐺 − 𝐼𝑁] ⋅ 𝐼𝐷𝐹𝐺−𝐼𝑁
𝐾𝑑
 
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇) − 𝐼𝐷𝐹𝐺−𝐼𝑁] =
1
𝑏
⋅
[𝐷𝐹𝐺 − 𝐼𝑁] ⋅ 𝐼𝐷𝐹𝐺−𝐼𝑁
𝑎2𝐾𝑑
 
(S3.1) 
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The kinetic diagram in Scheme S3.1 contains a cyclic route composed of reversible binding/dissociation 
reactions and thermal transitions between DFG-IN/OUT conformations. According to the law of 
microscopic reversibility, the total free energy change equals zero along this cyclic path. This leads to the 
so-called detailed balance equation that requires the product of the equilibrium constants along the cycle 
to be equal to 1 (see, e.g, (Kholodenko et al., 1999; Kholodenko et al., 1998)). As a result, the equilibrium 
constant for a transition of the inhibitor-bound RAF from the DFG-OUT conformation to the DFG-IN 
conformation equals a2∙b (as shown in Scheme S3.1).  
[(𝐷𝐹𝐺 − 𝐼𝑁) − 𝐼𝐷𝐹𝐺−𝐼𝑁]
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇) − 𝐼𝐷𝐹𝐺−𝐼𝑁]
= 
[𝐷𝐹𝐺 − 𝐼𝑁]
[𝐷𝐹𝐺 − 𝑂𝑈𝑇]
⋅
[(𝐷𝐹𝐺 − 𝐼𝑁) − 𝐼𝐷𝐹𝐺−𝐼𝑁]
[𝐷𝐹𝐺 − 𝐼𝑁] ⋅ 𝐼𝐷𝐹𝐺−𝐼𝑁
⋅
[𝐷𝐹𝐺 − 𝑂𝑈𝑇] ⋅ 𝐼𝐷𝐹𝐺−𝐼𝑁
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇) − 𝐼𝐷𝐹𝐺−𝐼𝑁]
= 𝑎2𝑏 
(S3.2) 
 
Using the microscopic Kd’s and the equilibrium constants of conformational transitions, b and a2∙b, the 
apparent dissociation constant of DFG-IN inhibitor binding to RAF molecules (that reside in the same 
αC-helix position as the preferred position for binding of this DFG-IN inhibitor) can be expressed as 
follows,  
𝐾𝑑
𝑎𝑝𝑝 =
([𝐷𝐹𝐺 − 𝑂𝑈𝑇] + [𝐷𝐹𝐺 − 𝐼𝑁]) ⋅ [𝐼𝐷𝐹𝐺−𝐼𝑁]
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇) − 𝐼𝐷𝐹𝐺−𝐼𝑁] + [(𝐷𝐹𝐺 − 𝐼𝑁) − 𝐼𝐷𝐹𝐺−𝐼𝑁]
  =
𝑏 + 1
𝑏 +
1
𝑎2
𝐾𝑑 (S3.3) 
Here [𝐷𝐹𝐺 − 𝑂𝑈𝑇] + [𝐷𝐹𝐺 − 𝐼𝑁] and [(𝐷𝐹𝐺 − 𝑂𝑈𝑇) − 𝐼𝐷𝐹𝐺−𝐼𝑁] + [(𝐷𝐹𝐺 − 𝐼𝑁) − 𝐼𝐷𝐹𝐺−𝐼𝑁]  are the 
sums of the equilibrium concentrations of free and inhibitor-bound RAF molecules, respectively. The 
concentrations of RAF molecules in each conformational state are related by the equilibrium constants, as 
shown in Eqs. S3.1 and S3.2. Note that because the IN/OUT spontaneous thermal motions of the DFG-
motif can occur in any state of a RAF molecule (monomeric or dimeric, bound to inhibitor or free), the 
equilibrium constant b for these transitions depends on the specific state of a RAF molecule. For example, 
b depends on thermodynamic factors describing the allosteric inhibitor interactions with RAF monomers 
and dimers (see below). 
If the preference factor a2 for binding of a DFG-IN inhibitor to a DFG-OUT conformation is very large, 
𝑎2 → ∞, meaning that this DFG-IN inhibitor poorly binds to a DFG-OUT conformation, Eq. (S3.3) 
simplifies as follows,  
𝐾𝑑
𝑎𝑝𝑝  
𝑎2→∞
→    (1 +
1
𝑏
) ⋅ 𝐾𝑑 (S3.4) 
3.1.2. DFG-OUT inhibitors.  
A kinetic scheme for a DFG-OUT inhibitor binding to RAF and the thermal transitions between DFG-
OUT and DFG-IN conformations of free and inhibitor-bound RAF molecules is presented in 
Scheme S3.2. We assume that the RAF molecule states included in Scheme S3.2 maintain the preferred 
αC-helix position for binding of this DFG-OUT inhibitor. 
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Scheme S3.2 
Here, Kd is the smallest microscopic equilibrium dissociation constant for the DFG-OUT inhibitor 
binding to a specific RAF form in a DFG-OUT conformation, a1∙Kd is the dissociation constant for the 
DFG-OUT inhibitor binding to the same RAF form in a DFG-IN conformation (this constantequals the 
smallest microscopic Kd for DFG-OUT conformation multiplied by a preference factor a1 > 1), and b is 
the equilibrium constant for a transition of this RAF form (which is free of inhibitor) from a DFG-OUT 
conformation to a DFG-IN conformation. 
As discussed above, from the detailed balance equation it follows that the apparent dissociation constant 
for DFG-OUT inhibitor binding to RAF molecules can be expressed as follows (in these illustrative 
examples, we are assuming that the aC-helix conformation does not change, corresponding to preferential 
inhibitor binding),  
𝐾𝑑
𝑎𝑝𝑝 =
([𝐷𝐹𝐺 − 𝑂𝑈𝑇] + [𝐷𝐹𝐺 − 𝐼𝑁]) ⋅ [𝐼𝐷𝐹𝐺−𝑂𝑈𝑇]
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇) − 𝐼𝐷𝐹𝐺−𝑂𝑈𝑇] + [(𝐷𝐹𝐺 − 𝐼𝑁) − 𝐼𝐷𝐹𝐺−𝑂𝑈𝑇]
=  
𝑏 + 1
𝑏
𝑎1
+ 1
𝐾𝑑 (S3.5) 
If the preference factor a1 for binding of a DFG-OUT inhibitor to a DFG-IN conformation is very large, 
𝑎1 → ∞, meaning that this inhibitor poorly binds to a DFG-IN conformation, Eq. S3.5 simplifies as 
follows,  
𝐾𝑑
𝑎𝑝𝑝  
𝑎1→∞
→    (𝑏 + 1) ⋅ 𝐾𝑑 (S3.6) 
 
3.2. Taking into account the thermal motions of both the DFG-motif and αC-helix to calculate the 
apparent Kd’s for binding of structurally diverse RAF inhibitors.  
A kinetic diagram for an inhibitor binding to a RAF molecule and the thermal transitions between eight 
possible DFG-IN/OUT and αC-helix IN/OUT conformations of free and inhibitor-bound RAF forms is 
shown in Scheme S3.3.  
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 Scheme S3.3. 
We will denote the equilibrium constants for IN/OUT transitions of the DFG-motif at the fixed IN or 
OUT position of the αC-helix by b1 and b2, respectively. Similarly, we will denote the equilibrium 
constants for IN/OUT transitions of the αC-helix for the different IN or OUT states of the DFG-motif by 
c1 and c2, respectively. In other words, we have 
𝑏1 =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁]
[𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁]
 𝑏2 =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝑂𝑈𝑇]
[𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇]
 (S3.7) 
 
𝑐1 =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁]
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝑂𝑈𝑇]
 𝑐2 =
[𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁]
[𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇]
 (S3.8) 
The detailed balance principle imposes the following constraints 
𝑏1
𝑏2
=
𝑐1
𝑐2
 (S3.9) 
If b1=b2 then movements of the DFG-motif and αC-helix are independent. If b1>b2 cooperativity exists 
between DFG and αC motions. Following Eq. S3.9, we introduce the cooperativity coefficient 𝛾 and 
make the following substitutions: 
𝑏1 = 𝛾𝑏 
(S3.10) 
𝑏2 = 𝑏 
𝑐1 = 𝛾𝑐 
𝑐2 = 𝑐 
At present, researchers have produced and tested three types of RAF inhibitors that preferably bind to (1) 
DFG-IN, αC-IN (CI/DI), (2) DFG-OUT, αC-IN (CI/DO) or (3) DFG-IN, αC-OUT (CO/DI) 
conformations of RAF molecules. Each inhibitor type binds preferably to one out of the possible four 
DFG-IN/OUT, αC-IN/OUT conformations. Preferential binding is described by the smallest microscopic 
Kd, but each inhibitor can also bind to other conformations (Park et al., 2012), yet with larger Kd’s. For 
each known RAF inhibitor type, List S3.1 presents the coefficients that multiply the smallest microscopic 
Kd to obtain the Kd’s for binding of this inhibitor type to less preferable DFG and αC-helix conformations. 
For instance, the first row in List S3.1 shows that a CI/DI inhibitor (𝐼𝐶𝐼/𝐷𝐼) binds with the smallest 
microscopic Kd to the preferred DFG-IN, αC-IN RAF conformation, but its Kd for binding to the DFG-
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OUT, αC-IN conformation equals 𝑎21
𝐶𝐼/𝐷𝐼
𝐾𝑑, its Kd of binding to DFG-IN, αC-OUT conformation equals 
𝑎12
𝐶𝐼/𝐷𝐼
𝐾𝑑, and its binding Kd to DFG-OUT, αC-OUT conformation equals 𝑎22
𝐶𝐼/𝐷𝐼
𝐾𝑑.    
List S3.1. Binding Kds to different RAF conformations for three types of RAF inhibitors  
Type of RAF 
inhibitor 
Kd for binding 
to DFG-IN, αC-
IN 
conformation 
Kd for binding to 
DFG-OUT, αC-IN 
conformation 
Kd for binding to 
DFG-IN, αC-OUT 
conformation 
Kd for binding to 
DFG-OUT, αC-
OUT conformation 
DFG-IN, αC-IN 
(𝐼𝐶𝐼/𝐷𝐼) 
𝐾𝑑 𝑎21
𝐶𝐼/𝐷𝐼
𝐾𝑑 𝑎12
𝐶𝐼/𝐷𝐼
𝐾𝑑 𝑎22
𝐶𝐼/𝐷𝐼
𝐾𝑑 
DFG-OUT, αC-IN 
(𝐼𝐶𝐼/𝐷𝑂) 
𝑎11
𝐶𝐼/𝐷𝑂
𝐾𝑑 𝐾𝑑 𝑎12
𝐶𝐼/𝐷𝑂
𝐾𝑑 𝑎22
𝐶𝐼/𝐷𝑂
𝐾𝑑 
DFG-IN, αC-OUT 
(𝐼𝐶𝑂/𝐷𝐼) 
𝑎11
𝐶𝑂/𝐷𝐼
𝐾𝑑 𝑎21
𝐶𝑂/𝐷𝐼
𝐾𝑑 𝐾𝑑 𝑎22
𝐶𝑂/𝐷𝐼
𝐾𝑑 
 
Interactions of different types of inhibitors (I) with each possible conformation (DFG-IN/OUT, αC-helix-
IN/OUT) of a RAF molecule are shown in Schemes S3.4a, S3.4b and S3.4c for 𝐼𝐶𝐼/𝐷𝐼 (S3.4a), 𝐼𝐶𝐼/𝐷𝑂 
(S3.4b) and 𝐼𝐶𝑂/𝐷𝐼 (S3.4c) inhibitors. The microscopic dissociation constants and the equilibrium 
constants for conformational changes are indicated.  As above, we assume that any specific 
phosphorylation state and binding partner(s) of this RAF molecule do not change over the reactions 
shown in these Schemes.  
 Scheme S3.4a for 𝐼𝐶𝐼/𝐷𝐼  
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 Scheme S3.4b for 𝐼𝐶𝐼/𝐷𝑂 
 Scheme S3.4c for 𝐼𝐶𝑂/𝐷𝐼 
 
These schemes are valid for every BRAF molecule and CRAF molecule appearing in the model. For 
example, in the BRAF-CRAF dimerization cycle and allosteric inhibitor interactions with RAF 
monomers and dimers shown in the lumped reaction Scheme S3.5 at the left, the binding of inhibitor to a 
BRAF molecule is expanded into 12 reactions that take into account all possible positions of the DFG-
motif and αC-helix.  
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 Scheme S3.5 
For a cycle of the 12 inhibitor binding and thermal motion reactions shown in Schemes S3.3-S3.5, we can 
write the following equations which capture the relationships between the equilibrium concentrations of 
RAF molecules that have different positions for the DFG motif and αC-helix and that are bound to 
different inhibitor types,  
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁]
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝑂𝑈𝑇]
= 𝛾 ⋅ 𝑐 
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁]
[𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁]
= 𝛾 ⋅ 𝑏 
(S3.11) 
[𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁]
[𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇]
= 𝑐 
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁]
[𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇]
= 𝛾 ⋅ 𝑏 ⋅ 𝑐 
[(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝐼/𝐷𝐼] = [𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝐼/𝐷𝐼]/𝐾𝑑 
[(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝑂𝑈𝑇) − 𝐼𝐶𝐼/𝐷𝐼] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝐼/𝐷𝐼]/𝐾𝑑
𝛾𝑐 ⋅ 𝑎12
𝐶𝐼/𝐷𝐼
 
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝐼/𝐷𝐼] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝐼/𝐷𝐼]/𝐾𝑑
𝛾𝑏 ⋅ 𝑎21
𝐶𝐼/𝐷𝐼
 
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇) − 𝐼𝐶𝐼/𝐷𝐼] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝐼/𝐷𝐼]/𝐾𝑑
𝛾𝑏𝑐 ⋅ 𝑎22
𝐶𝐼/𝐷𝐼
 
[(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝐼/𝐷𝑂] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝐼/𝐷𝑂]/𝐾𝑑
𝑎11
𝐶𝐼/𝐷𝑂
 
[(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝑂𝑈𝑇) − 𝐼𝐶𝐼/𝐷𝑂] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝐼/𝐷𝑂]/𝐾𝑑
𝛾𝑐 ⋅ 𝑎12
𝐶𝐼/𝐷𝑂
 
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝐼/𝐷𝑂] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝐼/𝐷𝑂]/𝐾𝑑
𝛾𝑏
 
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇) − 𝐼𝐶𝐼/𝐷𝑂] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝐼/𝐷𝑂]/𝐾𝑑
𝛾𝑏𝑐 ⋅ 𝑎22
𝐶𝐼/𝐷𝑂
 
[(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝑂/𝐷𝐼] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝑂/𝐷𝐼]/𝐾𝑑
𝑎11
𝐶𝑂/𝐷𝐼
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[(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝑂𝑈𝑇) − 𝐼𝐶𝑂/𝐷𝐼] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝑂/𝐷𝐼]/𝐾𝑑
𝛾𝑐
 
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝑂/𝐷𝐼] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝑂/𝐷𝐼]/𝐾𝑑
𝛾𝑏 ⋅ 𝑎21
𝐶𝑂/𝐷𝐼
 
[(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇) − 𝐼𝐶𝑂/𝐷𝐼] =
[𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] ⋅ [𝐼𝐶𝑂/𝐷𝐼]/𝐾𝑑
𝛾𝑏𝑐 ⋅ 𝑎22
𝐶𝑂/𝐷𝐼
 
For any inhibitor type (𝐼𝐶𝑥/𝐷𝑥), the apparent dissociation constant (𝐾𝑑 𝐶𝑥/𝐷𝑥
𝑎𝑝𝑝
) for inhibitor binding to a 
RAF molecule in a particular phosphorylation and dimerization state can be expressed as follows, 
𝐾𝑑 𝐶𝑥/𝐷𝑥
𝑎𝑝𝑝 =
([𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁] + [𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁] +
[(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝑥/𝐷𝑥] + [(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝑥/𝐷𝑥] +
 
+ [𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝑂𝑈𝑇] + [𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇]) ⋅ 𝐼
+ [(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝑂𝑈𝑇) − 𝐼𝐶𝑥/𝐷𝑥] + [(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇) − 𝐼𝐶𝑥/𝐷𝑥]
 
(S3.12) 
Here, [𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁],  [𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝑂𝑈𝑇], [𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁], [𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 −
𝑂𝑈𝑇], [(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝑥/𝐷𝑥], [(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝐼𝑁) − 𝐼𝐶𝑥/𝐷𝑥], [(𝐷𝐹𝐺 − 𝐼𝑁, 𝛼𝐶 −
𝑂𝑈𝑇) − 𝐼𝐶𝑥/𝐷𝑥] and [(𝐷𝐹𝐺 − 𝑂𝑈𝑇, 𝛼𝐶 − 𝑂𝑈𝑇) − 𝐼𝐶𝑥/𝐷𝑥] are the equilibrium concentrations of free and 
inhibitor-bound RAF molecules, respectively, that retain particular states of the DFG motif and αC-helix 
positions. These concentrations are related by the equilibrium constants of thermal transitions and the 
microscopic dissociation constants, as presented in Eqs. S3.11. Using Eqs. S3.11 and S3.12, the apparent 
dissociation constant for inhibitor binding to a RAF molecule in any particular phosphorylation and 
dimerization state can be expressed through the microscopic dissociation constants, the factors that 
describe the inhibitor preference for different conformational states of RAF molecules, and the 
equilibrium constants of IN/OUT transitions of the DFG-motif and αC-helix. 
For a DFG-IN, αC-IN inhibitor type (𝐼𝐶𝐼/𝐷𝐼), the apparent dissociation constant is expressed, as follows,  
𝐾𝑑 𝐶𝐼/𝐷𝐼
𝑎𝑝𝑝 =
𝛾𝑏𝑐 + 𝑏 + 𝑐 + 1
𝛾𝑏𝑐 +
𝑏
𝑎12
𝐶𝐼/𝐷𝐼 +
𝑐
𝑎21
𝐶𝐼/𝐷𝐼 +
1
𝑎22
𝐶𝐼/𝐷𝐼
⋅ 𝐾𝑑 
(S3.13a) 
For a DFG-OUT, αC-IN inhibitor type (𝐼𝐶𝐼/𝐷𝑂), the apparent dissociation constant is expressed, as 
follows, 
𝐾𝑑 𝐶𝐼/𝐷𝑂
𝑎𝑝𝑝 =
𝛾𝑏𝑐 + 𝑏 + 𝑐 + 1
𝛾𝑏𝑐
𝑎11
𝐶𝐼/𝐷𝑂 +
𝑏
𝑎12
𝐶𝐼/𝐷𝑂 + 𝑐 +
1
𝑎22
𝐶𝐼/𝐷𝑂
⋅ 𝐾𝑑 
(S3.13b) 
For a DFG-IN, αC-OUT (𝐼𝐶𝑂/𝐷𝐼) inhibitor type, the apparent dissociation constant is expressed, as 
follows, 
𝐾𝑑 𝐶𝑂/𝐷𝐼
𝑎𝑝𝑝 =
𝛾𝑏𝑐 + 𝑏 + 𝑐 + 1
𝛾𝑏𝑐
𝑎11
𝐶𝑂/𝐷𝐼 + 𝑏 +
𝑐
𝑎21
𝐶𝑂/𝐷𝐼 +
1
𝑎22
𝐶𝑂/𝐷𝐼
⋅ 𝐾𝑑 
(S3.13c) 
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Assuming that coefficients 𝑎𝑥𝑥
𝐶𝑥/𝐷𝑥
 that distinguish the dissociation constants of a particular inhibitor 
between the preferential RAF conformation and other conformations are large, Eqs. S3.13 simplify, as 
follows: 
𝐾𝑑 𝐶𝐼/𝐷𝐼
𝑎𝑝𝑝 𝑎12
𝐶𝐼/𝐷𝐼
,𝑎21
𝐶𝐼/𝐷𝐼
,𝑎22
𝐶𝐼/𝐷𝐼
→∞
→                1 +
1
𝛾𝑐
+
1
𝛾𝑏
+
1
𝛾𝑏𝑐
 (S3.13d) 
𝐾𝑑 𝐶𝐼/𝐷𝑂
𝑎𝑝𝑝 𝑎11
𝐶𝐼/𝐷𝑂
,𝑎12
𝐶𝐼/𝐷𝑂
,𝑎22
𝐶𝐼/𝐷𝑂
→∞
→                𝛾𝑏 +
𝑏
𝑐
+ 1 +
1
𝑐
  (S3.13e) 
𝐾𝑑 𝐶𝑂/𝐷𝐼
𝑎𝑝𝑝 𝑎11
𝐶𝑂/𝐷𝐼
,𝑎21
𝐶𝑂/𝐷𝐼
,𝑎22
𝐶𝑂/𝐷𝐼
→∞
→                𝛾𝑐 + 1 +
𝑐
𝑏
+
1
𝑏
 (S3.13f) 
 
List S3.2 below shows the estimated value ranges for the coefficients 𝑏, 𝑐 and 𝛾 based on the available 
literature. The last column gives the names of the apparent equilibrium dissociation constants for inhibitor 
binding to different states of CRAF and BRAF.  
List S3.2. Estimated ranges for the coefficients 𝒃, 𝒄 and 𝜸 based on the available literature.  
Different phospho-site states of CRAF 
and BRAF monomers and dimers 
Equilibrium 
constant for 
DFG-motif 
motions, 𝑏 
Equilibrium 
constant for 
αC-helix 
motions, 𝑐 
Cooperativity 
between DFG 
and αC 
motions, 𝛾 
Name of 
apparent 
dissociation 
constant 
CRAF 
pS259, monomer 0.01-0.05 0.005-0.01 1-10 
𝐾𝑑
𝑚𝐶 S259, S338, monomer 0.1-1 0.1-1 1-10 
S259, pS338, monomer 5-10 5-10 1-10 
S259, S338, bound to CRAF/BRAF, 
which is either free or bound to a 𝐼𝐶𝐼/𝐷𝐼 
or 𝐼𝐶𝐼/𝐷𝑂 inhibitor 
5-10 5-10 1-10 
𝐾𝑑
𝐷𝐼𝐶 
S259, pS338, bound to CRAF/BRAF, 
which is either free or bound to a 𝐼𝐶𝐼/𝐷𝐼 
or 𝐼𝐶𝐼/𝐷𝑂 inhibitor 
10-20 10-20 1-10 
S259, S338, bound to CRAF/BRAF, 
which is bound to a 𝐼𝐶𝑂/𝐷𝐼 inhibitor 
5-10 10-100 1-10 
𝐾𝑑
𝐷𝑂𝐶 
S259, pS338, bound to CRAF/BRAF, 
which is bound to a 𝐼𝐶𝑂/𝐷𝐼 inhibitor 
10-20 40-100 1-10 
BRAF 
pS365, monomer 0.01-0.05 0.005-0.01 1-10 
𝐾𝑑
𝑚𝐵 
S365, monomer 5-10 5-10 1-10 
S365, bound to CRAF/BRAF (mutant or 
WT), which is either free or bound to a 
𝐼𝐶𝐼/𝐷𝐼 or 𝐼𝐶𝐼/𝐷𝑂 inhibitor 
10-20 10-20 1-10 𝐾𝑑
𝐷𝐼𝐵 
S365, bound to CRAF/BRAF (mutant or 
WT), which is bound to a 𝐼𝐶𝑂/𝐷𝐼 
inhibitor 
10-20 40-100 1-10 𝐾𝑑
𝐷𝑂𝐵 
BRAFV600E 
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Monomer 5-10 5-10 1-10 𝐾𝑑
𝑚𝐸 
Bound to CRAF/BRAF (mutant or WT), 
which is either free or bound to a 𝐼𝐶𝐼/𝐷𝐼 
or 𝐼𝐶𝐼/𝐷𝑂 inhibitor 
10-20 10-20 1-10 𝐾𝑑
𝐷𝐼𝐸 
Bound to CRAF/BRAF (mutant or WT), 
which is bound to a 𝐼𝐶𝑂/𝐷𝐼 inhibitor 
10-20 40-100 1-10 𝐾𝑑
𝐷𝑂𝐸 
 
List S3.2 does not present the values of the apparent dissociation constants, because they may have the 
same names but different values for different states of RAF molecules, indicated in the first column of 
List S3.2. For example, CRAF phosphorylated and dephosphorylated on S338 have different equilibrium 
constants for both movements of DFG-motif and αC-helix. Moreover, we explore ranges of values for the 
coefficients 𝑏, 𝑐, and 𝛾 and, hence, the thermodynamic equilibrium constants of thermal motions. 
Therefore, for each inhibitor type and each RAF state the apparent dissociation constants are 
automatically calculated from Eqs. S3.13a-c using an Excel spreadsheet “Kds.xlsx” and incorporated into 
the supplied BioNetGen file “RAF_MEK_ERK.bngl”. 
From List S3.2, it follows that the probability to observe the DFG-OUT, αC-OUT state of a protomer is 
less than 1% in RAF dimers. The low probability of this state can explain why there are no reported PDB 
structures with RAF protomers in DFG-OUT, αC-OUT conformations (see Fig. 1D).There are no known 
CO/DO inhibitors that would lock a RAF protomer in this conformation.  
3.3 Relationships between the apparent Kd’s and thermodynamic factors that characterize allosteric 
inhibitor effects. 
The equilibrium constants of reactions in each cycle of RAF dimerization and inhibitor binding obey the 
detailed balance principle. According to this principle, the product of the equilibrium dissociation 
constants along a closed cycle of binding/dissociation reactions must be equal to 1, since the overall 
change in free energy is zero. Since the IN/OUT thermal motions include inhibitor-bound RAF states and 
RAF monomers and dimers, the detailed balance principle imposes constraints on the values of the 
apparent dissociation constants in the cycle of inhibitor binding and dimerization (see below).  
For a cycle of binding of an inhibitor to BRAF (B) and CRAF (C) monomers and a BRAF-CRAF 
heterodimer (BC), we have the following lumped reaction scheme (which does not elaborate different 
conformational states, see also Scheme S3.5),  
Scheme S3.6 
The detailed balance principle requires that the following conditions be satisfied, 
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𝐾9 ⋅ 𝐾5
𝐾4 ⋅ 𝐾8
= 1 
𝐾5 ⋅ 𝐾1
𝐾3 ⋅ 𝐾7
= 1 
𝐾4 ⋅ 𝐾1
𝐾2 ⋅ 𝐾6
= 1 
𝐾10 ⋅ 𝐾3
𝐾8 ⋅ 𝐾6
= 1 
𝐾10 ⋅ 𝐾2
𝐾7 ⋅ 𝐾9
= 1 (S3.14) 
The thermodynamic constraints allow us to express the dissociations constants, K4 – K10, in terms of the 
dimerization constant K1, inhibitor binding constants K2 and K3 and thermodynamic factors, f, g1, and g2 
(Kholodenko, 2015). The facilitation factor (f), which relates the dimerization constants of free monomers 
(K1) and inhibitor-bound and free monomers (K4), describes the inhibitor-induced change in dimerization 
affinity (Kholodenko, 2015).  If the facilitation factor f is less than 1, the dimers with only one bound 
molecule of inhibitor are stabilized by the inhibitor (Kholodenko, 2015). The thermodynamic factor g1 
describes the differences in binding of the first inhibitor molecule to different protomers in an asymmetric 
dimer. The thermodynamic factor g2 connects the dissociation constant K5 for the binding of the second 
inhibitor molecule to a dimer with one inhibitor molecule bound and the dissociation constant K2 for the 
inhibitor binding to a monomer. When g2 > 1 the second inhibitor molecule binds to a dimer with one 
inhibitor molecule bound less effectively than the inhibitor binds to a kinase monomer. The expressions 
that relate thermodynamic factors and apparent dissociation constants are given in List S3.3. 
Equations S3.14 allow us to obtain the following relationships between the thermodynamic factors g1 and 
g2 and the apparent dissociation constants.  
For a 𝐼𝐶𝑂/𝐷𝐼 inhibitor, these relationships are captured by the following expressions,  
𝑔1 =
𝐾𝑑
𝐷𝑂𝐶
𝐾𝑑
𝐷𝑂𝐵 ⋅
𝐾𝑑
𝑚𝐵
𝐾𝑑
𝑚𝐶  𝑔2 =
𝐾𝑑
𝐷𝑂𝐵
𝐾𝑑
𝑚𝐵  (S3.15) 
In addition, the detailed balance relationships require that the following condition is satisfied 
𝐾𝑑
𝐷𝐼𝐵
𝐾𝑑
𝐷𝑂𝐵 =
𝐾𝑑
𝐷𝐼𝐶
𝐾𝑑
𝐷𝑂𝐶 (S3.16) 
Although the values of each apparent dissociation constant are different for different RAF states, they all 
must satisfy Eqs. S3.16. The 𝑎-coefficients (𝑎11
𝐶𝐼/𝐷𝐼
, 𝑎12
𝐶𝐼/𝐷𝐼
, etc.) are specific for every inhibitor. 
Coefficients 𝛾, 𝑏 and 𝑐 characterize a given state of a RAF molecule (determined by its binding partners 
and the phosphorylation status of its phospho-sites). Thus, for specific values of the 𝑎-coefficients and a 
given RAF molecule state, Eq. S3.16 imposes thermodynamic constraints on the coefficients, 𝛾, 𝑏 and 𝑐, 
which are accounted for in the model. 
For 𝐼𝐶𝐼/𝐷𝐼 and 𝐼𝐶𝐼/𝐷𝑂 inhibitors, the analogs of Eq. S3.15 are the following,  
𝑔1 =
𝐾𝑑
𝐷𝐼𝐶
𝐾𝑑
𝐷𝐼𝐵 ⋅
𝐾𝑑
𝑚𝐵
𝐾𝑑
𝑚𝐶  𝑔2 =
𝐾𝑑
𝐷𝐼𝐵
𝐾𝑑
𝑚𝐵  (S3.17) 
For each inhibitor type (𝐼𝛼𝐼/𝐷𝐼, 𝐼𝛼𝐼/𝐷𝑂, and 𝐼𝛼𝑂/𝐷𝐼), Eqs. S3.15, S3.16 or S3.17 relate the thermodynamic 
factors gi with the apparent Kd’s of inhibitor binding defined in List S3.2.  
Eqs. S3.14-S3.17 allow us to relate the phenomenological thermodynamics factors (g1, and g2) with the 
apparent Kd’s of inhibitor binding to different RAF forms. List S3.3 expresses the dissociations constants 
K4 – K10 in terms of phenomenological factors f, g1 and g2 introduced in Ref (Kholodenko, 2015) and in 
terms of the apparent dissociation constants introduced in List S3.2 and the factor f. For each RAF 
inhibitor, the value of the factor f is a unique feature that is not directly determined by the positions of the 
αC-helix and DFG motif.  
List S3.3. Reactions and relationships between equilibrium dissociation constants for a model 
of BRAF-CRAF heterodimerization and allosteric inhibitor effects 
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Reaction 
Number 
Reactions 
Equilibrium Dissociation 
Constants Expressed in 
Terms of Factors f, g1 and g2 
Equilibrium Dissociation Constants 
Expressed in Terms of Apparent 
Dissociation Constants and the 
Factor f 
1 B + C ↔ B-C 𝐾1  𝐾1  
2 B + I ↔ BI 𝐾2  𝐾𝑑
𝑚𝐵  
3 C + I ↔ CI 𝐾3  𝐾𝑑
𝑚𝐶  
4 B-C + I ↔ BI-C 𝐾4 = 𝑓 ⋅ 𝐾2  𝐾4 = 𝑓 ⋅ 𝐾𝑑
𝑚𝐵  
5 B-C + I ↔ B-CI 𝐾5 = 𝑔1 ⋅ 𝑓 ⋅ 𝐾3  𝐾5 =
𝐾𝑑
𝐷𝐼𝐶
𝐾𝑑
𝐷𝐼𝐵 ⋅ 𝑓 ⋅ 𝐾𝑑
𝑚𝐵   
6 BI + C ↔ BI-C 𝐾6 = 𝑓 ⋅ 𝐾1  𝐾6 = 𝑓 ⋅ 𝐾1  
7 B + CI ↔ B-CI 𝐾7 = 𝑔1 ⋅ 𝑓 ⋅ 𝐾1  𝐾7 = 𝑓 ⋅
𝐾𝑑
𝑚𝐵
𝐾𝑑
𝑚𝐶 ⋅
𝐾𝑑
𝐷𝐼𝐶
𝐾𝑑
𝐷𝐼𝐵 ⋅ 𝐾1  
8 BI-C + I ↔ BI-CI 𝐾8 = 𝑔1 ⋅ 𝑔2 ⋅ 𝐾3  
For 𝐼𝐶𝑂/𝐷𝐼, 𝐾8 = 𝐾𝑑
𝐷𝑂𝐶  
For 𝐼𝐶𝐼/𝐷𝐼 and 𝐼𝐶𝐼/𝐷𝑂: 𝐾8 = 𝐾𝑑
𝐷𝐼𝐶  
9 B-CI + I ↔ BI-CI 𝐾9 = 𝑔2 ⋅ 𝐾2  
For 𝐼𝐶𝑂/𝐷𝐼, 𝐾9 = 𝐾𝑑
𝐷𝑂𝐵  
For 𝐼𝐶𝐼/𝐷𝐼 and 𝐼𝐶𝐼/𝐷𝑂, 𝐾9 = 𝐾𝑑
𝐷𝐼𝐵  
10 BI + CI ↔ BI-CI 𝐾10 = 𝑓 ⋅ 𝑔1 ⋅ 𝑔2 ⋅ 𝐾1  
For 𝐼𝐶𝑂/𝐷𝐼, 𝐾10 = 𝑓 ⋅
𝐾𝑑
𝐷𝑂𝐶
𝐾𝑑
𝑚𝐶 ⋅ 𝐾1  
For 𝐼𝐶𝐼/𝐷𝐼 and 𝐼𝐶𝐼/𝐷𝑂, 𝐾10 = 𝑓
𝐾𝑑
𝐷𝐼𝐶
𝐾𝑑
𝑚𝐶 𝐾1  
 
Binding of two different inhibitors to RAF molecules. Below we analyze the binding of two different 
inhibitors (I1 and I2) to RAF monomers and dimers in the RAF dimerization cycle. The reaction schemes 
are presented below, 
Scheme S3.7. 
In Scheme S3.7 and in text below, the subscripts a and b refer to inhibitors I1 and I2.  
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Detailed balance principle requires that the following conditions must be satisfied: 
𝐾9𝑎 ⋅ 𝐾5𝑎
𝐾4𝑎 ⋅ 𝐾8𝑎
= 1 
𝐾5𝑎 ⋅ 𝐾1
𝐾3𝑎 ⋅ 𝐾7𝑎
= 1 
𝐾4𝑎 ⋅ 𝐾1
𝐾2𝑎 ⋅ 𝐾6𝑎
= 1 
𝐾10𝑎 ⋅ 𝐾3𝑎
𝐾8𝑎 ⋅ 𝐾6𝑎
= 1 
(S3.18) 
𝐾9𝑏 ⋅ 𝐾5𝑏
𝐾4𝑏 ⋅ 𝐾8𝑏
= 1 
𝐾5𝑏 ⋅ 𝐾1
𝐾3𝑏 ⋅ 𝐾7𝑏
= 1 
𝐾4𝑏 ⋅ 𝐾1
𝐾2𝑏 ⋅ 𝐾6𝑏
= 1 
𝐾10𝑏 ⋅ 𝐾3𝑏
𝐾8𝑏 ⋅ 𝐾6𝑏
= 1 
𝐾12 ⋅ 𝐾5𝑏
𝐾4𝑎 ⋅ 𝐾11
= 1 
𝐾15 ⋅ 𝐾5𝑎
𝐾4𝑏 ⋅ 𝐾14
= 1 
𝐾16 ⋅ 𝐾3𝑎
𝐾6𝑏 ⋅ 𝐾14
= 1 
𝐾13 ⋅ 𝐾3𝑏
𝐾6𝑎 ⋅ 𝐾11
= 1 
𝐾16 ⋅ 𝐾2𝑏
𝐾7𝑎 ⋅ 𝐾15
= 1 
𝐾10𝑎 ⋅ 𝐾2𝑎
𝐾7𝑎 ⋅ 𝐾9𝑎
= 1 
𝐾10𝑏 ⋅ 𝐾2𝑏
𝐾7𝑏 ⋅ 𝐾9𝑏
= 1 
𝐾13 ⋅ 𝐾2𝑎
𝐾7𝑏 ⋅ 𝐾12
= 1 
Similarly to the one-inhibitor case, the thermodynamic constraints S3.18 allow us to express dissociations 
constants K4 – K16 in terms of the dimerization constant K1, inhibitor binding constants K2a, K2b, K3a and 
K3b and thermodynamic factors, fa, fb, g1a, g1b, g2a, g2b, g3a and g3b. Thermodynamic factors fa, fb, g1a, g1b, 
g2a, g2b describe the same effects as for the one-inhibitor case, and subscripts a and b refer to inhibitors I1 
and I2. The factor g3a quantifies the difference (normalized on facilitation factors fa and fb ) in the 
dissociation constants of I1 binding to a free RAF monomer versus to the protomer in RAF dimer, when 
the other protomer is occupied by I2. Likewise, the factor g3b describes the difference (normalized on 
facilitation factors fa and fb) in dissociation constants of I2 binding to monomer versus protomer in RAF 
dimer, when the other protomer is occupied by I1. Note that we have redefined factors g3a and g3b 
compared to Ref. (Kholodenko, 2015) to make expressions for the dissociation constants K13 and K16 
symmetric with respect to fa and fb (see List S3.4). If we denote the factor g3a defined in Ref. 
(Kholodenko, 2015) as 𝑔3𝑎
∗ , it can be expressed via the factor g3a introduced here, as follows, 𝑔3𝑎
∗ =
 𝑔3𝑎 ⋅ √𝑓𝑎/𝑓𝑏. Likewise, the factor 𝑔3𝑏
∗  defined in Ref. (Kholodenko, 2015) is expressed via the factor g3b, 
as follows, 𝑔3𝑏
∗ = 𝑔3𝑏√𝑓𝑏/𝑓𝑎.  
 
 
Equations S3.18 allow us to obtain the following relationships between the thermodynamic factors g1a, 
g1b, g2a, and g2b and the apparent dissociation constants. If both I1 and I2 are DFG-IN, αC-OUT inhibitors, 
these relationships read,  
𝑔1𝑎 =
𝐾𝑑𝑎
𝐷𝑂𝐶
𝐾𝑑𝑎
𝐷𝑂𝐵 ⋅
𝐾𝑑𝑎
𝑚𝐵
𝐾𝑑𝑎
𝑚𝐶  𝑔1𝑏 =
𝐾𝑑𝑏
𝐷𝑂𝐶
𝐾𝑑𝑏
𝐷𝑂𝐵 ⋅
𝐾𝑑𝑏
𝑚𝐵
𝐾𝑑𝑏
𝑚𝐶  
(S3.19) 
𝑔2𝑎 =
𝐾𝑑𝑎
𝐷𝑂𝐵
𝐾𝑑𝑎
𝑚𝐵  𝑔2𝑏 =
𝐾𝑑𝑏
𝐷𝑂𝐵
𝐾𝑑𝑏
𝑚𝐵  
In addition, the detailed balance relationships require the following conditions to be satisfied 
𝐾𝑑𝑎
𝐷𝐼𝐵
𝐾𝑑𝑎
𝐷𝑂𝐵 =
𝐾𝑑𝑎
𝐷𝐼𝐶
𝐾𝑑𝑎
𝐷𝑂𝐶 =
𝐾𝑑𝑏
𝐷𝐼𝐵
𝐾𝑑𝑏
𝐷𝑂𝐵 =
𝐾𝑑𝑏
𝐷𝐼𝐶
𝐾𝑑𝑏
𝐷𝑂𝐶 (S3.20) 
Thermodynamic coefficients for binding of CI/DI and CI/DO inhibitors and their combinations are 
readily obtained after substituting 𝐾𝑑
𝐷𝑂𝐵 by 𝐾𝑑
𝐷𝐼𝐵 and 𝐾𝑑
𝐷𝑂𝐶 by 𝐾𝑑
𝐷𝐼𝐶. For example, for a pair of CI/DO (a) 
and CO/DI (b) inhibitors, Eqns. S3.19 read, 
𝑔1𝑎 =
𝐾𝑑𝑎
𝐷𝐼𝐶
𝐾𝑑𝑎
𝐷𝐼𝐵 ⋅
𝐾𝑑𝑎
𝑚𝐵
𝐾𝑑𝑎
𝑚𝐶  𝑔1𝑏 =
𝐾𝑑𝑏
𝐷𝑂𝐶
𝐾𝑑𝑏
𝐷𝑂𝐵 ⋅
𝐾𝑑𝑏
𝑚𝐵
𝐾𝑑𝑏
𝑚𝐶  (S3.21) 
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𝑔2𝑎 =
𝐾𝑑𝑎
𝐷𝐼𝐵
𝐾𝑑𝑎
𝑚𝐵  𝑔2𝑏 =
𝐾𝑑𝑏
𝐷𝑂𝐵
𝐾𝑑𝑏
𝑚𝐵  
The detailed balance relationships S3.18 in this case require the following condition to be satisfied 
𝐾𝑑𝑏
𝐷𝐼𝐵
𝐾𝑑𝑏
𝐷𝑂𝐵 =
𝐾𝑑𝑏
𝐷𝐼𝐶
𝐾𝑑𝑏
𝐷𝑂𝐶 (S3.22) 
Eqs. S3.21-S3.22 will be valid for the pair of CI/DI (a) and CO/DI (b) inhibitors as well. 
Eqs. S3.18-S3.12 allow us to relate the phenomenological thermodynamics factors (g1a, g1b, g2a and g2b) 
with the apparent Kd’s of inhibhitor binding to different RAF forms. List S3.4 expresses the dissociation 
constants, K4 – K16 in terms of the phenomenological factors fa, fb, g1a, g1b, g2a, and g2b and also in terms 
of the apparent dissociation constants introduced in List S3.2 and smaller numbers of free parameters, 
which are g3a, g3b, fa and fb. As above, the value of the factors g3 and f are unique features of each 
inhibitor that are not directly determined by the positions of the αC-helix and DFG motif.  
 
List S3.4. Reactions and relationships between equilibrium dissociation constants for a model of 
BRAF-CRAF heterodimers and two allosteric inhibitors 
No. Reactions 
Equilibrium dissociation 
constants expressed in terms 
of phenomenological 
thermodynamics factors 
Relationships between the Kd’s that 
minimize the number of unknown 
thermodynamics factors 
1 B + C ↔ B-C 𝐾1  𝐾1  
2a B + I1 ↔ BI1 𝐾2𝑎  𝐾𝑑𝑎
𝑚𝐵  
2b B + I2 ↔ BI2 𝐾2𝑏  𝐾𝑑𝑏
𝑚𝐵  
3a C + I1 ↔ CI1 𝐾3𝑎  𝐾𝑑𝑎
𝑚𝐶  
3b C + I2 ↔ CI2 𝐾3𝑏  𝐾𝑑𝑏
𝑚𝐶  
4a B-C + I1 ↔ BI1-C 𝐾4𝑎 = 𝑓𝑎 ⋅ 𝐾2𝑎  𝐾4𝑎 = 𝑓𝑎 ⋅ 𝐾𝑑𝑎
𝑚𝐵  
4b B-C + I2 ↔ BI2-C 𝐾4𝑏 = 𝑓𝑏 ⋅ 𝐾2𝑏  𝐾4𝑏 = 𝑓𝑏 ⋅ 𝐾𝑑𝑏
𝑚𝐵  
5a B-C + I1 ↔ B-CI1 𝐾5𝑎 = 𝑔1𝑎 ⋅ 𝑓𝑎 ⋅ 𝐾3𝑎  𝐾5𝑎 =
𝐾𝑑𝑎
𝐷𝐼𝐶
𝐾𝑑𝑎
𝐷𝐼𝐵 ⋅ 𝑓𝑎 ⋅ 𝐾𝑑𝑎
𝑚𝐵   
5b B-C + I2 ↔ B-CI2 𝐾5𝑏 = 𝑔1𝑏 ⋅ 𝑓𝑏 ⋅ 𝐾3𝑏  𝐾5𝑏 =
𝐾𝑑𝑏
𝐷𝐼𝐶
𝐾𝑑𝑏
𝐷𝐼𝐵 ⋅ 𝑓𝑏 ⋅ 𝐾𝑑𝑏
𝑚𝐵  
6a BI1 + C ↔ BI1-C 𝐾6𝑎 = 𝑓𝑎 ⋅ 𝐾1  𝐾6𝑎 = 𝑓𝑎 ⋅ 𝐾1  
6b BI2 + C ↔ BI2-C 𝐾6𝑏 = 𝑓𝑏 ⋅ 𝐾1  𝐾6𝑏 = 𝑓𝑏 ⋅ 𝐾1  
7a B + CI1 ↔ B-CI1 𝐾7𝑎 = 𝑔1𝑎 ⋅ 𝑓𝑎 ⋅ 𝐾1  𝐾7𝑎 = 𝑓𝑎 ⋅
𝐾𝑑𝑎
𝑚𝐵
𝐾𝑑𝑎
𝑚𝐶 ⋅
𝐾𝑑𝑎
𝐷𝐼𝐶
𝐾𝑑𝑎
𝐷𝐼𝐵 ⋅ 𝐾1  
7b B + CI2 ↔ B-CI2 𝐾7𝑏 = 𝑔1𝑏 ⋅ 𝑓𝑏 ⋅ 𝐾1  𝐾7𝑏 = 𝑓𝑏 ⋅
𝐾𝑑𝑏
𝑚𝐵
𝐾𝑑𝑏
𝑚𝐶 ⋅
𝐾𝑑𝑏
𝐷𝐼𝐶
𝐾𝑑𝑏
𝐷𝐼𝐵 ⋅ 𝐾1  
8a BI1-C+I1 ↔ BI1-CI1 𝐾8𝑎 = 𝑔1𝑎 ⋅ 𝑔2𝑎 ⋅ 𝐾3𝑎  
For 𝐼1
𝐶𝑂/𝐷𝐼
: 𝐾8𝑎 = 𝐾𝑑𝑎
𝐷𝑂𝐶  
For 𝐼1
𝐶𝐼/𝐷𝐼
 & 𝐼1
𝐶𝐼/𝐷𝑂
: 𝐾8𝑎 = 𝐾𝑑𝑎
𝐷𝐼𝐶  
8b BI2-C+I2 ↔ BI2-CI2 𝐾8𝑏 = 𝑔1𝑏 ⋅ 𝑔2𝑏 ⋅ 𝐾3𝑏  
For 𝐼2
𝐶𝑂/𝐷𝐼
: 𝐾8𝑏 = 𝐾𝑑𝑏
𝐷𝑂𝐶  
For 𝐼2
𝐶𝐼/𝐷𝐼
 & 𝐼2
𝐶𝐼/𝐷𝑂
: 𝐾8𝑏 = 𝐾𝑑𝑏
𝐷𝐼𝐶  
9a B-CI1+I1 ↔ BI1-CI1 𝐾9𝑎 = 𝑔2𝑎 ⋅ 𝐾2𝑎  
For 𝐼1
𝐶𝑂/𝐷𝐼
: 𝐾9𝑎 = 𝐾𝑑𝑎
𝐷𝑂𝐵  
For 𝐼1
𝐶𝐼/𝐷𝐼
 & 𝐼1
𝐶𝐼/𝐷𝑂
: 𝐾9𝑎 = 𝐾𝑑𝑎
𝐷𝐼𝐵  
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9b B-CI2+I2 ↔ BI2-CI2 𝐾9𝑏 = 𝑔2𝑏 ⋅ 𝐾2𝑏  
For 𝐼2
𝐶𝑂/𝐷𝐼
: 𝐾9𝑏 = 𝐾𝑑𝑏
𝐷𝑂𝐵  
For 𝐼2
𝐶𝐼/𝐷𝐼
 & 𝐼2
𝐶𝐼/𝐷𝑂
: 𝐾9𝑏 = 𝐾𝑑𝑏
𝐷𝐼𝐵  
10a BI1+CI1 ↔ BI1-CI1 𝐾10𝑎 = 𝑓𝑎 ⋅ 𝑔1𝑎 ⋅ 𝑔2𝑎 ⋅ 𝐾1  
For 𝐼1
𝐶𝑂/𝐷𝐼
: 𝐾10𝑎 = 𝑓𝑎 ⋅
𝐾𝑑𝑎
𝐷𝑂𝐶
𝐾𝑑𝑎
𝑚𝐶 ⋅ 𝐾1  
For 𝐼1
𝐶𝐼/𝐷𝐼
 & 𝐼1
𝐶𝐼/𝐷𝑂
: 𝐾10𝑎 = 𝑓𝑎
𝐾𝑑𝑎
𝐷𝐼𝐶
𝐾𝑑𝑎
𝑚𝐶 𝐾1  
10b BI2+CI2 ↔ BI2-CI2 𝐾10𝑏 = 𝑓𝑏 ⋅ 𝑔1𝑏 ⋅ 𝑔2𝑏 ⋅ 𝐾1  
For 𝐼2
𝐶𝑂/𝐷𝐼
: 𝐾10𝑏 = 𝑓𝑏 ⋅
𝐾𝑑𝑏
𝐷𝑂𝐶
𝐾𝑑𝑏
𝑚𝐶 ⋅ 𝐾1  
For 𝐼2
𝐶𝐼/𝐷𝐼
 & 𝐼2
𝐶𝐼/𝐷𝑂
: 𝐾10𝑏 = 𝑓𝑏
𝐾𝑑𝑏
𝐷𝐼𝐶
𝐾𝑑𝑏
𝑚𝐶 𝐾1  
11 BI1-C+I2 ↔ BI1-CI2 𝐾11 = 𝑔1𝑏𝑔3𝑎√𝑓𝑏/𝑓𝑎 ⋅ 𝐾3𝑏  𝐾11 = 𝑔3𝑎√𝑓𝑏/𝑓𝑎 ⋅
𝐾𝑑𝑏
𝐷𝐼𝐶
𝐾𝑑𝑏
𝐷𝐼𝐵 ⋅ 𝐾𝑑𝑏
𝑚𝐵  
12 B-CI2+I1 ↔ BI1-CI2 𝐾12 = 𝑔3𝑎 ⋅ √𝑓𝑎/𝑓𝑏 ⋅ 𝐾2𝑎  𝐾12 = 𝑔3𝑎√𝑓𝑎/𝑓𝑏 ⋅ 𝐾𝑑𝑎
𝑚𝐵  
13 BI1+CI2 ↔ BI1-CI2 𝐾13 = 𝑔1𝑏𝑔3𝑎√𝑓𝑎𝑓𝑏 ⋅ 𝐾1  𝐾13 = 𝑔3𝑎
𝐾𝑑𝑏
𝐷𝐼𝐶
𝐾𝑑𝑏
𝐷𝐼𝐵
𝐾𝑑𝑏
𝑚𝐵
𝐾𝑑𝑏
𝑚𝐶 ⋅ √𝑓𝑎𝑓𝑏 ⋅ 𝐾1  
14 BI2-C+I1 ↔ BI2-CI1 𝐾14 = 𝑔1𝑎𝑔3𝑏√𝑓𝑎/𝑓𝑏 ⋅ 𝐾3𝑎  𝐾14 = 𝑔3𝑏√𝑓𝑎/𝑓𝑏 ⋅
𝐾𝑑𝑎
𝐷𝐼𝐶
𝐾𝑑𝑎
𝐷𝐼𝐵 ⋅ 𝐾𝑑𝑎
𝑚𝐵  
15 B-CI1+I2 ↔ BI2-CI1 𝐾15 = 𝑔3𝑏 ⋅ √𝑓𝑏/𝑓𝑎 ⋅ 𝐾2𝑏  𝐾15 = 𝑔3𝑏√𝑓𝑏/𝑓𝑎 ⋅ 𝐾𝑑𝑏
𝑚𝐵  
16 BI2+CI1 ↔ BI2-CI1 𝐾16 = 𝑔1𝑎𝑔3𝑏 ⋅ √𝑓𝑎𝑓𝑏 ⋅ 𝐾1  𝐾16 = 𝑔3𝑏
𝐾𝑑𝑎
𝐷𝐼𝐶
𝐾𝑑𝑎
𝐷𝐼𝐵
𝐾𝑑𝑎
𝑚𝐵
𝐾𝑑𝑎
𝑚𝐶 ⋅ √𝑓𝑎𝑓𝑏 ⋅ 𝐾1  
 
Similar reactions of homodimerization of RAF molecules, inhibitor binding and resulting relationships 
between the equilibrium dissociation constants and the thermodynamic factors describing allosteric 
effects are presented in the files “Kds.xlsx” and “RAF_MEK_ERK.bngl”.  
 
4. Total kinase activity of different monomeric and dimeric RAF forms.  
The total kinase activity is proportional to the weighted sum of the concentrations of inhibitor-free 
monomers and dimers and partially inhibited dimers (see List S3.4). Inhibitor bound RAF monomers and 
RAF dimers that have bound two inhibitor molecules are taken to have no kinase activity.  
List S4.1. Relative activities of different RAF kinase forms.  
Molecule description 
Rule-based representation of 
the molecule (Chylek et al., 
2014) 
Kinase activity 
relative to active 
BRAF monomer 
RAF monomers and dimers that are inhibitor-free  
Active WT BRAF monomer BRAF(bI) 1 
WT BRAF homodimer 
BRAF(Dm!1,bI). 
BRAF(Dm!1,bI) 
2 
CRAF monomer not phosphorylated on S338, 
regardless of state of S642 
CRAF(S338~0,S642~?,cI) 0 
CRAF monomer phosphorylated on S338 and 
not phosphorylated on S642 
CRAF(S338~P,S642~0,cI) 0.2 
CRAF monomer phosphorylated on S338 and 
S642 
CRAF(S338~P,S642~P,cI) 0 
CRAF homodimer, both molecules are not CRAF(S338~0, S642~?,Dm!1,cI). 0.01 
26 
 
phosphorylated on S338, regardless of state of 
S642 
CRAF(S338~0, S642~?,Dm!1,cI) 
CRAF homodimer, both molecules are 
phosphorylated on S642, regardless of state of 
S338 
CRAF(S338~?, S642~P,Dm!1,cI). 
CRAF(S338~?, S642~P,Dm!1,cI) 
0.01 
CRAF homodimer with only one protomer 
phosphorylated S338 and not phosphorylated 
on S338 
CRAF(S338~P,S642~0,cI). 
CRAF(S338~0, S642~?,cI) 
0.2 
CRAF homodimer, both molecules are 
phosphorylated on S338 and not 
phosphorylated on S642 
CRAF(S338~P, S642~0,Dm!1,cI). 
CRAF(S338~P, S642~0,Dm!1,cI) 
0.4 
CRAF homodimer with one protomer 
phosphorylated S338 and another protomer 
phosphorylated on S642 
CRAF(S338~P,S642~0,cI). 
CRAF(S338~?, S642~P,cI) 
0.2 
Heterodimer with CRAF not phosphorylated 
on S338 (regardless of state of S642) and WT 
BRAF 
CRAF(S338~0, S642~?,Dm!1,cI). 
BRAF(Dm!1,bI) 
15 
Heterodimer with CRAF phosphorylated on 
S642 (regardless of state of S338) and WT 
BRAF 
CRAF(S338~?, S642~P,Dm!1,cI). 
BRAF(Dm!1,bI) 
15 
Heterodimer with CRAF phosphorylated on 
S338 and not phosphorylated on S642 and 
WT BRAF 
CRAF(S338~P, S642~0,Dm!1,cI). 
BRAF(Dm!1,bI) 
30 
BRAFV600E monomer BRAFV600E(EI) 2 
BRAFV600E homodimer  
BRAFV600E(Dm!1, EI). 
BRAFV600E(Dm!1, EI) 
4 
Heterodimer with BRAFV600E and WT 
BRAF 
BRAF(Dm!1,bI). 
BRAFV600E(Dm!1, EI) 
3 
Heterodimer with BRAFV600E and CRAF 
not phosphorylated on S338 (regardless of 
state of S642) 
CRAF(S338~0, S642~?,Dm!1,cI). 
BRAFV600E(Dm!1,EI) 
15 
Heterodimer with BRAFV600E and CRAF 
phosphorylated on S642 (regardless of state 
of S338) 
CRAF(S338~?, S642~P,Dm!1,cI). 
BRAFV600E(Dm!1,EI) 
15 
Heterodimer with BRAFV600E and CRAF 
phosphorylated on S338 and not 
phosphorylated on S642 
CRAF(S338~P, S642~0,Dm!1,cI). 
BRAFV600E(Dm!1,EI) 
30 
RAF dimers bound to one inhibitor molecule 
CRAF homodimer with one inhibitor bound, 
protomer free from inhibitor is 
phosphorylated on S338 and not 
phosphorylated on S642 
CRAF(S338~P,S642~0,Dm!1,cI). 
CRAF(S338~?, S642~?,Dm!1,cI!2). 
Inh(RAFI!2) 
0.2 
CRAF homodimer with one inhibitor bound, 
protomer free from inhibitor is 
dephosphorylated on S338 regardless of state 
of S642 
CRAF(S338~0,S642~?,Dm!1,cI). 
CRAF(S338~?,S642~?,Dm!1,cI!2). 
Inh(RAFI!2) 
0 
CRAF homodimer with one inhibitor bound, 
protomer free from inhibitor is 
phosphorylated on S642 regardless of state of 
S338 
CRAF(S338~?,S642~P,Dm!1,cI). 
CRAF(S338~?,S642~?,Dm!1,cI!2). 
Inh(RAFI!2) 
0 
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WT BRAF homodimer with one inhibitor 
molecule bound it 
BRAF(Dm!1,bI). 
BRAF(Dm!1,bI!2). 
Inh(RAFI!2) 
1 
Heterodimer with CRAF not phosphorylated 
on S338 (regardless of state of S642) and WT 
BRAF, inhibitor molecule is bound to CRAF 
BRAF(Dm!1,bI). 
CRAF(S338~0,S642~?,Dm!1,cI!2). 
Inh(RAFI!2) 
8 
Heterodimer with CRAF not phosphorylated 
on S338 (regardless of state of S642) and WT 
BRAF, inhibitor molecule is bound to BRAF 
CRAF(S338~0,S642~?,Dm!1,cI). 
BRAF(Dm!1,bI!2). 
Inh(RAFI!2) 
8 
Heterodimer with CRAF phosphorylated on 
S642 (regardless of state of S338) and WT 
BRAF, inhibitor molecule is bound to CRAF 
BRAF(Dm!1,bI). 
CRAF(S338~?,S642~P,Dm!1,cI!2). 
Inh(RAFI!2) 
8 
Heterodimer with CRAF phosphorylated on 
S642 (regardless of state of S338) and WT 
BRAF, inhibitor molecule is bound to BRAF 
CRAF(S338~?,S642~P,Dm!1,cI). 
BRAF(Dm!1,bI!2). 
Inh(RAFI!2) 
8 
Heterodimer with CRAF phosphorylated on 
S338 and dephosphorylated on S642 and WT 
BRAF, inhibitor molecule is bound to CRAF 
BRAF(Dm!1,bI). 
CRAF(S338~P,S642~0,Dm!1,cI!2). 
Inh(RAFI!2) 
15 
Heterodimer with CRAF phosphorylated on 
S338 and dephosphorylated on S642 and WT 
BRAF, inhibitor molecule is bound to BRAF 
CRAF(S338~P, S642~0,Dm!1,cI). 
BRAF(Dm!1,bI!2). 
Inh(RAFI!2) 
15 
Heterodimer with CRAF not phosphorylated 
on S338 (regardless of state of S642) and WT 
BRAFV600E, inhibitor molecule is bound to 
CRAF 
BRAFV600E(Dm!1,bI). 
CRAF(S338~0,S642~?,Dm!1,cI!2). 
Inh(RAFI!2) 
8 
Heterodimer with CRAF not phosphorylated 
on S338 (regardless of state of S642) and WT 
BRAFV600E, inhibitor molecule is bound to 
BRAFV600E 
CRAF(S338~0,S642~?,Dm!1,cI). 
BRAFV600E(Dm!1,bI!2). 
Inh(RAFI!2) 
8 
Heterodimer with CRAF phosphorylated on 
S642 (regardless of state of S338) and WT 
BRAFV600E, inhibitor molecule is bound to 
CRAF 
BRAFV600E(Dm!1,bI). 
CRAF(S338~?,S642~P,Dm!1,cI!2). 
Inh(RAFI!2) 
8 
Heterodimer with CRAF phosphorylated on 
S642 (regardless of state of S338) and WT 
BRAFV600E, inhibitor molecule is bound to 
BRAFV600E 
CRAF(S338~?,S642~P,Dm!1,cI). 
BRAFV600E(Dm!1,bI!2). 
Inh(RAFI!2) 
8 
Heterodimer with CRAF phosphorylated on 
S338 and dephosphorylated on S642 and WT 
BRAFV600E, inhibitor molecule is bound to 
CRAF 
BRAFV600E(Dm!1,bI). 
CRAF(S338~P,S642~0,Dm!1,cI!2). 
Inh(RAFI!2) 
15 
Heterodimer with CRAF phosphorylated on 
S338 and dephosphorylated on S642 and WT 
BRAFV600E, inhibitor molecule is bound to 
BRAFV600E 
CRAF(S338~P, S642~0,Dm!1,cI). 
BRAFV600E(Dm!1,bI!2). 
Inh(RAFI!2) 
15 
Dimer of WT BRAF and BRAFV600E with 
one inhibitor molecule bound to WT BRAF 
BRAF(Dm!1,bI). 
BRAFV600E(Dm!1,bI!2). 
Inh(RAFI!2) 
1 
Dimer of WT BRAF and BRAFV600E with 
one inhibitor molecule bound to BRAFV600E 
BRAFV600E(Dm!1,bI). 
BRAF (Dm!1,bI!2). 
2 
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Inh(RAFI!2) 
 
5. Parameters of the model 
List S5.1. Model parameters 
Parameter Value Description 
MEK_level 1600 nM Total concentration of MEK 
ERK_level 3000 nM Total concentration of ERK 
BRAF_level* 50 nM Total concentration of WT BRAF 
CRAF_level* 50 nM Total concentration of CRAF 
BE_level* 25 nM Total concentration of BRAFV600E 
RasT* 25 nM Concentration of active RAS 
Ph1_tot 100 nM Total concentration of MEK phosphatase 
MKP3_tot 100 nM Total concentration of ERK phosphatase 
p1 7 
Effect of ERK feedback phosphorylation on RAF binding to 
RAS-GTP 
p2 16 Effect of PM localization of chemicals on reaction Kd 
p3 7 
Effect of ERK feedback phosphorylation on RAF 
dimerization 
k_on_typ 0.001 (nM·s)-1 Scale of forward reaction rate of protein binding 
k_on_typ_a 
0.1 (nM·s)-1 
10-4 (nM·s)-1 
Forward reaction rate of inhibitor 1 binding to RAF for the 
cases of high (highest value) and low (lowest value) koff 
k_on_typ_b 
0.1 (nM·s)-1 
10-4 (nM·s)-1 
Forward reaction rate of inhibitor 2 binding to RAF for the 
cases of high (highest value) and low (lowest value) koff 
kC1 k_on_typ (nM·s)-1 Forward rate constant of CRAF binding to RAS-GTP 
KC1 400 nM Kd of CRAF binding to RAS-GTP 
kC_1 KC1·kC1 s-1 
Backward rate constant of CRAF binding to RAS-GTP 
(Kd = 400 nM) 
kB1 k_on_typ (nM·s)-1 Forward rate constant of BRAF binding to RAS-GTP 
KB1 80 nM Kd of BRAF binding to RAS-GTP 
kB_1 KB1·kC1 s-1 
Backward rate constant of BRAF binding to RAS-GTP 
(Kd = 80 nM) 
kCCd1 k_on_typ (nM·s)-1 Forward rate constant of CRAF homodimerization 
KCCd1 4000 nM Kd of CRAF homodimerization 
kCCd_1 KCCd1·kCCd1 s-1 
Backward rate constant of CRAF homodimerization (Kd = 
4000 nM) 
kBBd1 k_on_typ (nM·s)-1 Forward rate constant of BRAF homodimerization 
KBB1 4000 nM Kd of BRAF homodimerization 
kBBd_1 KBBd1·kBBd1 s-1 
Backward rate constant of BRAF homodimerization (Kd = 
2000 nM) 
kCBd1 k_on_typ (nM·s)-1 Forward rate constant of BRAF-CRAF heterodimerization 
KCBd1 4000 nM Kd of BRAF-CRAF heterodimerization 
kCBd_1 KCBd1·kCCd1 s-1 
Backward rate constant of B/CRAF heterodimerization 
(Kd = 4000 nM) 
kdERC1 k_on_typ (nM·s)-1 
Forward rate of ERK feedback phosphorylation of CRAF on 
S642 
KdERC1 50 nM Kd of ERK binding to CRAF 
kdERC_1 KdERC1·kdERC1 s- Backward rate CRAF phosphorylation by ERK (Kd = 50 
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1 nM) 
kcatER 0.5 s-1 
Catalytic rate constant of ERK feedback phosphorylation of 
CRAF 
pEC 5 Ratio between ERK affinities to S642 and pS642 CRAF 
VmaxS642 0.1 s-1 The CRAF S642 dephosphorylation rate 
kdERB1 k_on_typ (nM·s)-1 
Forward rate of ERK feedback phosphorylation of BRAF on 
T753 
KdEERB1 50 nM Kd of ERK binding to BRAF 
kdERB_1 
KdERB1·kdERB1 s-
1 
Backward rate of ERK phosphorylation of BRAF (Kd = 50 
nM) 
pEB 5 Ratio between ERK affinities to T753 and pT753 BRAF 
VmaxERKT753 0.1 s-1 The BRAF T753 dephosphorylation rate 
kdERBE1 k_on_typ (nM·s)-1 
Forward rate constant of ERK phosphorylation of 
BRAFV600E on T753 
KdERBE1 50 nM Kd of ERK binding to BRAFV600E 
kdERBE_1 
KdERBE1·kdERB1 
s-1 
Backward rate constant BRAFV600E phosphorylation by ERK 
(Kd = 50 nM) 
pEBE 5 Ratio between ERK affinities to T753 and pT753 BRAFV600E 
VmaxERKT753BE 0.1 s-1 The BRAFV600E T753 dephosphorylation rate 
kpS338 0.03 s-1 Phosphorylation rate of CRAF on S338 on PM 
kS338 0.03 s-1 Dephosphorylation rate of CRAF on S338 
kS259 0.015 s-1 Rate of CRAF phosphorylation on S259 in cytoplasm 
pM259 25 Decrease of rate of CRAF phosphorylation on S259 on PM 
kS_259 0.0003 s-1 Rate of CRAF dephosphorylation on S259 in cytoplasm 
pMd259 100 Increase of rate of CRAF dephosphorylation on S259 on PM 
kS365 0.015 s-1 Rate of BRAF phosphorylation on S365 in cytoplasm 
pM365 25 Decrease of rate of BRAF phosphorylation on S365 on PM 
kS_365 0.0003 s-1 Rate of BRAF dephosphorylation on S365 in cytoplasm 
pMd365 100 Increase of rate of BRAF dephosphorylation on S365 on PM 
kBE1 kB1 (nM·s)-1 Forward rate constant of BRAFV600E binding to RAS-GTP 
kBE_1 kB_1 s-1 Backward rate constant of BRAFV600E binding to RAS-GTP  
fa** 0.01 Facilitation of RAF dimerization by inhibitor a 
fb** 0.01 Facilitation of RAF dimerization by inhibitor b 
g3a** 1 Thermodynamic factor g3 for inhibitor a 
g3b** 1 Thermodynamic factor g3 for inhibitor b 
alphaa_11** 1 Thermodynamic factor 𝑎11 for inhibitor a (see section S3.3) 
alphaa_12** 1 Thermodynamic factor 𝑎12 for inhibitor a (see section S3.3) 
alphaa_21** 1 Thermodynamic factor 𝑎21 for inhibitor a (see section S3.3) 
alphaa_22** 1 Thermodynamic factor 𝑎22 for inhibitor a (see section S3.3) 
alphab_11** 1 Thermodynamic factor 𝑎11 for inhibitor b (see section S3.3) 
alphab_12** 1 Thermodynamic factor 𝑎12 for inhibitor b (see section S3.3) 
alphab_21** 1 Thermodynamic factor 𝑎21 for inhibitor b (see section S3.3) 
alphab_22** 1 Thermodynamic factor 𝑎22 for inhibitor b (see section S3.3) 
b_C_pS259_m** 0.01 
Equilibrium constant for DFG-motif transitions in pS259 
CRAF monomer 
c_C_pS259_m** 0.01 
Equilibrium constant for αC-helix transitions in pS259 
CRAF monomer 
g_C_pS259_m** 2 
Constant of cooperativity between IN/OUT transitions of 
DFG-motif and αC-helix for pS259 CRAF monomers 
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b_C_S259_S338_m** 0.1 
Equilibrium constant for DFG-motif transitions in S259, 
S338 CRAF monomer 
c_C_S259_S338_m** 0.1 
Equilibrium constant for αC-helix transitions in S259, S338 
CRAF monomer 
g_C_S259_S338_m** 2 
Constant of cooperativity between IN/OUT transitions of 
DFG-motif and αC-helix for S259, S338 CRAF monomers 
b_C_S259_pS338_m** 1 
Equilibrium constant for DFG-motif transitions in S259, 
pS338 CRAF monomer 
c_C_S259_pS338_m** 1 
Equilibrium constant for αC-helix transitions in S259, pS338 
CRAF monomer 
g_C_S259_pS338_m** 2 
Constant of cooperativity between IN/OUT transitions of 
DFG-motif and αC-helix for S259, pS338 CRAF monomers 
b_C_S259_S338_dimIN** 0.1 
Equilibrium constant for DFG-motif transitions in S259, 
S338 CRAF protomer in dimer, the other protomer is in αC-
IN 
c_C_S259_S338_dimIN** 1 
Equilibrium constant for αC-helix transitions in S259, S338 
CRAF protomer in dimer, the other protomer is in αC-IN 
g_C_S259_S338_dimIN** 2 
Constant of cooperativity between transitions of DFG and 
αC-helix for S259, S338 CRAF protomer in dimer, the other 
protomer is in αC-IN 
b_C_S259_pS338_dimIN** 10 
Equilibrium constant for DFG transitions in S259, pS338 
CRAF protomer in dimer, the other protomer is in αC-IN 
c_C_S259_pS338_dimIN** 10 
Equilibrium constant for αC-helix transitions in S259, pS338 
CRAF protomer in dimer, the other protomer is in αC-IN 
g_C_S259_pS338_dimIN** 2 
Constant of cooperativity between transitions of DFG-motif 
and αC-helix for S259, pS338 CRAF protomer in dimer, the 
other protomer is in αC-IN 
b_B_pS365_m** 0.01 
Equilibrium constant for DFG-motif transitions in pS365 
BRAF monomer 
c_B_pS365_m** 0.01 
Equilibrium constant for αC-helix transitions in pS365 
BRAF monomer 
g_B_pS365_m** 2 
Constant of cooperativity between IN/OUT transitions of 
DFG-motif and αC-helix for pS365 BRAF monomers 
b_B_S365_m** 1 
Equilibrium constant for DFG-motif transitions in S365 
BRAF monomer 
c_B_S365_m** 1 
Equilibrium constant for αC-helix transitions in S365 BRAF 
monomer 
g_B_S365_m** 2 
Constant of cooperativity between IN/OUT transitions of 
DFG-motif and αC-helix for S365 BRAF monomers 
b_B_S365_dimIN** 10 
Equilibrium constant for DFG-motif transitions in S365 
BRAF protomer in dimer, the other protomer is in αC-IN 
c_B_S365_dimIN** 10 
Equilibrium constant for αC-helix transitions in S365 BRAF 
protomer in dimer, the other protomer is in αC-IN 
g_B_S365_dimIN** 2 
Constant of cooperativity between transitions of DFG and 
αC-helix for S365 BRAF protomer in dimer, the other 
protomer is in αC-IN 
b_B_S365_dimOUT** 10 
Equilibrium constant for DFG-motif transitions in S365 
BRAF protomer in dimer, the other protomer is in αC-OUT 
c_B_S365_dimOUT** 500 
Equilibrium constant for αC-helix transitions in S365 BRAF 
protomer in dimer, the other protomer is in αC-OUT 
g_B_S365_dimOUT** 2 
Constant of cooperativity between transitions of DFG and 
αC-helix for S365 BRAF protomer in dimer, the other 
protomer is in αC-OUT 
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b_BE_m** 1 
Equilibrium constant for DFG-motif transitions in 
BRAFV600E monomer 
c_BE_m** 1 
Equilibrium constant for αC-helix transitions in 
BRAFV600E monomer 
g_BE_m** 2 
Constant of cooperativity between IN/OUT transitions of 
DFG-motif and αC-helix for BRAFV600E monomers 
b_BE_dimIN** 10 
Equilibrium constant for DFG transitions in BRAFV600E 
protomer in dimer, the other protomer is in αC-IN 
c_BE_dimIN** 10 
Equilibrium constant for αC-helix transitions in BRAF-
V600E protomer in dimer, the other protomer is in αC-IN 
g_BE_dimIN** 2 
Constant of cooperativity between transitions of DFG and 
αC-helix for BRAFV600E protomer in dimer, the other 
protomer is in αC-IN 
b_BE_dimOUT** 10 
Equilibrium constant for DFG transitions in BRAFV600E 
protomer in dimer, the other protomer is in αC-OUT 
c_BE_dimOUT** 500 
Equilibrium constant for αC-helix transitions in BRAF-
V600E protomer in dimer, the other protomer is in αC-OUT 
g_BE_dimOUT** 2 
Constant of cooperativity between transitions of DFG and 
αC-helix for BRAFV600E protomer in dimer, the other 
protomer is in αC-OUT 
Kda 10 Dissociation constant for inhibitor a 
Kdb 10 Dissociation constant for inhibitor b 
pBE1*** 2 
Effect of ERK phosphorylation on BRAFV600E binding to 
RAS-GTP 
kBEBEd1 k_on_typ (nM·s)-1 Forward rate constant of BRAFV600E homodimerization 
KBEBEd1 200 nM Kd of BRAFV600E homodimerization 
kBEBEd_1 
KBEBEd1· 
kBEBEd1 s-1 
Backward rate constant of BRAFV600E homodimerization 
(Kd = 200 nM) 
pBE3*** 1.7 
Effect of ERK feedback phosphorylation on BRAFV600E 
dimerization 
kBEBd1 kBEBEd1 (nM·s)-1 
Forward rate constant of WT BRAF and BRAFV600E 
dimerization 
kBEBd_1 kBEBEd_1 s-1 
Backward rate constant of WT BRAF and BRAFV600E 
dimerization 
pBEB3*** 1.7 
Effect of phosphorylation of BRAFV600E by ERK on 
dimerization with BRAF 
p3BEpB*** 1.7 
Effect of phosphorylation of BRAF by ERK on dimerization 
with BRAFV600E 
kBECd1 kBEBEd1 (nM·s)-1 Forward rate constant of CRAF and BRAFV600E dimerization 
kBECd_1 kBEBEd_1 s-1 
Backward rate constant of CRAF and BRAFV600E 
dimerization 
pBEC3*** 1.7 
Effect of phosphorylation of BRAFV600E by ERK on 
dimerization with CRAF 
p3BEpC*** 1.7 
Effect of phosphorylation of CRAF by ERK on dimerization 
with BRAFV600E 
k2a_pS365 k_on_typ_a (nM·s)-1 Forward rate constant of inhibitor 1 binding to pS365 BRAF 
k2b_pS365 k_on_typ_b (nM·s)-1 Forward rate constant of inhibitor 2 binding to pS365 BRAF 
k_2a_pS365 
K2a_pS365· 
k2a_pS365 s-1 
Backward rate constant of inhibitor 1 binding to pS365 
BRAF  
(value of Kd= K2a_pS365 is calculated in xls file) 
k_2b_pS365 K2b_pS365· 
Backward rate constant of inhibitor 2 binding to pS365 
BRAF  
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k2b_pS365 s-1 (value of Kd= K2b_pS365 is calculated in xls file) 
k2a_S365 k_on_typ_a (nM·s)-1 Forward rate constant of inhibitor 1 binding to S365 BRAF 
k2b_S365 k_on_typ_b (nM·s)-1 Forward rate constant of inhibitor 2 binding to S365 BRAF 
k_2a_S365 
K2a_S365· 
k2a_S365 s-1 
Backward rate constant of inhibitor 1 binding to S365 BRAF  
(value of Kd= K2a_S365 is calculated in xls file) 
k_2b_S365 
K2b_S365· 
k2b_S365 s-1 
Backward rate constant of inhibitor 2 binding to S365 BRAF  
(value of Kd= K2b_S365 is calculated in xls file) 
k2Ea k_on_typ_a (nM·s)-1 Forward rate constant of inhibitor 1 binding to BRAFV600E 
k2Eb k_on_typ_b (nM·s)-1 Forward rate constant of inhibitor 2 binding to BRAFV600E 
k_2Ea K2Ea·k2Ea s-1 
Backward rate constant of inhibitor 1 binding to BRAFV600E  
(value of Kd= K2Ea is calculated in xls file) 
k_2Eb K2Eb·k2Eb s-1 
Backward rate constant of inhibitor 2 binding to BRAFV600E  
(value of Kd= K2Ea is calculated in xls file) 
k3a_pS259_S338 k_on_typ_a (nM·s)-1 
Forward rate constant of inhibitor 1 binding to pS259/S338 
CRAF 
k3b_pS259_S338 k_on_typ_b (nM·s)-1 
Forward rate constant of inhibitor 2 binding to pS259/S338 
CRAF 
k_3a_pS259_S338 
K3a_pS259_S338· 
k3a_pS259_S338 s-1 
Backward rate constant of inhibitor 1 binding to pS259/S338 
CRAF  
(value of Kd= K3a_pS259_S338 is calculated in xls file) 
k_3b_pS259_S338 
K3b_pS259_S338· 
k3b_pS259_S338 s-1 
Backward rate constant of inhibitor 2 binding to pS259/S338 
CRAF  
(value of Kd= K3a_pS259_S338 is calculated in xls file) 
k3a_S259_S338 k_on_typ_a (nM·s)-1 
Forward rate constant of inhibitor 1 binding to S259/S338 
CRAF 
k3b_S259_S338 k_on_typ_b (nM·s)-1 
Forward rate constant of inhibitor 2 binding to S259/S338 
CRAF 
k_3a_S259_S338 
K3a_S259_S338· 
k3a_S259_S338 s-1 
Backward rate constant of inhibitor 1 binding to S259/S338 
CRAF  
(value of Kd= K3a_S259_S338 is calculated in xls file) 
k_3b_S259_S338 
K3b_S259_S338· 
k3b_S259_S338 s-1 
Backward rate constant of inhibitor 2 binding to S259/S338 
CRAF  
(value of Kd= K3a_S259_S338 is calculated in xls file) 
k3a_S259_pS338 k_on_typ_a (nM·s)-1 
Forward rate constant of inhibitor 1 binding to S259/pS338 
CRAF 
k3b_S259_pS338 k_on_typ_b (nM·s)-1 
Forward rate constant of inhibitor 2 binding to S259/pS338 
CRAF 
k_3a_S259_pS338 
K3a_S259_pS338· 
k3a_S259_pS338 s-1 
Backward rate constant of inhibitor 1 binding to S259/pS338 
CRAF  
(value of Kd= K3a_S259_pS338 is calculated in xls file) 
k_3b_S259_pS338 
K3b_S259_pS338· 
k3b_S259_pS338 s-1 
Backward rate constant of inhibitor 2 binding to S259/pS338 
CRAF  
(value of Kd= K3a_S259_pS338 is calculated in xls file) 
kRAFMEK1 k_on_typ (nM·s)-1 Forward rate constant of first MEK phosphorylation by RAF 
KRAFMEK1 1500 nM Kd of RAF binding to MEK 
kRAFMEK_1 
KRAFMEK1· 
kRAFMEK1  s-1 
Backward rate constant of 1st MEK phosphorylation by RAF 
(Kd=1500 nM) 
kRAFMEK2 k_on_typ (nM·s)-1 
Forward rate constant of second MEK phosphorylation by 
RAF 
KRAFMEK2 1000 nM Kd of RAF binding to MEK 
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kRAFMEK_2 
KRAFMEK2· 
kRAFMEK1  s-1 
Backward rate constant of 2nd MEK phosphorylation by 
RAF (Kd=1000 nM) 
kcatRAFMEK1 0.5 s-1 
Catalytic rate constant of first MEK phosphorylation by 
RAF  
kcatRAFMEK2 0.5 s-1 
Catalytic rate constant of second MEK phosphorylation by 
RAF  
kPPMEK1 k_on_typ (nM·s)-1 Forward rate constant of ppMEK dephosphorylation 
KPPMEK1 2000 nM Kd of phosphatase binding to MEK 
kPPMEK_1 
KPPMEK1· 
kPPMEK1 s-1 
Backward rate constant of ppMEK dephosphorylation 
(Kd = 2000 nM) 
kcatPPMEK 0.1 s-1 Catalytic rate constant of pMEK dephosphorylation 
kPMEK1 k_on_typ Forward rate constant of pMEK dephosphorylation 
KPMEK1 2000 nM Kd of phosphatase binding to MEK 
kPMEK_1 
KPMEK1· 
kPMEK1 
Backward rate constant of pMEK dephosphorylation 
(Kd=2000 nM) 
kcatPMEK 0.5 s-1 Catalytic rate constant of pMEK dephosphorylation 
kMERKT1 k_on_typ Forward rate constant of ERK phosphorylation on T 
KMERKT1 2000 nM Kd of MEK binding to ERK 
kMERKT_1 
KMERKT1· 
kMERKT1 
Backward rate constant of ERK phosphorylation on T 
(Kd = 2000 nM) 
kcatMERKT1 0.001 s-1 Catalytic rate constant of ERK phosphorylation on T 
kMERKY1 k_on_typ Forward rate constant of ERK phosphorylation on Y 
KMERKY1 2000 nM Kd of MEK binding to ERK 
kMERKY_1 
KMERKY1· 
kMERKY1 
Backward rate constant of ERK phosphorylation on Y 
(Kd = 2000 nM) 
kcatMERKY1 0.1 s-1 Catalytic rate constant of ERK phosphorylation on Y 
kMERKT2 k_on_typ Forward rate constant of pERK phosphorylation on T 
KMERKT2 1000 nM Kd of MEK binding to ERK 
kMERKT_2 
KMERKT2· 
kMERKT2 
Backward rate constant of pERK phosphorylation on T 
(Kd = 1000 nM) 
kcatMERKT2 0.2 s-1 Catalytic rate constant of pERK phosphorylation on T 
kMERKY2 k_on_typ Forward rate constant of pERK phosphorylation on Y 
KMERKY2 1000 nM Kd of MEK binding to ERK 
kMERKY_2 
KMERKY2· 
kMERKY2 
Backward rate constant of pERK phosphorylation on Y 
(Kd = 1000 nM) 
kcatMERKY2 0.2 s-1 Catalytic rate constant of pERK phosphorylation on Y 
kPERKT1 k_on_typ Forward rate constant of pERK dephosphorylation on T 
KPERKT1 2000 nM Kd of phosphatase binding to ERK 
kPERKT_1 
KPERKT1· 
kPERKT1 
Backward rate constant of pERK dephosphorylation on T 
(Kd = 2000 nM) 
kcatPERKT1 1 s-1 Catalytic rate constant of pERK dephosphorylation on T 
kPERKT2 k_on_typ 
Forward rate constant of ERK phosphatase association with 
its product 
KPERKT2 10000 nM Kd of phosphatase binding to ERK 
kPERKT_2 
KPERKT2· 
kPERKT2 
Backward rate constant of ERK phosphatase association 
with its product 
kPERKY1 k_on_typ Forward rate constant of pERK dephosphorylation on Y 
KPERKY1 2000 nM Kd of phosphatase binding to ERK 
kPERKY_1 KPERKY1· Backward rate constant of pERK dephosphorylation on T 
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kPERKY1 (Kd = 2000 nM) 
kcatPERKY1 1 s-1 Catalytic rate constant of pERK dephosphorylation on Y 
kPERKY2 k_on_typ 
Forward rate constant of ERK phosphatase association with 
its product 
KPERKY2 10000 nM Kd of phosphatase binding to ERK 
kPERKY_2 
KPERKY2· 
kPERKY2 
Backward rate constant of ERK phosphatase association 
with its product 
kPPERK1 k_on_typ Forward rate constant of ppERK dephosphorylation 
KPPERK1 2000 nM Kd of phosphatase binding to ERK 
kPPERK_1 
KPPERK1· 
kPPERK1 
Backward rate constant of ppERK dephosphorylation 
(Kd=2000 nM) 
kcatPPERK1 0.5 s-1 Catalytic rate constant of ppERK dephosphorylation 
kPPERK2 k_on_typ 
Forward rate constant of ERK phosphatase association with 
its product 
KPPERK2 10000 nM Kd of phosphatase binding to ERK 
kPPERK_2 
KPPEERK2· 
kPPERK2 
Backward rate constant of ERK phosphatase association 
with its product 
KA_actBRAFmon+ 1 Relative kinase activity of active BRAF monomer 
KA_actBRAFhom+ 2 Relative kinase activity of active BRAF homodimer 
KA_nactCRAFhom+ 0.01 Relative kinase activity of non-active CRAF homodimer 
KA_actCRAFm+ 0.2 Relative kinase activity of active CRAF monomer 
KA_hactCRAFhom+ 0.2 Relative kinase activity of half-active CRAF homodimer 
KA_CCI+ 0.2 Relative kinase activity of half-inhibited CRAF homodimer 
KA_actCRAFhom+ 0.4 Relative kinase activity of active CRAF homodimer 
KA_nactRAFhet+ 15 Relative kinase activity of non-active RAF heterodimer 
KA_act_RAF_het+ 30 Relative kinase activity of active RAF heterodimer 
KA_CnBI+ 8 Relative kinase activity of half-inhibited RAF heterodimer 
KA_CnIB+ 8 Relative kinase activity of half-inhibited RAF heterodimer 
KA_CaBI+ 15 Relative kinase activity of half-inhibited RAF heterodimer 
KA_CaIB+ 15 Relative kinase activity of half-inhibited RAF heterodimer 
KA_BEm+ 2 Relative kinase activity of BRAFV600E monomer 
KA_BEhom+ 4 Relative kinase activity of BRAFV600E homodimer 
KA_BEBa+ 3 Relative kinase activity of BRAFV600E-BRAF dimer 
KA_BEBn+ 2 Relative kinase activity of BRAFV600E-BRAF dimer 
KA_BECa+ 30 Relative kinase activity of BRAFV600E-CRAF dimer 
KA_BECn+ 15 Relative kinase activity of BRAFV600E-CRAF dimer 
KA_BEBaI+ 2 
Relative kinase activity of half-inhibited BRAFV600E-
BRAF dimer 
KA_BEIBa+ 2 
Relative kinase activity of half-inhibited BRAFV600E-
BRAF dimer 
KA_BEBnI+ 2 
Relative kinase activity of half-inhibited BRAFV600E-
BRAF dimer 
KA_BEIBn+ 2 
Relative kinase activity of half-inhibited BRAFV600E-
BRAF dimer 
KA_BECaI+ 15 
Relative kinase activity of half-inhibited BRAFV600E-
CRAF dimer 
KA_BEICa+ 15 
Relative kinase activity of half-inhibited BRAFV600E-
CRAF dimer 
KA_BECnI+ 8 Relative kinase activity of half-inhibited BRAFV600E-
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CRAF dimer 
KA_BEICn+ 8 
Relative kinase activity of half-inhibited BRAFV600E-
CRAF dimer 
KA_BEBEI+ 2 
Relative kinase activity of half-inhibited BRAFV600E 
homodimer 
 
* – if not specified otherwise in the figure legends 
** – if not specified otherwise in Excel spreadsheet “Kds.xlsx” 
*** – for the sensitivity analysis, the total control exerted by BRAFV600E feedback phosphorylation was 
calculated as the sum of the response coefficients to equal factional changes in the indicated parameters 
(for detail see, (Kholodenko et al., 1997; Kholodenko et al., 1998; Kholodenko and Westerhoff, 1995).  
For illustration purposes, this is depicted as the change in the parameter pBE3 in Fig. 7 and S7.  
+ – see List S4.1 
6. Assessment of drug synergy effects 
6.1 Conditions for drug additivity, synergy and antagonism.  
Loewe isoboles are straight lines for non-interacting drugs. Drug interactions are commonly described 
in terms of the Bliss independence or the Loewe additivity, synergy and antagonism (Yeh et al., 2009). 
Although the Bliss independence is an intuitively clear concept, it does not account for nonlinearity of 
dose-response curves, formally resulting in interactions of a drug with itself, when the drug dose increases 
(Greco et al., 1995; Keith et al., 2005). Therefore, we use Loewe isoboles that are lines of constant 
inhibition across a two-dimensional plane of two drug concentrations.  
Let ICZ1 and ICZ2 be the concentrations of inhibitors I1 and I2 that produce the same effect Z when given 
separately. Z indicates an arbitrary inhibition level, which can be, for example, 10, 20, 30, 50, 70 or 90%. 
We create a response surface by plotting lines of constant Z values on the (Y, X) plane where Y = [I1]/ICZ1 
and X = [I2]/ICZ2. If inhibitors, I1 and I2, do not interact with each other, the same effect Z is achieved not 
only by doses I1 = ICZ1, I2 = ICZ2, but also by any dose combination that satisfy the following equation,  
I1/ICZ1 + I2/ICZ2 = 1   (S6.1) 
Eq. S6.1 determines a straight line in the (Y, X) plane. Loewe isoboles that are straight lines indicate the 
absence of drug interactions, which is termed Loewe additivity (see scheme S6.1). If a combination of 
two drugs is more efficient than either of the two drugs on their own, i.e., they demonstrate synergy, the 
left part of Eq. S6.1 is less than 1, and the Loewe isoboles are concave. Conversely, if drugs antagonize 
each other the Loewe isoboles are convex (see scheme S6.1).  
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 Scheme S6.1 
Importantly, to assess synergy effects by Loewe isoboles we can use either absolute inhibitor doses or 
doses normalized by ICZ1 and ICZ2. Normalization of drug doses results only in the linear stretching or 
compression of the Loewe isoboles along the vertical and horizontal axes (see Scheme S6.1). In the case 
of the Loewe additivity each straight line given by Eq. S6.1 will still be the straight line, even if I1 and I2 
are not normalized by ICZ1 and ICZ2. In case of drug synergy or antagonism, each concave or convex line 
will remain concave or convex, respectively.  
When the number of data points across the two-dimensional plane of inhibitor doses is insufficient to 
reconstruct the Loewe isoboles, the Talalay-Chou combination index (CI) can be used (Chou, 2006). For 
any particular drug combination and a dose ratio, the CI allows detecting whether the Loewe isoboles are 
under a straight line of non-interacting drugs, i.e., isoboles are concave, or they are above this line, i.e, 
convex.  
𝐶𝐼 =
𝐼1
𝐼𝐶𝑍1
+
𝐼2
𝐼𝐶𝑍2
  (S6.2) 
Therefore, circumventing the need to search the entire response surface of drug mixtures, the CI indicates 
synergy when CI < 1 and antagonism when CI > 1 (Chou, 2006). The definition of the Talalay-Chou 
combination index CI (see Eq. S6.2) can be extended to analyze not only the levels of signal inhibition 
ICZ, but also the levels of signal activation above the basal level. For levels of the signal above the basal 
level there can be two concentration points that result in the same signal level (see Figs 3-5). In such 
cases the concentration value on the descending part of the dose-response curve is chosen. For example, 
for dose-response curves in Figs 3-5, the higher concentration values should be chosen during analysis of 
synergy effects between RAF inhibitors for the cases of activation of the ERK pathway by RAF 
inhibitors. For example, in Figure 5B the doses of inhibitors were normalized on the doses that result in 
250% of ppERK activation to interpret experimental data. It can be clearly seen that the dose-response 
curves for a combination of B0R and sorafenib is essentially lower than dose-response curves for either 
inhibitor applied separately (Fig. 5B). 
6.2. Measures of drug effects in the case of paradoxical pathway activation by a drug 
Both Loewe isoboles and the Talalay-Chou combination index have been methods that are developed to 
assess effects of drugs which can only inhibit a target process and not activate it. RAF inhibitors are 
known to activate ERK signaling at low doses and inhibit signaling at high doses. Thus, these methods 
are not directly applicable for low doses of RAF inhibitors. To assess the efficiency of a drug 
combination for both low and high drug doses we have also calculated area under normalized dose-
response curves in present paper (Kholodenko, 2015; Pozdeyev et al., 2016; Yadav et al., 2014). 
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6.3. Optimal stoichiometry of drug combinations 
For a combination of two independent drugs (𝐼1 and 𝐼2), the total dose is the same for each point on the 
straight line of drug additivity (Scheme 6.1). However, if two drugs exhibit synergy, their total dose 
changes for different points on the Loewe isobole. Note that the drug doses can be normalized by the 
corresponding IC levels or given in absolute, molar concentrations. For each inhibition effect Z, the 
optimal drug doses (𝐼1
∗ and 𝐼2
∗) correspond to the point on the ICZ isobole that yields the minimal total 
dose (T). The minimum of the absolute molar doses and the minimum of the normalized doses are 
obtained by solving the conditional extremum problem, Eq. S6.3a and Eq. S6.3b, respectively  
𝐼1
∗ + 𝐼2
∗ = min(𝐼1 + 𝐼2)|𝐼1,𝐼2∈𝐼𝐶𝑍 = 𝑇 (S6.3a) 
𝐼1
∗
𝐼𝐶𝑍1
+
𝐼2
∗
𝐼𝐶𝑍2
= min (
𝐼1
𝐼𝐶𝑍1
+
𝐼2
𝐼𝐶𝑍2
)|
𝐼1,𝐼2∈𝐼𝐶𝑍
= 𝑇𝑛𝑜𝑟𝑚 (S6.3b) 
 
Finding of the conditional minimums in Eqs. 6.3 is illustrated in Scheme S6.2. Here, lines 𝐼1 + 𝐼2 = 𝑇 
and 
𝐼1
∗
𝐼𝐶𝑍1
+
𝐼2
∗
𝐼𝐶𝑍2
= 𝑇𝑛𝑜𝑟𝑚 are the tangent lines that touch the ICZ isobole at the point where the sum of 
molar or normalized drug doses is minimal. 
 Scheme S6.2 
Importantly, the distinctive features of Loewe isoboles that separate synergy, additivity and antagonism 
do not depend on the normalization method, or even absolute, non-normalized inhibitor doses can be 
plotted (Kholodenko, 2015). Thus, if two drugs show synergy at a certain ICZ level, both molar (see Eqn. 
S6.3a) and normalized (see Eqn. S6.3b) total doses for a drug combination will be lesser than the dose of 
each drug on its own that causes the same inhibition level (see Scheme S6.2). The converse statement is 
also true, i.e. if the same inhibition effect (ICZ) can be achieved by combining these two drugs at the 
lower molar or normalized sum of their doses compared to the dose of each drug on its own. 
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7. Induction of RAF dimerization increases the concentration of RAS-RAF complexes and RAF 
priming 
RAF inhibitors inhibit RAF kinase activity, lock RAF molecules in specific conformations, and induce 
dimerization of RAF molecules (Hatzivassiliou et al., 2010; Karoulia et al., 2016; Kholodenko, 2015; 
Poulikakos et al., 2010). It was experimentally observed that RAF inhibitors increase the concentrations 
of RAS-RAF complexes (Hatzivassiliou et al., 2010; Karoulia et al., 2016). These data were interpreted 
as proof that RAF inhibitors can directly promote RAS-RAF interaction (Karoulia et al., 2016), although 
a structural mechanism explaining this effect is unknown. Here we show that induction of RAF 
dimerization is sufficient to explain the increase in the RAS-RAF complex concentration caused by RAF 
inhibitors.  
As an illustration, first we consider a simplified, toy model of RAF recruitment by active RAS to the 
plasma membrane and subsequent RAF dimerization. A complete list of reactions for the simplified 
model is presented in List S7.1. 
List S7.1. Reactions and relationships between equilibrium dissociation constants for a toy 
model of RAF recruitment of plasma membrane and dimerization 
Reaction 
number 
Reactions 
Equilibrium Dissociation 
Constants 
1 RAS + RAF ↔ RAS-RAF 𝐾1 = 𝐾𝑅𝐴𝑆  
2 RAF + RAF ↔ RAF-RAF 𝐾2 = 𝐾𝑑𝑖𝑚  
3 RAS-RAF + RAS-RAF ↔ RAS-RAF-RAF-RAS 𝐾3 = 𝐾𝑑𝑖𝑚/𝑝2
2  
4 RAS-RAF-RAF + RAS ↔ RAS-RAF-RAF-RAS 𝐾4 = 2𝐾𝑅𝐴𝑆/𝑝2
2  
5 RAS-RAF + RAF ↔ RAS-RAF-RAF 𝐾5 = 𝐾𝑑𝑖𝑚  
6 RAF-RAF + RAS ↔ RAS-RAF-RAF 𝐾6 = 𝐾𝑅𝐴𝑆/2  
 
In List S7.1 factor 𝑝2 accounts for effects of spatial localization of RAF molecules in the near-membrane 
space, which results in an increase of their local concentration with respect to the cytoplasmic volume 
(Kholodenko et al., 2000). 
The simplified model allows one to obtain an analytical expression for the total concentration of RAS-
RAF complexes ([𝑅𝐴𝑆 − 𝑅𝐴𝐹]𝑇) at steady states (see Eq. S7.1). 
[𝑅𝐴𝑆 − 𝑅𝐴𝐹]𝑇 = [𝑅𝐴𝑆 − 𝑅𝐴𝐹] + 2[𝑅𝐴𝑆 − 𝑅𝐴𝐹 − 𝑅𝐴𝐹 − 𝑅𝐴𝑆] + [𝑅𝐴𝑆 − 𝑅𝐴𝐹 − 𝑅𝐴𝐹] = 
=
[𝑅𝐴𝑆] ⋅ [𝑅𝐴𝐹]
𝐾𝑅𝐴𝑆
⋅ (1 +
2 ⋅ [𝑅𝐴𝐹]
𝐾𝑑𝑖𝑚
+
2 ⋅ 𝑝2
2 ⋅ [𝑅𝐴𝑆] ⋅ [𝑅𝐴𝐹]
𝐾𝑅𝐴𝑆 ⋅ 𝐾𝑑𝑖𝑚
) 
(S7.1) 
Equation S7.1 shows that a decrease in the dissociation constant for RAF dimerization, 𝐾𝑑𝑖𝑚, leads to an 
increase of the total concentration of RAS-RAF complexes. In other words, an increase in the affinity of 
RAF dimerization accounts for an increase in the concentration of RAS-RAF complexes. 
The simplified model illustrates that if a RAF inhibitor increases the RAF dimerization affinity, it 
inevitably promotes RAS-RAF interaction. We have used our full model to check whether the induction 
of RAF dimerization by RAF inhibitors can account for the known effect of promotion of RAS-RAF 
interaction and RAF priming. Fig. S6E shows that an increase in inhibitor concentration results in an 
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increase of CRAF and BRAF bound to RAS-GTP. The highest amount of RAS-RAF complexes 
corresponds to inhibitors that induce the highest levels of RAF dimerization and paradoxical activation. 
 
8. Alternative mechanisms of RAF inhibitor resistance  
Not only RAS oncogenic mutations (or overexpression of receptor tyrosine kinases resulting in high 
RAS-GTP levels) confer resistance to RAF inhibitors (Nazarian et al., 2010; Straussman et al., 2012), but 
also other mechanisms, such as BRAFV600E splice variants (Poulikakos et al., 2011) and CRAF 
overexpression (Lito et al., 2013; Montagut et al., 2008). In this section we will consider the efficiency of 
inhibitor combinations in cells that exhibit these resistance mechanisms. We do not analyze the cases 
when resistance to RAF inhibitors is explained by bypassing of signaling through MEK, e.g. COT 
overexpression (Lito et al., 2013). 
To describe RAS-to-ERK signaling in the case when p61 BRAFV600E splice variants are expressed, the 
corresponding additional p61 BRAFV600E molecule was added to our rule-based model. The modified 
file (“RAF_MEK_ERK_SV.bngl”) is provided in Supplemental files. p61 splice variant of mutant 
BRAFV600E lacks RBD domain (Poulikakos et al., 2011). In the model, this splice variant is assumed to 
have 10-fold higher affinity for dimerization. The simulation results show that a combination of CO/DI 
and CI/DO inhibitors demonstrates synergy and effectively inhibit ERK signaling in cells expressing 
splice variants of mutant BRAF (Fig. S6F). Model also suggests if RAF inhibitor resistance is caused by 
CRAF overexpression, both a combination of CI/DI and CI/DO inhibitors, and a combination of CO/DI 
and CI/DO inhibitors demonstrate strong synergistic effects in inhibition of ERK signaling (Figs. S6G 
and S6H). 
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Figure S1 related to Figure 1. (A) Overlay of two structures, one of which is αC-helix-IN (4YHT, blue 
color), and the other is αC-helix-OUT (3TV4, red color). The αC-helix angle ω, which defines IN (ω > 54o) 
or OUT (ω < 52o) positions is highlighted in blue and red. (B) Overlay of the 46 BRAF dimer structures 
analysed showing the αC-helix IN and OUT in blue and red respectively.  (C) Overlay of two structures one 
of which is DFG-IN (4YHT, blue color) and the other is DFG-OUT (4DBN, red color). The L505-F595 
distance, which defines IN (d < 7 Å) and OUT (d > 9.5 Å) conformations, is depicted in blue and red lines, 
respectively. (D) Overlay of the 45 BRAF dimer structures analysed showing the DFG IN (blue) and OUT 
(red) (3C4C was not included because it has a different DFG conformation). (E) Distribution of the DFG 
conformations in 90 BRAF kinase domain protomers based on the analysis of 45 BRAF dimer structures 
deposited in PDB.  
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Supplemental Figure 2
Figure S2 related to Figure 2. Kinetic schemes of the rules governing: (A) CRAF binding to RAS and 
CRAF activation cycle; (B) BRAF binding to RAS and BRAF activation cycle; (C) Influence of ERK 
feedback phosphorylation on binding of RAF kinases to RAS; (D) RAF hetero-dimerization cycle; (E) 
Influence of ERK feedback phosphorylation on CRAF-BRAF hetero-dimerization. Protein domain 
designations are the same as in Fig. 2. Parameter notations on the arrows are explained in the SI, 
sections 1 and 2, see also List S5.1.  
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Supplemental Figure 3
Figure S3 related to Figure 3. (A-F) Model-predicted relative contribution of kinase activity of RAF 
monomers and dimers into the total RAF kinase activity during treatment with CO/DI (A, D), CI/DO 
(B, E) and CI/DI (C, F) inhibitors and in the absence of inhibitors (inserts) for cells with heterozygous 
(A-C) and homozygous (D-F) BRAFV600E mutation and WT RAS. (G-J) Model-predicted response 
of MEK and ERK signaling to: CO/DI and CI/DO inhibitors and their combination (G, I), CI/DI and 
CO/DI inhibitors and their combination (H), and CI/DI and CI/DO inhibitors and their combination 
(J) in cells with homozygous (G) and heterozygous (H-J) BRAFV600E mutation. Inhibitor doses are 
normalized by IC50. The residence time 1/koff of CO/DI and CI/DI inhibitors is 1 s. The residence 
times 1/koff of CI/DO inhibitor are 1 s (B, E, G, J) and 10
4 s (I). In each combination, the ratio of 
CO/DI and CI/DO inhibitor doses is 1.2:1, the ratio of CI/DI and CO/DI inhibitor doses is 1.2:1, and 
the ratio of CI/DI and CI/DO inhibitor doses is 1.2:1. Parameters for (A-C) and (H-J) are: [RAS-
GTP]=25 nM, [BRAFV600E]=25 nM, [BRAFWT]=25 nM. Parameters for (D-F) and (G) are: [RAS-
GTP]=25 nM, [BRAFV600E]=50 nM, [BRAFWT]=0 nM.  The remaining parameters are given in Lists 
S4.1 and S5.1 in SI. In panels (G-J), the inserts assess synergy, additivity or antagonism, using the 
Talalay-Chou combination index (CI). 
Figure S4 related to Figure 4. Predictive simulations of Loewe isoboles demonstrate antagonism 
rather than synergy of inhibiting ERK signaling by combinations of CO/DI RAF inhibitor and MEK 
inhibitor in cells bearing oncogenic RAS and WT BRAF (cf. Figs. S5 and 5). [RAS-GTP]=250 nM, 
[BRAFV600E]=0, [BRAFWT]=50 nM, basal ppERK level is 480 nM.  
Supplemental Figure 4
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Supplemental Figure 5
Figure S5 related to Figure 5. (A-E) Model predicted stationary responses to CI/DI and CI/DO 
inhibitors and their combination of: (A) CRAF phosphorylation on S259 and S338; (B) RAF 
heterodimers bound with two molecules of RAF inhibitor; (C) MEK signaling; (D-E) ERK 
signaling. (C) Talalay-Chou index for MEK and ERK inhibition is presented on the insert. [RAS-
GTP]=250 nM (A-E), [RAS-GTP]=100 nM (D), [BRAFV600E]=0, [BRAFWT]=50 nM, basal ppERK 
levels are 480 nM (A-E) and 279 nM (D), the ratio of CI/DI and CI/DO inhibitor doses applied in 
combination is 2.2:1 (A-E). (F-I). ERK (F-G, I) and MEK (H) signaling responses in growing 
MEL-JUSO (NRASQ61L/WT, HRASG13D/G13D, BRAFWT/WT) cells to SB-590885 (CI/DI), sorafenib 
(CI/DO) and their combination, which are measured using MESOSCALE (F) and LUMINEX (G-
H) systems, and Western Blot (I), 24 hr. The Western Blots (I) are taken from a single membrane 
which was obtained using multistrip western blotting (Aksamitiene et al., 2007). For inhibitor 
combinations, the ratio of SB590885 to sorafenib is 1:1.5. The ppERK responses are plotted vs the 
absolute concentrations of inhibitors applied separately and vs the sum of the absolute 
concentrations for their combination. 
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Figure S6 related to Figure 6. Model-predicted responses of MEK (B-C, E-F) and ERK (A, D, G) 
signaling to CI/DI, CO/DI inhibitors and their combination (A-B, D-E) and to CO/DI, CI/DO 
inhibitors and their combination (C, F, G). The residence times toff ~1/koff of CO/DI inhibitor are 1 s 
(A-C, G) and 104 s (D-F). Inserts assess synergy, additivity or antagonism, using the AUC (A, D, G) 
and CI (B, C, E-G).The residence times of CI/DO inhibitor are 1 s (C, F) and 104 s (G). Inhibitor 
doses are normalized by IC50, the total doses shown for the combination correspond to the optimal 
ratios of inhibitor doses. [RAS-GTP]=250 nM, [BRAFV600E]=0, [BRAFWT]=50 nM, basal ppERK 
level is 484 nM. The ratios of CI/DI and CO/DI inhibitor doses applied in combination are 3:5 (A-
B) and 1:1 (D-E). The ratios of CO/DI and CI/DO inhibitor doses applied in combination are 1:1 
(C, F, G).  
Supplemental Figure 6
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Supplemental Figure 7
Figure S7 related to Figure 7. (A-D) Model-predicted stationary responses of ERK (A-B) and MEK 
(C-D) signaling in cells with oncogenic RAS mutation and heterozygous BRAFV600E mutation to: 
CI/DI and CO/DI inhibitors and their combination (A-B), CO/DI and CI/DO inhibitors and their 
combination (C), and CI/DI and CI/DO inhibitors and their combination (D). The residence time 
toff ~1/koff of all inhibitors is 1 s. Inhibitor doses are normalized by IC50. In combinations, the ratio of 
CI/DI and CO/DI inhibitor doses are 1:1 (A) and 2.2:1 (B), the ratio of CO/DI and CI/DO inhibitor 
doses is 1:1 (C), and the ratio of CI/DI and CI/DO inhibitor doses is 6:1 (D). [RAS-GTP]=250 nM, 
[BRAFV600E]=25 nM, [BRAFWT]=25 nM, basal ppERK level is 2151 nM. (E) Model-predicted 
response of RAS-RAF complexes concentration to different RAF inhibitors in cells with WT BRAF 
and oncogenic RAS. [RAS-GTP]=250 nM, [BRAFV600E]=0, [BRAFWT]=50 nM, basal ppERK level is 
480 nM. (F) Model-predicted stationary response of ERK signaling to CO/DI, CI/DO inhibitors and 
their combination in cells with WT RAS and p61 splice variant of heterozygous BRAFV600E. [RAS-
GTP]=25 nM, [BRAFV600E]=0, [p61BRAFV600E]=25 nM, [BRAFWT]=25 nM, basal ppERK level is 
1627 nM. Inhibitor doses are normalized by IC50. In combination, the ratio of CO/DI and CI/DO 
inhibitor doses is 7:1. (A, B, F) Inserts assess drug synergy using the Talalay-Chou combination index 
(CI). G-H. Model-predicted stationary responses of ERK signaling in cells with WT RAS, 
heterozygous BRAFV600E mutation and CRAF overexpression to: CI/DI, CI/DO inhibitors and their 
combination, and to CO/DI, CI/DO inhibitors and their combination. Inhibitor doses are normalized by 
IC50 (G) and IC30 (H). [RAS-GTP]=25 nM, [BRAFV600E]=25 nM, [BRAFWT]=25 nM, [CRAF]=250 
nM, basal ppERK level is 2603 nM. (I–J)  Sensitivities of the areas under dose-response curves 
(AUC) to parameter changes for a combination of CO/DI (inhibitor a) and CI/DO (inhibitor b) RAF 
inhibitors in cells bearing both oncogenic RAS and BRAFV600E mutations (I) or only oncogenic 
RAS and WT BRAF (J). 
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